The effects of American Diabetes Association (ADA) diabetes self-management education and continuous glucose monitoring on diabetes health beliefs, behaviors and metabolic control by Meisenhelder-Smith, Jodee
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
2006
The effects of American Diabetes Association
(ADA) diabetes self-management education and
continuous glucose monitoring on diabetes health
beliefs, behaviors and metabolic control
Jodee Meisenhelder-Smith
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Meisenhelder-Smith, Jodee, "The effects of American Diabetes Association (ADA) diabetes self-management education and
continuous glucose monitoring on diabetes health beliefs, behaviors and metabolic control" (2006). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/2628
The Effects of American Diabetes Association (ADA) Diabetes Self-Management 
Education and Continuous Glucose Monitoring on Diabetes Health Beliefs, 
Behaviors and Metabolic Control 
 
 
by 
 
 
Jodee Meisenhelder-Smith 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
Department of Community and Family Health 
College of Public Health 
University of South Florida 
 
 
 
Major Professor:  Robert J. McDermott Ph.D. 
Carol Bryant, Ph.D. 
Elizabeth Gulitz, Ph.D. 
Jeffery Kromrey, Ph.D. 
Brendan O’Malley, M.D. 
 
 
 
Date of Approval: 
November 14, 2006 
 
 
 
 
Keywords: Health Belief Model, Glycosylated hemoglobin, Diabetes patient care 
assessment, diabetes outcomes, outpatient program 
 
 
© Copyright 2006, Jodee Meisenhelder-Smith 
 
Dedication 
To  my dad, Joseph Meisenhelder who inspired me to be a diabetes educator, to 
my mom, Twila Meisenhelder-Hiatt, my husband, Michael Smith, and all my 
family: Tyler, Dwana, Leslee, Barbara, Herb, Jean, Joe, Jolie, Cliff, Clifford, 
Clodagh, Bill,  Brigette  and Philip. 
Acknowledgements 
Special thanks to the staff of the Diabetes Care Institute, University 
Community Hospital, Tampa, Florida, my doctoral committee, Monika Wahi, 
M.P.H. and MiniMed Medronic. 
 
Note to the Reader 
The original version of this document contains color that is provides 
assistance in understanding some of the data presented. The original 
dissertation is on file with the USF library in Tampa, Florida. 
i 
 
 
Table of Contents 
List of Tables ........................................................................................................ v 
List of Figures ......................................................................................................vii 
The Effects of American Diabetes Association (ADA) Diabetes                         
Self-Managementviii Education and Continuous Glucose Monitoring        
on Diabetes Health Beliefs, Behaviors and Metabolic Control ................. viii 
Chapter One:  Introduction ................................................................................... 1 
Diabetes Self-Management Education ...................................................... 6 
Statement of the Problem ........................................................................ 18 
Purpose of the Study ............................................................................... 25 
Significance of the Problem ..................................................................... 27 
Hypothesis ............................................................................................... 30 
Research Questions ................................................................................ 31 
Research Plan ......................................................................................... 34 
Assumptions ............................................................................................ 39 
Delimitations ............................................................................................ 40 
Limitations................................................................................................ 41 
Definitions of Terms................................................................................. 42 
Chapter Two: Review of the Literature ............................................................... 47 
Overview of Diabetes............................................................................... 48 
ii 
Etiology and Classification ............................................................ 48 
Epidemiology................................................................................. 50 
Diabetes Related Complications ................................................... 51 
The Expanded Health Belief Model ......................................................... 54 
Factors Affecting Metabolic Control ......................................................... 61 
Diabetes-Specific Health Belief Instruments ............................................ 66 
Comprehensive Diabetes Self-Care Management Training..................... 74 
Continuous Glucose Monitoring............................................................... 81 
Implications for Future Research ............................................................. 83 
Chapter Three: Methods..................................................................................... 86 
Purpose of the Study ............................................................................... 87 
Hypothesis ............................................................................................... 89 
Research Questions ................................................................................ 90 
Research Plan ......................................................................................... 93 
Population and Sample ................................................................. 93 
Procedures.................................................................................... 99 
Physiological Instrumentation ..................................................... 100 
Psychosocial Instrumentation...................................................... 103 
Expanded Health Belief Model Questionnaire Reliability and  
Validity Results................................................................. 108 
The ADA Diabetes Self-Care Management Training Program.... 128 
Intensive Follow-up Care ............................................................ 144 
iii 
Documentation............................................................................ 146 
Data Collection and Analysis ...................................................... 147 
Summary ............................................................................................... 150 
Chapter Four: Results ...................................................................................... 151 
Introduction ............................................................................................ 151 
Participant Characteristics ..................................................................... 152 
Drop Out versus Completers....................................................... 159 
Research Question 1 results.................................................................. 182 
Research Questions 2-11 results........................................................... 188 
Chapter Five: Discussion.................................................................................. 196 
Summary ............................................................................................... 197 
Limitations.............................................................................................. 200 
Conclusions ........................................................................................... 207 
Implications for Diabetes Education, Clinical Practice, and             
Glycemic Control......................................................................... 208 
Implications for Public Health................................................................. 211 
Lessons Learned and Recommendations for Future Research............. 213 
References ....................................................................................................... 217 
Appendices....................................................................................................... 253 
Appendix 1:  Assessment and Education Records and Baseline  
Evaluation Form.......................................................................... 254 
Appendix 2:  Sample Flyer for Advertising Program .............................. 260 
iv 
Appendix 3:  Informed Consent Form .................................................... 262 
Appendix 4:  Study Forms...................................................................... 276 
Appendix 5:  Follow-up Evaluation Form and Dex Glucometer         
Monitoring System Summary ...................................................... 302 
Appendix 6:  Diabetes Self-management Education Schedule.............. 308 
Appendix 7:  Patient Satisfaction Questionnaire .................................... 310 
Appendix 8:  Educational Materials........................................................ 313 
Appendix 9:  Division of Nursing Standards/Policies/Procedures .......... 316 
Appendix 10:  Box-plot and Stem-leaf Diagrams of Continuous         
Variables at Baseline .................................................................. 324 
Appendix 11:  Chronbach Alpha Results for Individual Questions ......... 330 
Appendix 12:  SAS Output for Research Questions .............................. 339 
About the Author............................................................................................... 388 
 
 
v 
 
 
List of Tables 
Table 1:  Exclusion Criteria................................................................................. 95 
Table 2:  Minimum Sample Sizes per Group for Testing the Hypothesis               
of Equal Group Effects in a Two Group RM Design ........................... 97 
Table 3:  Revised Diabetes Health Belief Model Questionnaire                 
Formulae .......................................................................................... 110 
Table 4:  Reliability of Health Belief Scales and Subscales.............................. 113 
Table 5:  Cronbach Alpha Results for Health Belief Scales and               
Subscales at Times 1 and 2 ............................................................. 115 
Table 6:  Diabetes Self-care Practice Assessment........................................... 121 
Table 7:  Matrix of the Educational Sessions and Applications of                       
the Expanded Health Belief Model Concepts ................................... 136 
Table 8:  Characteristics of Study Population Before Education             
Intervention....................................................................................... 148 
Table 9:  Baseline Characteristics by Treatment Group: Categorical        
Covariates ........................................................................................ 154 
Table 10:  Baseline Age, Health Belief Scores, and Hemoglobin               
(HgbA1c) by Group........................................................................ 156 
Table 11:  Characteristics of Completers vs. Dropouts:  Categorical       
Covariates...................................................................................... 161 
vi 
Table 12.  Characteristics of Completers vs. Dropouts: Continuous        
Covariates at Baseline................................................................... 163 
Table 13.  Characteristics of Completers vs. Dropouts by Treatment              
Group:  Categorical Covariates...................................................... 168 
Table 14.  Characteristics of Completers vs. Dropouts by Treatment Group:  
Continuous Covariates .................................................................. 172 
Table 15.  Baseline Characteristics by Treatment Group for Those with  
Complete Follow-up: Categorical Covariates................................. 177 
Table 16:  Baseline Characteristics by Treatment Group for Those with  
Complete Follow-up:  Continuous Covariates................................ 191 
Table 17:  Results from Repeated Measures ANOVA Analysis of        
Hemoglobin at Weeks 1, 12, and 24, Control vs. Intensive............ 185 
Table 18:  Hemoglobin (Hgb1ac) at 1-year Follow-up ...................................... 187 
 
 
vii 
 
 
List of Figures 
Figure 1:  Study Design ...................................................................................... 38 
Figure 2:  Theoretical Framework: Factors Influencing Metabolic Control              
of Diabetes ......................................................................................... 63 
Figure 3:  Model of Diabetes Education.............................................................. 67 
Figure 4:  The Health Belief Model as Predictor of Diabetes Self-care       
Behavior ............................................................................................. 85 
Figure 5:  Pilot Study Results ........................................................................... 102 
Figure 6:  Loss to Follow-Up............................................................................. 160 
Figure 7:  Mean Hemoglobin at Weeks 1, 12, and 24 by Group....................... 186 
Figure 8:  Baseline Health Belief Profiles by Group.......................................... 189 
Figure 9:  Week 24 Health Belief Profiles by Group ......................................... 190 
Figure 10:  Health Belief Profiles in Differences from Baseline to                   
Week 24 by Group......................................................................... 191 
Figure 11:  Health Belief Profiles at Weeks 1 and 24 by Group........................ 192 
 
 
viii 
The Effects of American Diabetes Association (ADA) Diabetes Self-
Management Education and Continuous Glucose Monitoring on Diabetes 
Health Beliefs, Behaviors and Metabolic Control 
 
 
Jodee Meisenhelder-Smith 
 
 
ABSTRACT 
 
 
The purpose of this study was to determine whether adults with type 2 
diabetes participating in American Diabetes Association (ADA) diabetes self-
management education (DSME) randomly assigned to an intensive follow-up 
group (IFG), utilizing continuous glucose monitoring system (CGMS), or a 
standard follow-up group (SFG) have any significant differences in mean HgbA1c 
values and health belief scores over time. Baseline HgbA1c values and health 
beliefs were measured using the revised Expanded Health Belief Model (HBM) 
questionnaire.  The questionnaire measured the 8 HBM domains: perceived 
susceptibility; severity; treatment benefit; cues to action; motivation; barriers; self-
efficacy and structural elements.   Twelve weeks after DSME, patients returned 
for follow-up based on random assignment.  The SFG received routine follow-up 
care:  HgbA1c measurements; behavioral goals and education assessments.  
The IFG received routine follow-up and CGMS.  Patients wore the CSMS for 72 
hours and recorded their daily food, blood glucose values, medications and 
ix 
physical activities. Results were analyzed and reviewed with patients.  Both 
groups returned in 24 weeks for HgbA1c measurements and to complete the 
HBM questionnaire.  A repeated measure ANOVA analysis showed a statistically 
significant reduction in mean HgbA1c at each time period (F=86.75. p>.0001 ) 
from week 1 to week 12 (SFG 8.6-7.1; IFG 8.5 –7.1,) and from week 12 to week 
24 ( SFG 7.1 to 6.9; IFG 7.1 – 7.0). There were no significant differences found 
between the groups.  (F = 0.17 p > 0.87). Following DMSE and follow-up 
intervention some health belief scores improved but no significant differences 
were found between groups except for severity scores. (SFG 27.05, IFG 25.00, 
p=0.03).  The power of the study to detect small differences between the groups 
was affected by the higher than anticipated attrition and the significant lowering 
of HgbA1c in the education arm of the study.  Both groups achieved a high 
success rate (58% IFG; 55% SFG) to lower the HgbA1c to the ADA goal of less 
than 7.  DSME and follow-up care (both standard follow-up and more intensive 
follow-up) achieved a significant lowering of HgbA1c (1.6%), which has been 
shown to reduce diabetes related morbidity and health costs. 
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Chapter One:  Introduction 
Diabetes mellitus is a major public health concern associated with 
substantial morbidity, mortality, health care utilization, and costs (American 
Diabetes Association, 2005; Wagner, Sandhu, Newton, McCulloch, Ramsey, & 
Grothaus, 2001; Gilmer, O ’Connor, Manning, & Rush, 1997; Carter Center of 
Emory University, 1985; Ray, Thamer, Taylor, Fehrenbach, & Ratner, 1996; Ray, 
Willis, & Thamer, 1993; Rubin, Altman, & Mendelson, 1994; UKPDS Group, 
1998; Westerhall, Olson, & Destafano, 1992; Winburger, Cowper, Kirkman, & 
Vinicor, 1990).  The Centers for Disease Control and Prevention (CDC)) 
estimates over 20 million Americans are afflicted with the disease (CDC, 2006).  
Diabetes contributes to nearly 200,000 deaths annually, and is the leading cause 
of kidney failure, blindness, leg and foot amputations.  Persons with diabetes are 
between two and four times more likely to have heart disease, and five times 
more likely to have a stroke than non-diabetics (Bellenir & Dresser, 1995).  The 
estimated direct and indirect costs of diabetes are $132 billion (ADA, 2005). 
Research over the past decade has found that many diabetes-related 
complications once thought to be an inevitable progression of the disease can be 
prevented with strict glycemic control.  The Diabetes Control and Complications 
Trial (DCCT, 1993) demonstrated that by keeping blood glucose levels as close 
to normal as possible, microvascular complications such as retinopathy, 
 2 
neuropathy, and nephropathy can be averted.  Patients with insulin dependent 
diabetes mellitus (IDDM) who already showed early vascular complications were 
able to slow the progression of their complications with tight glycemic control.  
Fishbein and Palumbo (1995) also reported delay of onset and slowing of 
progression of diabetes-related complications.  Several studies, including the 
DCCT, provided overwhelming evidence that a direct relationship exists between 
the level of glycemic control and the risk of developing complications such as 
diabetic retinopathy, neuropathy, nephropathy, and other vascular complications 
(DCCT, 1993; Klein, Klein, Moss, Davis, & DeMets, 1984; Nathan, Singer, 
Godine, Harrington, & Permuter, 1986; Ohkubo, et al., 1995; UKPDS 33, 1998). 
In the United Kingdom Prospective Diabetes Study (UKPDS), a clear relationship 
between control of hyperglycemia and reduction of diabetes morbidity and 
mortality with type 2 diabetes strengthened the evidence for aggressive glycemic 
control in all diabetes populations. 
Intensive diabetes management has relied heavily on blood glucose 
monitoring.  Persons with diabetes who regularly monitor their blood glucose 
levels and work closely with their healthcare providers have fewer diabetes 
complications. In one study, people who increased the frequency of their self-
monitoring of blood glucose or exercise after attending DSME lowered their 
HgbA1c by a mean of 2.9% (Clement 1995). The International Diabetes Center, 
(IDC,2001) practice guidelines recommend type 2 patients not on insulin should 
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test their blood glucose three times per day when newly diagnosed, adjusting 
therapy if test results are outside the target range. Type 2 patients on insulin 
should test their blood glucose four times a day. 
Diabetes care requires a high degree of self -care.  Persons with diabetes 
are often asked to make major lifestyle changes such as practicing glucose self-
monitoring, maintaining reasonable body weight, adjusting meal composition, 
size, and timing, following a medication regimen and performing other preventive 
practices.  Behavioral changes such as modifying food intake and exercise were 
found to be the most difficult adjustments to make (Robiner & Keel, 1997). 
Simplifying regimen complexity and providing guidance about the specific meal 
plan or exercise recommended may help overcome perceived barriers.  Glucose 
monitoring barriers such as fear of needles and soreness to fingers can be 
addressed to increase patient’s acceptance and willingness to practice self-
monitoring.  New glucose monitoring techniques can be used to help identify 
glucose excursions and help patients understand the importance of monitoring 
their blood glucose levels.  New, less invasive glucose monitoring procedures 
can assist in motivating the patient as to the importance of the various diabetes 
therapies. 
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A new glucose monitoring device approved by the Food and Drug Administration 
(FDA) in 1999, the Continuous Glucose Monitoring System (CGMS) developed 
by MiniMed Inc., provides a novel and minimally invasive technique that 
continually measures glucose levels using a miniscule (0.5ul) sample of dermal 
interstitial fluid.  The CGMS records tissue glucose levels at five-minute intervals 
for up to three days.  Previous studies have shown that dermal interstitial glucose 
measurements by the CGMS closely correlate to capillary glucose meter 
measurements and venous blood laboratory values (Jansson, Fowelin, Smith, & 
Lonnroth, 1988; Service, O’Brien, Wise, Ness, & LeBlanc, 1997; Bolinder, 
Hagstrom-Toft, Ungerstedt, & Arner, 1997). 
Although capillary self-monitoring of blood glucose (SMBG) levels has 
been a mainstay in intensive management of diabetes, the true variations in 
blood glucose levels may not be detected by conventional SMBG recording. The 
glucose sensor data in conjunction with frequent SMBG measures can be helpful 
to identify glucose excursions including asymptomatic hypoglycemia.  The 
information obtained from the sensor can facilitate decisions concerning diabetes 
management and provide evaluation of treatment options.  The sensor may also 
be used to help patients see the glycemic effects of food intake and exercise 
directly, and may motivate or act as cues to facilitate behavior change.  A pilot 
study using the MiniMed continuous glucose monitoring system in nine poorly 
controlled type 1 subjects (mean HgbA1c 9.9%) showed a reduction of mean 
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HgbA1c to 8.8 % in a five-week period (Bolinder, Hagstrom-Toft, Ungerstedt, & 
Arner, 1997).  This study attempts to evaluate the potential for continuous 
glucose monitoring to identify glucose patterns and help patients understand why 
appropriate changes in their diabetes management is needed.  During the follow-
up visit perceived barriers to self-care can be addressed.  Patients can be 
assisted with any difficulty in following their meal plan, exercise, taking their 
medications or monitoring blood glucose. 
Achieving good metabolic control is dependent on effectively educating 
and motivating the person with diabetes to comply with the medical regimen and 
adopt certain self-care behaviors.  This study seeks evidence as to whether the 
data obtained from the sensor can lead to improved HgbA1c values by facilitating 
understanding of patient-specific patterns of glucose control and in facilitating 
diabetes self-management.  The proposed hypothesis also suggests that patients 
receiving intensive follow-up care are more likely to improve their diabetes self-
management behaviors, and thus, improve their glycemic control than those 
receiving standard follow-up care. 
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Diabetes Self-Management Education 
The concept of diabetes education is not new.  Diabetes education has 
been viewed by experts as an essential part of diabetes care.  Dr. Elliott P. 
Joslin, one of the pioneers of diabetes education and creator of the renown Joslin 
Diabetes Clinic in Boston, Massachusetts, stated that “the diabetic who knows 
the most lives the longest” (Krall, 1985, p. 465).  Clement (1995, p. 1204), 
defined diabetes self-management education as a “process of providing the 
person with diabetes with the knowledge and skills needed to perform self-care, 
manage crises, and make lifestyle changes required to successfully manage this 
disease.” 
Most researchers agree that a minimal threshold level of diabetes 
knowledge is essential before any improvements in metabolic control can be 
expected.    Factors such as the patient's beliefs, attitudes, medical treatment, 
medical history, psycho-social support, and environment may also influence 
whether a person with diabetes is willing or able to make the necessary 
behavioral changes to improve metabolic control  (Alogna, 1980; Anderson, 
Fitzgerald, & Oh, 1993; Ary, Toobert, Wilson, & Glasgow, 1986; Beeney & Dunn, 
1990; Cerkoney & Hart, 1980; Glasgow, Hampson, Strycker, & Ruggiero, 1997; 
Haire-Joshu, 1988; Herman & Dasbach, 1994; Rubin & Peyrot, 1992; Schafer, 
McCaul, & Glasgow, 1986; Schlenk & Hart, 1984).  Meta-analyses of diabetes 
education by  Norris (2003), Brown (1993; 1988) and Padgett, Mumford, Hynes, 
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and Carter (1988) concluded there is an overall beneficial effect of diabetes 
education. 
Although these earlier studies unanimously reported the beneficial effects 
of diabetes education, they seldom focused on tangible clinical outcomes such 
as improved glycemic control, reduced incidence of diabetes-related 
complications, decreased utilization of health care, or healthcare costs.  One 
exception, a study conducted by Miller, Goldstein, and Nicolaisen (1978), found 
that after implementing a comprehensive diabetes self-management training 
program, the rate of acute complications requiring hospitalization was reduced.  
This dramatic reduction in complications was estimated to save three million 
dollars in healthcare costs. 
During the 1970s, groups such as the American Diabetes Association 
(ADA), the American Association of Diabetes Educators (AADE), and the 
Diabetes Education Study Group (DESG) of the European Association began 
initiatives to establish diabetes education standards.  These standards were 
designed to provide more structure and less variability in quality of education 
received by patients with diabetes.  In 1983, the National Diabetes Advisory 
Board established by Congress developed the National Standards for Diabetes 
Education.  Diabetes self- management education (DSME) programs accredited 
and recognized by the American Diabetes Association can be measured in terms 
of structure, process, and outcomes.  Program content was standardized to 
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include an overview of diabetes, stress and psychosocial adjustment, family 
involvement and social support, nutrition, exercise and activity, medications, 
blood glucose monitoring and ketone testing, interpretation and application of test 
results, relationships among nutrition, exercise, medications, and blood glucose 
levels, prevention, detection, and treatment of acute and chronic complications, 
foot, dental and skin care, behavioral change strategies, benefits of good 
glycemic control, community resources, and special considerations for travel, 
sick days, and pregnancy (ADA, 1996b; 1998).  The National Standards for 
DSME are designed to define quality diabetes self-management education that 
can be implemented in diverse settings and will facilitate improvement in health 
care outcomes. Standards are, therefore, periodically reviewed and revised to 
reflect advances in scientific knowledge and health care. 
ADA approved programs must have standardized curricula that meet the 
needs of their target population.  Instructional objectives are assessed to ensure 
that patients are equipped with the knowledge and skills to manage their 
diabetes day-to-day.  Participants practice self-care skills such as insulin 
administration, glucose monitoring, meal planning, and getting actively involved 
in planning goals and strategies to overcoming barriers to self-care.  Programs 
meeting the standards set by the National Advisory Board are recognized and 
accredited by the American Diabetes Association.  ADA approved education 
programs employ a goal-oriented, empowerment approach that may enhance the 
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patients' ability to identify and accomplish realistic goals.   Problem-solving and 
coping skills are also utilized to help patients and their families deal with the 
barriers that interfere with goal achievement.  ADA approved programs employ 
multi-disciplinary team members who must meet stringent qualifications such as 
having valid professional licenses and registration, and experience in their area 
of expertise.  Certification as diabetes educators is recommended and 16 hours 
of approved diabetes education principles are required per year. 
Studies have shown that structured diabetes self- management education 
programs have been successful at improving metabolic control (Garrard, Mullen, 
Joynes, McNeil, & Etzwiler, 1990; Glasgow, Toobert, & Hampton, 1992; 
Mazzuca, et al., 1986; Peyrot & Rubin, 1994).  Reductions in the number of 
hospitalizations, ketoacidosis episodes, and amputations have been attributed to 
comprehensive diabetic education programs (Miller & Goldstein, 1972; 
Mulhauser, et al., 1983).  Structured diabetes education that stresses both 
knowledge and self-care behaviors assumes a causal path from learning to 
changed patient performance, and from altered performance to changes in 
clinical and psychosocial outcomes (Mazzuca, et al., 1986).  
Peyrot and Rubin (1994) found that patients who improved their diabetes 
self-care behaviors improved their glycemic control.  Assessment of the priority 
populations needs help to maximize the effectiveness of self-management 
education.  Educational programs that identify demographic variables, ethnic 
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background, formal education level, diabetes health beliefs, barriers to 
participation, and other factors in diabetes self-management are more effective 
than ones just applying a didactic approach (Ingersoll, Orr, Herold, & Golden, 
1986; Peyrot & Rubin, 1988; Rubin, Peyrot, & Saudek, 1993; Skyler, Seigler, & 
Reeves, 1982). 
Peyrot and Rubin (1994) suggested in their study that it is possible to help 
patients who are at different levels of self-care proficiency.  A step-wise approach 
to diabetes self-care management helping individuals to improve where they 
need the most improvement can favorably influence their glycemic control.  
Whereas some patients may advance from not adhering to certain aspects of 
diabetes care to better adherence, others may acquire advanced self-care skills.  
For DSME to reduce HgbA1c values, participants must not only learn the 
diabetes care skills, but also be motivated to maintain them.  A further goal of 
diabetes education is to help patients develop coping skills to overcome their 
attitudinal and emotional barriers to different aspects of diabetes management.  
Educators discuss potential options for addressing problematic situations. 
     The most frequently utilized behavioral model for understanding and 
predicting diabetes self-care behavior is the expanded Health Belief Model.  
Although the model is concerned with the person’s objective environment, and 
past history and experience, the main concern is with the person’s subjective 
state or personal orientation.  The Health Belief Model (HBM) proposes that a 
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person is likely to take action concerning a health condition if the perceived 
benefits of action outweigh the perceived costs or barriers.  Barriers are defined 
“as those things which arouse negative feelings or attitudes toward a given 
action” (Salazar, 1991, p. 129).   Even if an action is perceived as beneficial in 
reducing a threat, if it is also perceived as inconvenient, expensive, unpleasant, 
painful or upsetting, the person may still decide not to take action.   
A variable added recently to the HBM to strengthen its ability to predict 
and explain behavior is Bandura’s concept of self-efficacy (1977a; 1977b; 1992).  
Self-efficacy is defined as an individual’s beliefs about their ability to perform the 
behavior.  Bandura postulated that self-efficacy is one of the most important 
prerequisites for behavior change. 
The Expanded Health Belief Model (Burns, 1992), which incorporated self-
efficacy, has been useful in explaining why some persons with diabetes are able 
to improve their metabolic control post-intervention and others are not (Alogna, 
1980; Becker, Maiman, Kirscht, Haefner, & Drachman, 1977; Cerkoney & Hart, 
1980; Harris, et al., 1982; Harris, Linn, Skyler, & Sandifer, 1987; Pham, Forton, & 
Thibaudeau, 1996; Wdowik, Kendall, & Harris, 1997).  The Expanded Health 
Belief Model theorizes that for persons to modify behavior, they must perceive 
the benefits are greater than the perceived disadvantages.  The Expanded 
Health Belief Model is especially useful when explaining how the patient's 
attitudes can influence self-care behaviors, and ultimately, metabolic outcomes.  
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Applying the components of the Health Belief Model, (the perceived susceptibility 
to diabetes related complications; perceived severity or threat of these 
complications; perceived benefits of averting these complications; perceived 
psycho-social and financial cost of treatment, perceived self-efficacy) help to 
predict who will be compliant with diabetes self-care behaviors.   
In a comprehensive review, Janz and Becker (1984) provided strong 
empirical support for the HBM and recommended that the dimensions of the 
HBM be incorporated into health education programs.  This review identified 
perceived barriers as being the most powerful dimension of the HBM.  The 
second most powerful dimension was perceived susceptibility. The study 
concluded that educators should identify and focus on perceived barriers and 
perceived susceptibility.  The Expanded HBM is especially useful in diabetes 
management where focus on lifestyle behavior requires long-term changes.  
People must not only feel the benefits outweigh the cost to perform and sustain 
diabetes self-care behaviors, but they also must feel competent to make the 
desired changes in behavior. 
Numerous studies related to health behavior have examined self-efficacy.  
Strecher, DeVillis, Becker, and Rosenstock (1986) reviewed 21 studies 
employing the self-efficacy construct and found self-efficacy to be a strong 
predictor of success at changing health behaviors.  In a similar review of self-
efficacy studies, Lawrance and McLeroy (1986) concluded that self-efficacy was 
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a strong predictor of behavior.  
Programs that address these beliefs and help motivate patients to modify 
their lifestyles, by developing coping and problem-solving skills to overcome 
barriers to self-care, have been more successful at improving glycemic control 
(Garrard, et al., 1990; Mazzuca, et al., 1986; Mulhauser, et al., 1987; Peyrot & 
Rubin, 1988; Peyrot & Rubin, 1994; Rubin, Peyrot, & Saudek, 1991; Rubin, 
Peyrot, & Saudek, 1993; Wooldridge, Wallston, Graber, Brown, & Davidson, 
1992).  The intensive follow-up is hypothesized to motivate patients to modify 
their exercise and food intakes by providing a better understanding of their 
glycemic effects as observed by the continuous glucose sensor. The data 
obtained from the sensor can be used to teach patients how their lifestyle affects 
their metabolic control, and what they can do to control blood glucose levels.  
Numerous studies demonstrate that health beliefs are positively correlated 
with diabetes self-care adherence (Alogna, 1980; Cerkoney & Hart, 1980; Harris 
& Linn, 1985; Kirscht, 1974; Kirscht, 1976; Maiman & Becker, 1974) and that 
both health beliefs and adherence to diabetes self-care are correlated with 
glycemic control (Harris & Linn, 1985; Schafer, Glasgow, McCaul, & Dreher, 
1983). 
Wooldridge, et al. (1992) found that Hgb A1c improved significantly from 
pre- to post-education in a subgroup of patients who also improved health 
beliefs; however, they were unable to associate these improvements with self-
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reported adherence or Hgb A1c directly. The question as to whether improvement 
of health beliefs and attitudes towards diabetes can be achieved by diabetes self-
management education, and whether these changes can in turn, improve 
diabetes  self-care behaviors and glycemic control, need to be answered.  
The proposed study will attempt to answer this question by employing a health 
belief assessment tool, the Expanded Health Belief Model Questionnaire, to 
assess health beliefs, attitudes, diabetes self-care adherence, and other factors 
that influence diabetes control before and after an educational intervention. A 
standard follow-up group will be compared to those in an intensive follow-up 
group pre-intervention (week1), and at the 24th week post follow-up. 
Using the patient assessment and the revised Expanded Health Belief 
Model Questionnaire (EHBMQ), the diabetes educators during the education and 
follow-up intervention will attempt to modify beliefs and attitudes that received a 
poor or low score (<2).  To improve low scores on perceived benefits/importance 
of care, the diabetes educator will emphasize that diabetes is a serious disease 
with short- and long-term complications; will describe microvascular and 
macrovascular complications and their relationship to chronic high blood glucose 
levels; and will describe diabetes hyperosmolar coma, symptoms of uncontrolled 
diabetes and their relationship to high blood glucose levels.  For those scoring 
low on perceived benefits of treatment, emphasis on consequences of poor 
control will be discussed.  Benefits of preventing complications, increased well-
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being and physical health will be stressed.  The psychological aspects of being in 
control of diabetes rather than being controlled by the disease will be 
emphasized.  Participants with a poor score on barriers will be assisted in 
identifying and dealing with specific barriers to self-care management.  For 
patients scoring low on perceived ability, the educator will emphasize that all 
diabetes self-care skills can be learned.  Self-confidence can be enhanced by 
teaching coping skills, and assisting participants in mastering self-management 
skills.  Patients will be assisted in forming their own behavioral goals, and setting 
up personal contracts. 
The literature suggests that the response to comprehensive diabetes 
education is complex and is mediated by a number of variables.  Patient 
characteristics such as type and mode of therapy, co-morbidity, duration of 
disease, ethnicity, educational background, socio-economic background, and 
age are among the numerous factors that can all influence response to education 
efforts (Anderson, Wolf, Burkhart, Cornell, & Bacon, 1989; Glasgow, Toobert, & 
Hampson, 1992; Irvine, Saunders, Blank, & Carter, 1990; Jacobson, Adler, 
Wolfsdorf, Anderson, & Derby, 1990; Wing, Epstein, Norwalk, Scott, & Gooding, 
1987).  To control the influence of these factors a random assignment to either 
the control or the intervention group and the incorporation of a repeated measure 
design will be used to decrease systematic error and individual variance. 
Several subgroups exist within the diabetes patient population.  These 
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groups are based on treatment type.  Treatments may include diet control, oral 
diabetes medications, and insulin.  Treatment type can act as a cofounder.  The 
literature suggests that patients receiving insulin may have different health beliefs 
and Hgb A1c values than those treated without insulin (Greene, et al., 1991; 
Hartwell, et al., 1986; Jacobson, et al., 1990; Mulhauser & Berger, 1993; Peyrot 
& Ruben, 1988).   
The study sample will be limited to persons with type 2 diabetes.  After 
blocking for insulin use and applying randomization, the groups tends to equalize 
with sample size. The groups will be evaluated for any pre-intervention 
differences that may confound the results.     
In some studies (Glasgow, et al., 1997; Wooldridge, et al., 1992) the 
expanded HBM has been used to not only identify and explain diabetes self-care 
behavior, but also to address these beliefs and help motivate persons with 
diabetes to modify their lifestyles.  Educational programs focused on helping 
participants develop coping and problem-solving skill help to overcome barriers 
to self-care.  These studies have provided strong evidence that those programs 
that can modify  health beliefs and improve self-care performance are successful 
at improving glycemic control. 
The extent to which ADA diabetes self-management education and 
subsequent follow-up care modify self-care behaviors and beliefs, thereby 
improving HgbA1c values, needs to be assessed.  Comparing these variables 
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pre- and post-intervention will help determine if the proposed intervention has an 
effect on psychosocial factors such as attitudes, beliefs, self-care adherence, 
understanding of diabetes, self-care skills and social support.  Does intensive 
follow-up care make a difference or is standard follow-up just as effective?  
Standard follow-up care consists of a 12th week evaluation of individualized 
behavioral and educational goals and objectives and post-HgbA1c determination.  
Intensive follow-up differs from standard follow-up care by use of the continuous 
sensor placed during their 12-week follow-up visit.  The sensor is worn for 72 
hours while maintaining their usual daily activities.  Physical activities, 
medications, blood glucose readings and food intake are recorded on a daily log.  
The subjects return for removal of the sensor and the glucose data are 
downloaded to the computer.  The information gathered during the sensor period 
is examined and used to help patients make appropriate lifestyle changes. The 
glycemic effects due to food intake and exercise can be illustrated to the 
participant, possibly motivating the person to perform certain diabetes self-care 
behaviors.  Strategies are then developed to help overcome obstacles to 
diabetes management.   
The expanded HBM was selected to provide the theoretical framework for 
this study because the model has been significantly related to health behaviors 
and enables the practitioner to design interventions that focus on mutable factors 
such as beliefs, attitudes, and self-efficacy that can be influenced by education. 
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Statement of the Problem 
Despite the establishment of diabetes education standards more than a 
decade ago, most diabetes education offered to patients has consisted of piece-
meal instructions, at best (Clement, 1995).  Coonrod, Harris, and Betschart 
(1994) found that in a representative sample of the U.S. adult population with 
diabetes, only 35.1% had ever attended a diabetes education class.   Even more 
alarming was the fact that more than 75% of persons with type 2 diabetes had 
never received formal diabetes education.  Similarly, Snyder (1996) reported that 
65% of patients receive no diabetes education.  Despite the existence of 
diabetes standards of care recommendations for HgbA1c determinations -- 
minimally once or twice a year for type 2 patients with stable control and 
quarterly for those who required changes in diabetes therapy or in poor control -- 
only 40% had HgbA1c determinations (ADA, 2001). 
Fueled by the escalating cost of health care and the high healthcare 
utilization by persons with diabetes, controversy and debate continue as to 
whether diabetes education can effectively improve glycemic control and improve 
self-care behaviors.  Researchers, healthcare providers, and the person with 
diabetes need to arrive at some mutual agreement on what defines 
“effectiveness.”  Barnard (1938) defined effectiveness as “the accomplishment of 
recognized objectives of cooperative effort.”  This definition is especially 
applicable here where multiple perspectives need to be considered. 
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Diabetes education programs must not only be evaluated on whether they 
effectively lower Hgb A1C levels, but whether they foster changes in attitudes, 
beliefs, and diabetes self-care behaviors.  Standards provide a benchmark for 
quality for DSME based on a combination of best practice and best scientific 
evidence.  Standards of diabetes care are continually updated evolving as new 
evidence warrants.  New technologies offer health professionals new tools to 
evaluate diabetes management.  If persons receiving intensive follow-up 
employing these new technological advances have better outcomes, important 
evidence for a new standard of diabetes management will have been identified.    
The use of home glucose monitoring has become the mainstay of 
intensive management despite its limitations in detecting true variations in 
glucose levels.  Studies have shown that patients who are willing to monitor their 
blood glucose levels regularly and work with health professionals have lower 
HgbA1c values and fewer diabetes-related complications (Peyrot & Rubin, 1994; 
DCCT, 1993).  Despite growing evidence for tighter control, many patients do not 
receive adequate training or management of their diabetes.  To obtain optimal 
blood glucose control, patients are asked to make major lifestyle changes such 
as following a meal plan, monitoring their blood glucose, taking their medications, 
and getting regular exercise.  Diabetes self-care is demanding and frequently 
involves tasks that are unpleasant such as fingersticks, food restrictions or insulin 
injections.  Following a meal plan and exercising cause the greatest difficulty.    
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Lack of proper training is often to blame.  In one survey, 90% of the patients 
surveyed with diabetes never received diet instructions.  Many patients are told 
to lose weight and to exercise, but are given no instructions as to what to eat or 
what amount or mode of exercise is best (Ford & Herman, 1995). 
In addition, few type 2 patients are instructed to use a glucose meter or 
how to interpret the values they obtain.  The utility of SMBG depends on several 
factors such as the accuracy, the frequency of testing and ability to use the data 
to make daily diabetes care decisions.   Long-term glucose control may not 
improve unless frequency of testing is increased to five times a day.  Increasing 
the frequency of glucose monitoring is viewed by many authorities as unrealistic 
in light of the U.S. survey that reports that even among type 1 patients, only 
about 20% tested their own blood glucose. Of those type 1 patients participating 
in self-testing, only 15% tested blood glucose at least three times a day.  Harris 
et al. (1993) reported in a diabetes self-care survey of 1895 respondents that 
67% of patients did not monitor their own blood glucose levels. The most 
common reasons given for noncompliance were finger soreness, pain, 
inconvenience and fear of needles.  Although glucose monitoring has improved 
by requiring less blood, many patients still fail to test the recommended 
frequency.  Barriers such as soreness from multiple punctures, lack of ability to 
use the data obtained, or lack of insurance coverage for training and supplies are 
commonplace.  
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Many patients are taught the mechanics of how to use a glucose meter 
but receive little training in how to use the glucose data.  Harris et al. (1993) 
found that the frequency of home glucose monitoring was related to whether 
patients had received diabetes self-management education or not.  Those who 
had DSME were three times more likely to monitor their blood glucose levels at 
least daily than those who had no formal education.  Diabetes educators rely on 
SMBG to teach patients daily decision making.  The glucose results can be used 
to reinforce food intake decisions such as limiting carbohydrate portions to lower 
post prandial blood glucose levels, and to reinforce the beneficial glucose effects.  
Strategies to overcome the patients’ barriers to monitoring included use of 
alternate site glucose testing, use of less invasive glucose monitoring sensors, 
and proper training of the use of data. 
Further studies are needed to evaluate whether glucose data obtained 
from conventional blood glucose monitoring is adequate for making daily 
diabetes care decisions and for determining the necessary frequency of testing.  
Preliminary studies found that using a less invasive method of continuous 
glucose monitoring with the Minimed sensor was able to reflect the true 
variations that occur during ordinary daily life that were missed by conventional 
SMBG.  The sensor data were useful in making decisions regarding the effects of 
medication, food intake, and exercise.  Bode (1999) found in a five-week pilot 
study with nine type 1 patients, HgbA1c values were lowered significantly using 
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the sensor to adjust therapies. The sensor also may be useful to show patients 
the effects of their food choices on their blood glucose levels.  Sensor data 
coupled with a log that documents food intake, medications and activities can be 
used to assess glucose trends and provide feedback to the patient. 
A myth that compromises diabetes care is that glucose monitoring and 
diabetes education are only for persons with diabetes that requires insulin.  The 
findings of the UKPDS study (1998) provided strong support of the ADA’s 
position that rigorous treatment of  type 2 diabetes  is needed as well to lower 
HgbA1c levels and prevent complications.  For every 1% reduction in HgbA1c, 
microvascular complications were lowered 35%.  Despite the growing evidence 
that strict glycemic control is important in type 2 patients, the third National 
Health and Nutrition Examination Survey (NHANES III) showed the majority of 
patients with type 2 diabetes had HgbA1c levels over 8% (Harris, Eastman, 
Cowie, Flegal & Eberhardt, 1999).  Nationally, the mean HgbA1c for the diabetes 
population was 9.2%.  The same survey revealed that 59% of patients with 
diabetes never practiced SMBG.  Only 11% to17% practiced SMBG at least once 
a day.  ADA recommends blood glucose testing in type 2 patients at least twice a 
day. 
Inadequate diabetes care practices by healthcare providers may be 
partially to blame.  In an HMO setting survey by Peters, Legorreta, Ossorio, and 
Davidson (1996), only 44% of the diabetes patients had HgbA1c levels tested at 
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least twice a year. The ADA (2001) recommends that healthcare providers 
conduct thorough medical examinations, physical and laboratory examinations 
including HgbA1c, and formulate a complete management plan with the diabetes 
team and patient. 
Investigators still have been unsuccessful at overcoming the many 
obstacles of study design and methods that plagued earlier studies.  They have 
found it difficult to separate the effects of diabetes education from medical 
treatment and other demographic, psychosocial, and clinical factors that 
influence glycemic control.  The major obstacle to performing a long-term, 
prospective, randomized clinical trial is the ethical issue of denying education to a 
control group.  No long-term comparisons can be made between the metabolic 
outcome of an education group versus a no-education group. When comparing 
various types of education interventions compared to a control there is a smaller 
treatment effect requiring impractical sample sizes.  Long term studies have  
more difficulties distinguishing the effectiveness of diabetes education from 
diabetes treatment and other factors (Bloomgarden, et al., 1987; Clement, 1995; 
Delamater, et al., 1991; Hanefeld, et al., 1991; Kaplan, Hartwell, Wilson, & 
Wallace, 1987; Korhonen, et al., 1983; Litzelman, et al., 1993; Mazzuca, et al., 
1986; Raz, Soskolne, & Stein, 1988; Rettig, Shrauger, Recker, Gallagher, & 
Wiltse, 1986; Vanninen, Uusitupa, Siitonen, Laitinen, & Lansimies, 1992; Vinicor, 
et al., 1987).   
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The International Diabetes Center in Minneapolis (2001) used a staged 
diabetes management approach. During the medical nutritional stage they 
reported that up to a 1% reduction in HgbA1c may be expected.  In the oral agent 
stage, a cumulative 2% reduction of HgbA1c may be expected.  The combination 
oral agent stage or combination oral agent and insulin stage has a potential 2% 
to 4% reduction in HgbA1c values.  The various insulin stages have a 4% or 
greater potential reduction in HgbA1c values. 
Prior to the 1980s, no universal standards for diabetes education were in 
place.  Diabetes education being evaluated in studies varied tremendously in its 
intensity and composition as well as the type of sample population employed.  
Early studies could only suggest that certain educational interventions might be 
helpful in some populations, but could not generalize to other populations 
(Clement, 1995). These early studies failed to describe the education 
interventions adequately, or the basic education being compared.  Both the 
education intervention and the basic education varied from study-to-study, 
making comparisons difficult.  In some studies, basic education consisted of 
printed education materials and verbal instructions given to patients from their 
physician’s office (Delamater, et al., 1991; Litzelman, et al., 1993; Mazzuca, et 
al., 1986).  Others defined their control as those receiving minimal education 
from a dietitian and physician (Korhonen, et al., 1983; Raz, et al., 1988; Rettig, et 
al., 1986) or no specific education (Hanefeld, et al., 1991). 
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Purpose of the Study 
The purpose of the study is to determine if persons with type 2 diabetes 
participating in ADA diabetes self-management education (DSME) assigned to 
an intensive follow-up group achieve any significant differences in capillary 
HgbA1c values over time compared with controls receiving standard follow-up 
care.  Intensive follow-up differs from standard follow-up by utilizing the MiniMed 
continuous glucose monitoring system (CGMS) to analyze glucose patterns and 
responses to exercise, medications, food intake and daily activities.  During the 
DSME and follow-up sessions, educators will help patients identify factors that 
influence their diabetes-related behaviors including health beliefs, self-efficacy, 
self-care and coping skills.  Educators help patients identify diabetes-related 
problems and behaviors that are constructive or non-constructive in regards to 
meeting their diabetes goals.  The main objective of the study is to determine 
whether a statistically and clinically significant difference exists in the level of 
glycemic control between a randomly assigned intensive follow-up group after 
participating in diabetes self-management education and the standard follow-up 
group.  The second aim of the study is to determine if diabetes behavior and 
beliefs change differently following DSME for the intensive follow-up group 
compared to the standard follow-up group.  To examine the effectiveness of 
DSME and follow-up on these variables, a preliminary psychosocial assessment, 
the Expanded Health Belief Model Questionnaire, will be used.  Comparing these 
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variables pre- and post-intervention will help determine if the education and 
follow-up interventions result in any changes in diabetes-specific attitudes, 
beliefs, understanding, and adherence to recommended self-care procedures. 
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Significance of the Problem 
Mortality from diabetes has declined since the discovery of insulin.  
However, the growing number of people with the disease, and its chronic and 
debilitating nature, pose a major public health and clinical concern.  Diabetes is 
associated with higher hospitalization rates, greater length of stay, and greater 
hospital costs (ADA, 2005,1998b; Ray, et al., 1996).  Nationally, diabetes costs 
the health care system nearly $132 billion annually.  The 1992 estimates put the 
cost of health care for people with diabetes at approximately $11,157 per person 
compared to $2,604 for people without diabetes.  Today, on average, each 
hospitalized patient with diabetes costs $25,000 compared to $12,200 for 
patients without diabetes.  Nearly 15% of the total U.S. healthcare expenditures 
is spent on the 6% of the population with diabetes.  One out of every seven 
health care dollars is spent on diabetes.  Current estimates for both direct and 
indirect cost exceed $132 billion (ADA, 2005 1998b; Bellenir & Dresser, 1995; 
Ray, et al., 1993; Rubin, et al., 1994). 
The current cost associated with diabetes is but a fraction of future 
expected costs because of the aging population and growing number of residents 
who have the disease. The Centers for Disease Control and Prevention (CDC, 
2001) estimates by 2025 that 300 million people worldwide will have diabetes.  
Many elderly persons with diabetes are dependent on Medicaid or Medicare 
assistance.  Studies have shown that persons dependent on Medicaid and 
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persons lacking adequate insurance coverage have a two- to five-fold increase in 
hospitalizations for acute complications (Rubin, et al., 1994).  
In addition to the devastating financial costs, diabetes imposes a burden 
of illness, discomfort, disability, and premature death.  The CDC (2005) 
estimates that over 200,000 deaths per year can be attributed to diabetes.  In 
1990, there were 2.8 million diabetes-related hospital admissions, accounting for 
24.5 million hospital days (Bellenir & Dresser, 1995).  Many of these admissions 
were a direct result of knowledge deficits in self-management skills such as 
taking medications correctly, glucose monitoring, meal-planning, proper foot 
care, and following sick day guidelines.  Previous studies have shown that 50% 
to 80% of adults with diabetes, regardless of duration of the disease, had severe 
knowledge deficits about their disease (Miller, et al., 1978; Watkins, Williams, 
Martin, Hogan, & Anderson, 1997). 
Preventable acute complications, such as diabetic ketoacidosis, remain 
predominant causes of death among persons with type 1 diabetes.  According to 
a study by Herman, Teutsch, and Geiss (1987), 52,000 cases of ketoacidosis 
can be averted a year through major educational interventions aimed at 
improving glycemic control.  The Diabetes Control and Complications Trial (1996) 
demonstrated that intensive therapy coupled with comprehensive diabetes 
education resulted in a 76% reduction in retinopathy, a 36% to 56% reduction in 
nephropathy, and a 60% reduction in diabetic neuropathy. 
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Despite these promising results, clinical practice lags in applying these 
scientific advancements, mainly due to resistance by third-party payers to 
reimburse for comprehensive diabetes education.  A study by Weiner et al. 
(1995) on Medicare patients with type 2 diabetes found 84% had not received 
Hgb A1C measurements, despite standards that recommend these 
measurements be taken at least twice a year.  Some data suggest that the 
average Hgb A1c for persons with type 2 diabetes is 8.5% (Greenfield, Roger, 
Mangotich, et al., 1995).  Efforts are underway in some states, such as Florida, to 
enact legislation that requires insurance companies to cover the cost of diabetes 
care supplies needed for blood glucose monitoring and education services. Since 
July 1, 1998, Medicare provides reimbursement for diabetes supplies and 
education when provided by a certified provider.  In the present healthcare 
climate it is imperative that the outcomes of diabetes treatment, new 
technologies and diabetes education be evaluated.
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Hypothesis 
This prospective study compared the effectiveness of intensive follow-up 
group compared with standard care follow-up of participants of ADA diabetes 
self-management education program on metabolic control, diabetes health 
beliefs and behaviors.  A randomized pretest-posttest control group design tested 
the following null hypothesis:   
Ho: There is no significant difference in mean glycosylated hemoglobin 
(HgbA1c) value over time (week 1, week 12, and week 24) for participants of a 
diabetes self-management education program assigned to intensive follow-up 
group (CGMS utilized) compared to a standard follow-up control group.   
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Research Questions 
This investigation also addressed the following questions: 
1. Is there any significant difference in mean glycosylated hemoglobin 
values over time (week 1, week 12, and week 24) between those 
participants of the ADA comprehensive self-care management 
training randomly assigned to the intensive follow-up group and the 
standard follow-up control group? 
2. Are there any significant profile differences in mean Health Belief 
Model subscale scores (perceived barriers, severity, susceptibility, 
benefits, self-efficacy, cues to action, motivation and structural 
elements) between the participants receiving the ADA 
comprehensive self-care management training assigned the 
intensive follow-up and the standard follow-up control group over 
time?  
3. Is the difference between the week 1 and the week 24 mean 
perceived barrier scores of the intensive follow-up group 
significantly different compared to the standard follow-up control 
group? 
4. Is the difference between the week 1 and the week 24 mean 
perceived benefits score of the intensive follow-up group 
significantly different compared to the standard follow-up control 
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group? 
5. Is the difference between the week 1 and the week 24 mean 
perceived self-care ability scores of the intensive follow-up group 
significantly different compared to the standard follow-up control 
group? 
6. Is the difference between the week 1 and the week 24 mean 
perceived severity scores of the intensive follow-up group 
significantly different compared to the standard follow-up control 
group? 
7. Is there a significant difference between the week 1 and the week 
24 mean perceived susceptibility scores of participants receiving 
the ADA comprehensive self-care management training randomly 
assigned to the intensive follow-up group compared to the standard 
follow-up control group? 
8. Is there a significant difference between the week 1 and the week 
24 mean perceived cues to action scores of the participants 
receiving the ADA comprehensive self-care management training 
randomly assigned to the intensive follow-up group compared to 
the standard follow-up control group? 
9. Is there a significant difference between the week 1 and the week 
24 mean structural elements scores of participants receiving the 
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ADA comprehensive self-care management training randomly 
assigned to the intensive follow-up group compared to the standard 
follow-up control group? 
10. Is there a significant difference between  the mean diabetes self-
care practice scores of the participants receiving the ADA 
comprehensive self-care management training randomly assigned 
to the intensive follow-up group compared to the standard follow-up 
control group? 
This study sought evidence as to whether persons with diabetes type 2 
who participate in an ADA–approved DSME randomly assigned to the intensive 
follow-up group have any significant differences in their HgbA1c values, health 
beliefs, and diabetes self-care behaviors over time compared to a standard 
follow-up group.  The intensive follow-up group differs from the standard follow-
up group by using a continuous glucose sensor to determine blood glucose 
patterns and responses to exercise, medications, food intake, and other daily 
activities.  
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Research Plan 
The study sample was recruited from the Tampa Bay area, and consisted 
of English-speaking adults, 18 year of age or older who have been diagnosed 
with type 2 diabetes.  Exclusion criteria included:  having type 1 diabetes; 
pregnant women; patients with concomitant conditions or who are in poor general 
health that might impair their ability to participate in self-care activities; patients 
who had undergone a comprehensive diabetes self-care management training 
program within the past year; patients with any form of hemoglobinopathy; and 
patients who had Hgb A1c less than 7.0.  
Volunteers who signed the informed consent  were assessed initially by 
the diabetes care manager and completed the Expanded Health Belief Model 
Questionnaire (EHBMQ) .. Each volunteer’s Hgb A1C was assayed. Those 
persons who met the eligibility criteria were randomly assigned after blocking by 
treatment (insulin or not) to the intensive follow-up group following DSME, or to a 
standard follow-up control group.   Demographic and baseline information such 
as anthropometrics, blood chemistries, diet, medical, and social histories were 
obtained by the diabetes case manager.  Study participants received ADA-
approved DSME taught by a multi-discipline team of certified diabetes educators 
(including a diabetes nurse educator, registered dietitian, and exercise 
physiologist).  The ADA-approved curriculum “Life with Diabetes” included: 
complications and management of the disease; and skills necessary for good 
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control such as glucose monitoring, meal planning, foot care, sick day 
management, goal setting, stress management, and exercise.  Diabetes 
educators individualized education plans based on information compiled from the 
diabetes needs assessment and the EHBMQ.   
HgbA1c values were assessed at week 1, week 12, and week 24 (see 
Figure 1). Health Belief scores were assessed at week 1 and week 24.  Records 
of attrition and adherence were maintained and analyzed. Attrition is 
operationally defined as those research participants lost from the intervention or 
control group because they dropped out of the study, missed pre-testing or post-
testing, or were absent during the major educational sessions.  For this study, 
participants had to attend a minimum of 6 hours of sessions covering the major 
content areas in part 1 and 2.   
Strategies were employed to minimize attrition; including reminder 
postcards of appointments, follow-up phone calls, assistance with scheduling or 
rescheduling and establishing good rapport.  Subject characteristics and 
treatment conditions were compared between dropouts and completers to 
evaluate whether differential attrition threatened the internal validity of the study.  
To minimize selection bias, scheduling, random assignment, and data entry were 
conducted by a program assistant not directly involved in the delivery of the 
education program.   
The study sought a sample size of 159 participants to achieve adequate 
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power (.80) and alpha .05.  Estimates are based on a table of sample sizes for a 
two-group repeated measure design (Vonesh & Chinchilli, 1997), for a maximum 
correlation of .9, and to detect a minimum standard deviation of .50.  A group 
size of 60 is needed.  Due to the time and effort required of participants in this 
study, an attrition or drop-out rate of 35% for the intensive intervention group 
(additional 21) and 30% for the standard follow-up control group (additional 18) 
was added to the sample size.   
The primary response variable, Hgb A1C, was measured at the beginning 
of the trial at the first visit, and repeated at week 12 and 24.  Initially, the control 
(standard follow-up) versus the intervention (intensive follow-up) group was 
compared for significant differences in the response variable and other baseline 
characteristics.  The following study population characteristics were compared: 
gender, age, education, duration since diabetes diagnosis, physician type, 
hemoglobin A1c, diabetes treatment, and diabetes health belief scores. The 
Diabetes Health Belief Model subscales for perceived barriers, perceived 
benefits, perceived self-efficacy, perceived susceptibility, perceived severity, 
cues to action and structural elements were measured at week 1 and week 24. A 
profile analysis was employed to test parallelism using SAS procedures (1979). A 
test of parallelism determines whether the profiles are similar or whether a group-
by-variable interaction exists.  
The primary response variable, the mean Hgb A1C, was compared at 
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baseline, week 12, and week 24 for the two groups using ANOVA for repeated 
measures.  A profile analysis (2 between one within ANOVA) was used to 
compare the groups week 1 and week 24 on the eight major constructs of the 
HBM (perceived barriers, benefits, severity, susceptibility, cues to action, 
structural elements, motivation and self-efficacy scores. 
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Figure 1.   
Study Design  
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Assumptions 
For the purpose of this study it was assumed that: 
? Due to the direct relationship between blood glucose levels and the risks 
of diabetes-related complications, techniques that improve glycemic 
control over time reduce the risks of diabetes complications. 
? The benefits of improved glycemic control found among persons with type 
1 and type 2 diabetes would also apply to other types of diabetes as well. 
? Achieving and maintaining good metabolic control can reduce diabetes 
mortality and morbidity. 
? Comprehensive diabetes self-management programs that are accredited 
by the ADA must meet similar structure, process, and outcome standards. 
? The benefits of improved glycemic control such as healthier, more 
productive lives with fewer complications offset the additional expense of 
comprehensive diabetes programs. 
? Persons participating in the diabetes self-management training program 
are motivated to control their diabetes and value their health. 
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Delimitations 
 
The study is delimited to the following: 
1. Persons with type 2 diabetes referred to the trial by Tampa-area 
physicians. 
2. Persons with type 2 diabetes ≥18 years of age that give informed 
consent to participate in the study.  
3. Capillary Hgb A1C determinations.  
4. English-speaking adult volunteers who are physically and mentally 
able to perform self-care activities. 
5. Persons with diabetes with Hgb A1c values between 7.0 and 13.0. 
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Limitations 
This study is limited to the following: 
1. ADA-recognized diabetes self-management education programs that meet 
national standards might be different from other diabetes self-
management education programs.   
2. A sample made up of healthy volunteers referred to the Diabetes Care 
Institute at University Community Hospital Clinic by their physicians may 
be different from other diabetes populations.  
3. Because the sample is drawn from the Tampa Bay area, samples from 
other areas of Florida or the United States may be different. 
4. This is a short-term prospective randomized clinical trial and trials 
conducted over other time frames may yield different results. 
5. The revised diabetes Expanded Health Belief Model questionnaire used in 
this study is a self-report instrument; and other types of measures may 
yield different results. 
6. An empowerment education approach is used in this study group (the 
compliance approach and others may yield different results). 
7. Over a 24-week period subjects may learn diabetes management 
techniques on their own.
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Definitions of Terms 
Adherence — Extent to which a person’s behavior (in terms of medications, 
diets or life-style changes) coincides with medical adherence (Haynes, Taylor, & 
Sackett, 1979).   
Blood glucose — The main sugar that the body makes from three elements 
of food: proteins, fats, and carbohydrates, but mostly from carbohydrates.  
Glucose is the major source of energy for living cells and is carried to each cell 
through the bloodstream.  However, the cells cannot use glucose without the 
help of insulin (Bellenir & Dresser, 1995).  
Blood Glucose Meter — A machine that tests how much glucose is in the 
blood.  A specially coated strip containing a fresh sample of blood is inserted in a 
machine, which then calculates the correct level of glucose in the blood sample 
and shows the result in a digital display (Bellenir & Dresser, 1995).  
Diabetes Mellitus — A disease that occurs when the body is not able to use 
sugar as it should.  The body needs sugar for energy for daily activities.  It gets 
sugar when it changes food into glucose (a form of sugar).  Diabetes occurs 
when the body tries to use sugar in the blood for energy — but cannot because 
the pancreas is not able to make enough of a hormone called insulin, or because 
the body cannot use the insulin it does have.  The beta cells in areas of the 
pancreas called the Islets of Langerhans usually make insulin (Bellenir & 
Dresser, 1995).  
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Type 1 Diabetes — This type of diabetes is characterized by beta cell 
destruction, usually leading to absolute insulin deficiency.  Type 1 diabetes may 
have two forms — idiopathic referring to forms of the disease with no know 
etiology and immune-mediated resulting from a cellular mediated autoimmune 
destruction of the beta cells of the pancreas (ADA, 1998a). 
Type 2 Diabetes — This type of diabetes is defined as those individuals 
who have insulin resistance and usually relative insulin deficiency (1998a).   
Gestational Diabetes — Carbohydrate intolerance of variable severity with 
onset of first recognition during the present pregnancy (Freinkel, 1985).  
Diabetes Self-Management Training or Self-Management Education — 
Previously termed diabetes patient education, this term refers to the process 
whereby individuals learn to manage their diabetes (ADA, 1996).  
Diabetes Educator — Defined as any health professional who has 
mastered the core knowledge and skills in biological and social sciences, 
communication, counseling, and education and has a specific amount of 
experience in the care of persons with diabetes (AADE, 1992). 
Certified Diabetes Educator (CDE) — Certification in diabetes education 
designates the attainment of knowledge beyond basic core knowledge and skills.  
A CDE has at least 2000 hours of direct diabetes teaching experience and has 
successfully completed an examination that verifies contemporary diabetes 
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knowledge across multiple professional disciplines (American Dietetic 
Association, 1995).   
Glucose Tolerance Test — A test to see if a person has diabetes.  The 
test is given in a lab or doctor's office in the morning before the person has 
eaten.  The person first gives a blood sample.  Then the person drinks a liquid 
that has glucose in it.  At specified intervals, the person gives a sample of blood 
to see how the body deals with the glucose in the blood over time (Bellenir & 
Dresser, 1995).  
Hemoglobin A1c (Hgb A1C) or Glycated Hemoglobin — A form of 
hemoglobin that reflects the average blood glucose concentration over the past 
three months (ADA, 1993).  
Health Motivation — Measures concern for one’s own health (Becker, 
Brachman, & Kirscht, 1974).   
Incidence — How often a disease occurs; the number of new cases of a 
disease among a certain group of people for a certain period of time (Bellenir & 
Dresser, 1995).  
Insulin — A hormone that helps the body use glucose (sugar) for energy.  
The beta cells of the pancreas (in the areas called the Islet of Langerhans) make 
the insulin.  When the body cannot make enough insulin on its own, a person 
with diabetes must inject insulin from other sources, i.e., beef, pork, human 
 45 
insulin (recombinant DNA origin), or human insulin (pork-derived, semi-synthetic) 
(Bellenir & Dresser, 1995).  
Microvascular Complications — Means damage to small blood vessels 
generally affecting three organ systems: the eye (retinopathy), the kidneys 
(nephropathy), and the nerves (neuropathy) (ADA, 1993).  
Macrovascular Complications — Means damage due to atherosclerosis of 
large blood vessels resulting in reduced blood flow to tissues such as the heart, 
brain, and lower extremities (ADA, 1993).    
Cues to Action — Internal (symptoms) and external factors (health 
messages, lab reports) that lead or motivate a person to seek medical care or 
follow positive health practices (Rosenstock, 1994).  
Perceived Barriers — Measures the perceived psychological and 
situational obstacles that would have to be overcome in order to follow 
recommended actions (Janz & Becker, 1985).   
Perceived Benefits — Perceptions regarding the effectiveness of the 
treatment in reducing the threat, or measures the person’s faith in curative 
powers of their physician and the recommended actions (Rosenstock, 1974).   
Perceived Severity — Perception of consequences, and how much one 
perceives the illness will interfere with their lives (Rosenstock, 1974).   
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Perceived Susceptibility — Perceptions of threat of the illness, its 
complications, assessment of future risks associated with the disease 
(Rosenstock, 1974).   
Perceived Self-efficacy — Measures a person’s own assessment of their 
ability to perform certain tasks or engage in specific actions (Bandura, 1977a; 
1977b). 
Structural Elements — Modifying factors such as locus of control, 
understanding of the disease and the recommended actions, amount and quality 
of social support or peer influence, and prior experience or contact with the 
disease that may affect a person’s perceptions (Rosenstock, 1974).  
Prevalence Rate — Measures the number of people in a population who 
have the disease at a given point in time (Mausner & Bahn, 1974). 
 47 
 
 
Chapter Two: Review of the Literature 
This chapter is divided into nine sections: (a) an overview of diabetes, (b) 
etiology and classifications, (c) epidemiology, (d) diabetes related complications, 
(e) the Expanded Health Belief Model, (f) factors influencing metabolic control,  
(g) the diabetes-specific health belief instruments, (h) diabetes self-management 
education, (j) continuous glucose monitoring and (i) future implications.  
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Overview of Diabetes 
Diabetes mellitus is a chronic metabolic disorder in which the body is 
unable to produce or properly utilize insulin, a hormone that facilitates the 
conversion of sugar, starches, and other substrates into energy.  The diagnosis 
of diabetes is made when: 1) there is an unequivocal elevation of random plasma 
glucose of greater than or equal to 200 mg/dl (11.1 mmol/l), and classic 
symptoms of diabetes are present such as excessive thirst, urination, hunger and 
weight loss; 2) fasting plasma glucose (FPG) is greater or equal to 126 mg/dl (7.0 
mml/l); and 3) FPG is greater than or equal to 200 mg/dl during an oral two-hour 
plasma glucose (PG) tolerance test (Diabetes Care, 1998a). 
Etiology and Classification 
Although the etiology of diabetes is still unknown, it is thought to be more 
heterogeneous in nature with both genetic and environment factors possibly 
involved.  Factors such as family history, race, age, viruses, stress, and certain 
drugs or toxins are associated with its development.  In the 1970s, researchers 
found that patients with newly diagnosed insulin-dependent diabetes had self-
directed antibodies aimed at destroying their own beta cells and insulin.  During 
the 1980s, additional diabetes-related antibodies were discovered in patients 
prior to clinical diagnoses of the disease and thus act as a marker for subsequent 
diabetes.  Some investigators feel that some type of infection or exposure to 
certain viruses may trigger the auto-immune process in genetically susceptible 
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individuals.  By introducing a foreign protein that resembles a beta-cell protein, 
the immune system is fooled into attacking its own beta cells.  
As more became known about the heterogeneity of diabetes, the old 
classification of diabetes based on age of onset was replaced by revised 
classifications developed by the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus (Expert Committee, 1998a).  Juvenile-onset 
diabetes or insulin-dependent diabetes mellitus was renamed type1 diabetes, 
and maturity-onset diabetes or non-insulin-dependent diabetes mellitus was 
replaced with type 2 diabetes.  Separate categories were established for 
impaired glucose intolerance and gestational diabetes.  
Type 1 diabetes accounts for approximately 10% of the total diabetic 
population.  It is considered an autoimmune disease where inadequate insulin is 
secreted requiring daily injections of insulin to stay alive.  Patients with Type 1 
diabetes are highly prone to ketoacidosis and other classic symptoms of 
polydipsia, excess urination, constant hunger with an intense craving for sweets, 
fatigue, blurred vision, and rapid weight loss.  Type 1 diabetes generally occurs 
in childhood and is only second to cancer as the most chronic disorder affecting 
U.S. children (ADA, 1996; Bellenir & Dresser, 1995; CDC, 1997). 
The most common form of diabetes is called Type 2 and accounts for over 
90% of the cases of diabetes.  It generally occurs in adults over forty and is 
especially prevalent in people who are sedentary and obese (Bellenir & Dresser, 
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1995).  Nearly 80% of the people diagnosed with Type 2 diabetes are overweight 
(ADA, 1996).  The risk of developing diabetes also increases with age.   Type 2 
diabetes is more prevalent among Native American, Hispanic American and 
African-American populations.  More females are afflicted by type 2 diabetes 
than males.  Also, women who have had gestational diabetes are at high risk of 
acquiring type 2 diabetes.  Gestational diabetes is defined as diabetes that is 
discovered during pregnancy.  Secondary diabetes is a less common form of the 
disease resulting from another condition or medication (Bellenir & Dresser, 
1995). 
Epidemiology 
The prevalence of diabetes in the U.S. adult population is estimated at 
20.8 million, with approximately half being unaware of their disease (CDC, 2005).  
Insulin dependent diabetes mellitus (IDDM) or type 1 diabetes occurs in 
approximately 10% of all people with diabetes.  Although the risk for developing 
Type 1 diabetes is higher in individuals with a genetic disposition, the onset of 
Type 1 diabetes generally results when environmental factors such as viruses, 
toxic substances, or intensive stress triggers a progressive destruction of the 
beta-cells that produce insulin.  Prevalence is highest among Caucasians and 
among young people under 20 years of age.  
Type 2 diabetes accounts for nearly 90% of all cases of diabetes in the 
United States.  Generally due to the insipid nature of the disease, many persons 
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with type 2 diabetes are likely to have had the disease for several years by the 
time it is first diagnosed.  Persons who are overweight or obese have a higher 
risk of acquiring type 2 diabetes.   
Diabetes Related Complications 
Diabetes is a serious disease associated with severe neurological, 
cardiovascular, ocular, and renal complications.  It is the leading cause of 
blindness, amputations, and kidney disease in the U.S. (CDC, 2005).  Recent 
studies have reported delay of onset and slowing of progression of diabetes-
related morbidity (DCCT, 1993; Fishbein & Palumbo, 1995; Ohkubo, et al., 1995; 
UKPDS, 1997).  The most comprehensive diabetes study ever conducted, the 
Diabetes Control and Complications Trial (DCCT, 1993), demonstrated that 
intensive management of diabetes that strived to keep blood glucose levels as 
close to normal as possible successfully slowed the onset and progression of 
early vascular complications including eye, kidney, and nerve disease.  The 
DCCT trial demonstrated that intensive therapy compared to conventional 
therapy resulted in a 76% reduction in retinopathy, a 36-56% reduction in 
nephropathy, and a 60% reduction in diabetic neuropathy.  Although the DCCT 
was conducted among persons with type 1 diabetes, results are thought to 
benefit those with type 2 diabetes as well.   
Recently, studies (Ohkubo, et al., 1995; UKPDS, 1997) involving persons 
with type 2 diabetes have found that intensive control coupled with 
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comprehensive diabetes self-management training successfully improved 
metabolic control.  In another clinical trial aimed at the preventing or delaying the 
onset of diabetes, researchers found that preventing obesity could lower the risk 
of developing type 2 diabetes by nearly 50% (ADA, 1996a).  Unfortunately, 
clinical practice lags behind scientific advancements mainly due to the resistance 
by third-party payers to reimburse for many prevention and educational services. 
Prevention of acute and chronic complications relies on diabetes education that 
improves understanding and helps participants make appropriate behavioral 
changes to improve their metabolic control.  Providing education that only sets 
out to improve the diabetes knowledge of the participant has had disappointing 
results (Bloomgarden, et al., 1987; Beeney & Dunn, 1990).  For programs to 
effect desirable outcomes such as reductions in sick days, hospitalizations and 
length of stays, emergency visits, acute or chronic complications, and death 
rates, more comprehensive programs that employ a multidisciplinary team are 
essential.  Programs that target behavioral changes improve skills through 
practice, and assist participants in overcoming barriers to self-care have been 
proven more successful (Glasgow & Osteen, 1992).  
The objective of diabetes management is to keep glycemic levels in a 
range associated with few diabetes complications.  In the Kumamoto University 
Study (Ohkubo, et al., 1995), the glycemic threshold to prevent the onset and 
progression of diabetic micro-angiopathy was a Hgb A1c level less than 6.5% (4-
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6% being a normal Hgb. A1c).  The DCCT (1993) found a Hgb A1c level of 7% or 
lower was associated with fewer micro-vascular complications.  A mean 
improvement of Hgb A1c of 1% to 2% achieved in the first 10 years of overt 
diabetes could reduce micro-complications 30-70%.  The American Diabetes 
Association (1997a) recommends that Hgb A1c should be maintained below 7% 
to lower the risk of diabetes complications.  Corrective action needs to be taken 
for Hgb A1c levels exceeding 8%.  
Surveys by Klein (1995) and Mazze, Etzurlla, & Strock (1994) report that 
persons diagnosed with diabetes have an average Hgb A1c level of 8.5%.  Over 
50% of persons with type 2 diabetes have Hgb A1c above 8%.  A 1995 survey of 
medical patients with type 2 diabetes found that 84% of their 97,388 sample had 
not received a Hgb A1c measurement during the study period (July 1, 1990-June 
30, 1991).  Some researchers feel that persons with type 2 diabetes receive 
suboptimal medical care and inadequate diabetes education because health 
providers consider type 2 diabetes, especially those not requiring insulin, to have 
a mild form of the disease (Teza, Davis, & Hass, 1988).
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The Expanded Health Belief Model 
In search of practical solutions to problems relating to the failure of people 
to accept preventive health measures and comply with medical regimens, the 
Health Belief Model (HBM) was developed to help explain why individuals did or 
did not engage in a wide array of health-related actions.  Since that time, the 
HBM has generated a prolific amount of evidence to support its value in 
explaining why some people engage in health-related actions and others do not.  
The HBM has shown a degree of predictive value for preventive and compliance 
behaviors (Becker, 1976; Janz & Becker, 1984; Harrison, et al., 1992).  HBM 
investigations in general have found that individuals will usually take action to 
prevent, screen for, or to comply with medical regimens if they feel they are 
susceptible to a condition that poses a serious threat to them.  They are more 
likely to follow certain health recommendations if they believe that the treatment 
will be beneficial by reducing the perceived threat at an acceptable cost.  
Due to the model’s usefulness in explaining and predicting acceptance of 
health and medical care recommendations, the model has been utilized in a 
variety of setting and situations.  The HBM is the most frequently cited and 
applied social-psychological model used in Behavioral research (Wallston & 
Wallston, 1984).  Originally the HBM was designed to explain an individual’s 
willingness to participate in preventive health practices such as immunizations 
and screening for diseases like hypertension and cancer.  More recently the 
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HBM has been extended to describe compliance behavior during acute and 
chronic illnesses as well as to predict utilization of health services.  
According to the original Health Belief Model, behavior was explained by a 
combination of these four components: perceived susceptibility, perceived 
seriousness, perceived benefits, and perceived barriers or costs (Rosenstock, 
1974).  “Perceived susceptibility” refers to the individual’s perception of his or 
her vulnerability to a condition or health threat.  “Perceived severity” refers to 
the perception of the seriousness of the threat; this may include the person’s 
evaluation of the consequences both clinical and social.  “Perceived benefit” 
refers to the person’s perception of the effectiveness of the action in reducing the 
threat by reducing either the severity of the disease or the likelihood of contacting 
the disease.  “Perceived barriers or costs” refer to the person’s perceptions as 
to the various costs associated with following the recommended action.  Costs or 
barriers can be physical, emotional and socioeconomic, such as fear of side 
effects of the treatment, discomfort and pain stemming from the action or 
condition, complexity or difficulty of the regimen, high financial outlay and 
inconvenience (Janz & Becker, 1984). 
Rosenstock (1974) felt that besides the combined effects of susceptibility, 
severity, benefits and costs, a stimulus or cue to action was needed to trigger the 
decision-making process.  Cues to action may be internal (e.g. symptoms) or 
external (e.g. mass media communications, reminder postcards, posters).  In 
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addition, there are other modifying variables that may influence one’s health 
beliefs or decision to act.  Demographics (e.g., age, sex, race, ethnicity), socio-
psychological (e.g., social class, peer influence), and structural factors (e.g., 
knowledge about the disease, prior contact or experience with the disease) may 
affect a person’s perceptions and thus indirectly influence health-related 
behavior.  Rosenstock posited that factors such as educational attainment 
influence the patient’s knowledge and understanding of the disease or treatment, 
and as a result affects the patient’s compliance.  Complexity of the treatment and 
the patient’s interpersonal relationships with the health care staff, their own 
families, or significant others may also have a major impact on the patient’s 
health beliefs and willingness to comply with recommended health actions.  
In 1974, Becker, Drachman, and Kirscht (1974) added the construct health 
motivation to the HBM’s conceptual framework.  Health motivation was defined 
as an individual’s degree of interest in or concern about health in general.  
Becker, et al. theorized that a desire to attain or maintain health and to avoid 
illness resulted in a willingness to comply with health recommendations.  In 
recent studies (Friedman, Nelson, Webb, Hoffman, & Baer, 1994; Hallal, 1982; 
Kaplan, Ries, Prewitt, & Eakin, 1994; Toshima, Kaplan, & Ries, 1990; Trotta, 
1980) researchers have incorporated into the HBM self-efficacy theory to 
improve its usefulness in prediction and overall utility. Self-efficacy theory 
(Bandura, 1977; Bandura, 1986; Bandura, 1992) focuses on one’s perception 
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that he or she is capable of adopting the recommended behavior.  Bandura 
(1977) stresses that self-efficacy is essential for behavioral change and points 
out that people who regard outcomes as personally determined but lack the skills 
to take action would experience low self-efficacy and view the recommended 
action with a sense of futility. 
The Health Belief Model has been employed extensively to explain 
compliance with following prescribed diabetes regimens (Alogna, 1980; Becker, 
1976; Cerkoney & Hart, 1980; Harris & Linn, 1985; Harris, Skyler, & Linn, 1982; 
Pham, Forton, & Thibaudeau, 1996; Schlenk & Hart, 1984; Wooldridge, et al., 
1992).  Kirscht and Rosenstock (1977) observed that in illness behavior the 
perceived severity of the symptoms is the most salient factor for seeking care 
and complying with medical recommendations.  This finding was supported by 
the subsequent work of Cauffman, Peterson, and Emrick (1967) who found that 
immediate demands from acute symptoms may override ordinarily observed 
barriers to care.  With milder cases of illness, the decision to act would be more 
affected by barriers such as cost, time constraints, or other competing problems 
(Bice & White, 1969; Richardson, 1970).  
In examining diet compliance among obese patients with diabetes, Alogna 
(1980) focused on the HBM dimension of perceived severity and found a 
significant difference in this variable between compliant and noncompliant 
subjects. In their study among persons with type 2 diabetes, Cerkoney and Hart 
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(1980) demonstrated that there was a positive association for all four HBM 
variables and a significant correlation was attained for perceived severity and 
compliance.  Other investigators (Becker, et al., 1977; Harris, et al., 1982) 
examining the use of the HBM to explain compliance behavior of persons with 
diabetes have reached similar conclusions. 
The Health Belief Model is useful for examining beliefs that are likely to 
affect compliance.  A scale measuring health beliefs should look at perceptions 
of susceptibility; do they feel that their diabetes can result in complications if 
poorly controlled?  Do they anticipate an early cure?  Looking at costs/benefits or 
barriers can help determine if they feel the regimen is too complex, interferes 
with their lifestyle too much, or whether they believe that following the regimen is 
effective at improving their control of their health problems.  
Dunbar and Stunkard (1979) view the regimen as the single most 
important determinant of patient adherence.  In general, compliance is expected 
to improve with decreases in the regimen’s complexity, and barriers such as cost, 
convenience, and incompatibility with current lifestyle.  Strategies of the self-care 
training intervention should focus on simplifying the diabetic regimen.  Helping 
patient’s select easy behavioral tasks or recommending they tackle behaviors 
one at a time may foster self-confidence.  Health professionals also need to 
reinforce whatever compliance is achieved, and proceed in a step-wise fashion 
tailoring the regimen to the special needs of each patient.  
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The HBM has been extensively utilized to understand and predict diabetic 
self-care behavior (Kavanagh, 1993; Kingery & Glasgow, 1989; McCaul, 
Glasgow, & Schafer, 1987; Schafer, Glasgow, McCaul, & Dreher, 1983).  An 
early review of studies employing the HBM, Janz and Becker (1984), concluded 
perceived barriers as being the most powerful HBM dimension followed by 
perceived susceptibility.  In most chronic debilitating illnesses such as diabetes 
or cancer, most persons perceive the disease as serious. 
To make lifestyle changes, the person with diabetes must feel the benefits 
of lifestyle changes outweigh the cost to perform and sustain them.  Persons 
must feel competent that they can make the desired changes in behavior.  
Numerous studies suggest that self-efficacy is a strong predictor of behavior 
change (Jeffery, 1984; Kavanagh, Gooley, & Wilson, 1993; Kingery & Glasgow, 
1989; Lawrance, 1986; Littlefield, 1992; Strecher, et al., 1986).   
According to Bandura’s (1977) self-efficacy concept, behavior changes 
are a result of both efficacy expectations (beliefs that they can perform a 
particular task) and outcome expectations (beliefs that by performing a certain 
task certain results will occur).  Self-efficacy in adolescents with Type 1 diabetes 
was investigated by Grossman, et al. (1987).  They found a significant correlation 
between blood glucose values and beliefs they could do the various self-
management task.  Other studies (Jeffery, et al., 1984; Kingery & Glasgow, 1989; 
Littlefield, et al., 1992; McCaul, Glasgow, & Schafer, 1987) on diabetes and self-
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efficacy, especially among children and adolescents, have found that high 
degree of self-efficacy is correlated with better self-care behaviors.  McCaul, et 
al. (1987) found self-efficacy was the best predictor of compliance to the diabetic 
regimen in both adolescents and adults with diabetes.  Kingery and Glasgow 
(1989) found self-efficacy and outcome expectancies moderately strong 
predictors of adherence to exercise plans but found self-efficacy a slightly weaker 
predictor of dietary and glucose testing in person with type 2 diabetes.  Littlefield, 
et al. (1992) found that among adolescents with diabetes, self-efficacy was the 
strongest predictor of adherence. 
In the Health Belief Model, the person makes a subjective judgment about 
the potential consequences or outcomes by weighing the benefits versus the 
costs.  Both attitudes and beliefs are mutable, whereas other variables such as 
personal attributes (personality) or socio-demographic characteristics (age, sex, 
marital status) cannot be changed.  The HBM is useful in explaining behavior that 
is in the person’s direct control.  The concerns, attitudes, or beliefs are obtained 
from interviews and questionnaires from members of the target group.  Perceived 
barriers are the most influential determinant of behavior.  By determining the 
barriers most salient to the participants, interventions can be planned to focus on 
overcoming these issues, especially when program funding or resources are 
limited.
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Factors Affecting Metabolic Control 
The literature suggests that metabolic control is quite complex and is 
mediated by a number of variables.  Patient and clinical characteristics   (e.g. 
age, severity of their disease, type and mode of therapy, co-morbidity, duration of 
disease, and ethnicity) can all influence glycemic control (Anderson, Wolf, 
Burkhart, Cornell, & Bacon, 1989; Dunn, 1990; Glasgow & Osteen, 1992; 
Glasgow, Toobert, & Hampson, 1992; Irvine, Saunders, Blank, & Carter, 1990; 
Jacobson, Adler, Wolfsdorf, Anderson, & Derby, 1990; Wing, Epstein, Norwalk, 
Scott, & Gooding, 1987; Wooldridge, et al., 1992). 
Wooldridge, et al. (1992) proposed a theoretical framework incorporating 
the expanded Health Belief Model to illustrate the relationships between the 
motivation to control diabetes, the self-management behaviors required to control 
diabetes, and metabolic control (see Figure 2).  Numerous factors influence the 
person’s motivation to control diabetes including health beliefs, personal values 
and priorities, life experiences, psychological variables, knowledge of diabetes, 
and past medical experiences.  Factors that determine whether a person will 
perform self-care management behaviors are influenced by the person’s 
motivation to control diabetes, financial resources, emotional support, complexity 
of the regimen, disruption of one’s lifestyle, self-management skills, perceived 
barriers, locus of control, and cues to action.  Metabolic control is determined the 
persons’ diabetes self-care, medical interventions, severity of diabetes, and other 
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unknown variables.  Non-behavioral factors such as a person’s age, duration of 
disease, and other medical conditions affect metabolic control but are basically 
out of the direct control of the person with diabetes.  
The Health Belief Model has been used to help understand attitudes and 
beliefs that are related to diabetes compliance and metabolic control (Alogna, 
1980; Becker, Haefner & Maiman, 1987; Cerkoney & Hart, 1980; Harris, et al., 
1987; Janz & Becker, 1984; Pham, Forton, & Thibaudeau, 1996).  Studies have 
shown that health beliefs are positively correlated with compliance (Alogna, 
1980; Kirscht, 1974) and both health beliefs and compliance are correlated with 
metabolic control (Harris & Linn, 1985).  Investigators (Anderson, Funnell, et al., 
1989; Fitzgerald, 1997) suggest that future research should identify beliefs, 
attitudes and behaviors that influence the ability of persons with diabetes to 
successfully carry out diabetes self-care.  Educational efforts need to focus on 
developing effective strategies to help individuals overcome barriers and modify 
health beliefs and attitudes non-conductive to positive diabetes self-care 
behaviors.   
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Figure 2.   
Theoretical Framework: Factors Influencing Metabolic Control of Diabetes  
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Educational efforts need to focus on developing effective strategies to help 
individuals overcome barriers and modify health beliefs and attitudes non-
conductive to positive diabetes self-care behaviors.  Health beliefs and health 
behaviors are influenced by ethnic, cultural, and socioeconomic factors 
(Friedman, 1990).  Self-care plans recommended by health professionals need to 
accommodate these ethnic and cultural variations. 
The current research suggests that diabetes education effectiveness 
should focus on measuring mutable variables such as knowledge of diabetes, 
self-management skills, health beliefs and attitudes, and program components to 
foster better glycemic control (Beeney & Dunn, 1990; Glasgow, et al., 1997; 
Glasgow & Osteen, 1992; Wooldridge, et al., 1992).   
Glasgow and Osteen (1992) illustrated suggested various psycho-
behavioral variables that may influence glycemic control either directly or 
indirectly through their influence on self-care behaviors.  The model in Figure 3 
(revised from Glasgow & and Osteen, 1992) illustrates possible variables that 
affect glycemic control and those that are amenable to change by diabetes self-
management training.   Most frequently cited barriers were related to dietary 
adherence, followed by exercise and glucose testing.  Of the three HBM 
psychosocial constructs studied (barriers, treatment effectiveness, and 
seriousness), treatment effectiveness was the strongest predictor of self-
management.  
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Culminating evidence exists in the literature that comprehensive diabetes 
education can effectively reduce the morbidity and mortality associated with 
diabetes and its complications by improving glycemic control (Coonrod, et al., 
1986; DCCT, 1993; Mazzuca, et al., 1986; Ohkubo, et al., 1995; Pirart, 1978; 
UKPDS, 1995). Educational programs using a multi-disciplinary team approach 
and innovative strategies to develop self-care skills and address psychosocial 
issues tend to have more positive long-term effects on patient's well-being than 
traditional didactic approaches (Beeney & Dunn, 1990; Brown, 1988; Kaplan, et 
al., 1987; Mazzuca, et al., 1986; Wooldridge, et al., 1992).   
Few clinical studies have reported the impact of diabetes self-
management training on intervening variables of health beliefs, self-care ability, 
attitudes, and self-care behaviors which examining the effects on metabolic 
control (Anderson, 1986; Wooldridge, et al., 1992).  Wooldridge, et al., (1992) 
explored in their study whether health beliefs and attitudes could be changed by 
diabetes education.  They found that the health beliefs that were not conducive to 
performing diabetes self-care could be positively changed through a 
comprehensive diabetes self-management training program.  Their study showed 
significant improvements in Hgb A1c levels.  
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Diabetes-Specific Health Belief Instruments 
The Health Belief Model (HBM) has undergone extensive conceptual 
refining and empirical testing (Becker, 1974; Becker, Drachman, & Kirscht, 
1974a; Becker, Maiman, Kirscht, & Haefner, 1977; Janz & Becker, 1984; Kasl & 
Cobb, 1966; Maiman & Becker, 1974; Rosenstock, 1966; Strecher, et al., 1986).  
The re-conceptualization of the model adding the health motivation and self-
efficacy constructs improved the model’s ability to explain and predict behavior.  
The Expanded Health Belief Model is particularly useful in examining whether 
perceptions and situations that are limiting self-care behavior can be changed 
through intervention.  
A limitation of the Expanded Health Belief Model has been the absence of 
a reliable and valid diabetes-specific instrument that measures all the major 
dimensions of the model. Despite the development of numerous scales and 
questionnaires to measure the HBM, no consensus has been reached as ways to 
standardize measurement of the Expanded HBM variables.  
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Figure 3.   
Model of Diabetes Education  
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Early attempts to measure diabetes health beliefs suggested a 
relationship between the major HBM constructs of severity, susceptibility, 
benefits, and barriers to adherence to the diabetes regimen and metabolic 
control (Alogna, 1980; Cerkoney & Hart, 1980; Harris & Linn, 1985; Harris, 
Skyler, Linn, Pollack, & Teuskburg, 1982; Hurley, 1992; Lewis, Jennings, Ward, 
& Bradley, 1990).  Conclusions that could be drawn from these earlier studies are 
inconclusive due to use of unreliable and invalid instruments, limited samples, 
and use of global rather than diabetes-specific measures. 
The Expanded HBM, although conceptually sound, has limited practical 
utility with diabetes due to the absence of a reliable and valid diabetes-specific 
instrument that measures all the major dimensions of the model.  Although 
several diabetes health belief instruments have been developed based on the 
original HBM, none of the scales address all dimensions of the EHBM (Becker & 
Janz, 1985; Bradley, Lewis, Jennings, & Sandifer, 1987; Bradley, Lewis, 
Jennings, & Ward, 1990; Brownlee-Duffick, Peterson, Simonds, Kilo, & Hoetle, 
1987; Davis, Hess, Harrison, & Hiss, 1987; Gwen, Gwen, Gallin, & Condon, 
1983; Hurley, 1992).   
The Diabetes Health Belief Scale (DHBS) developed by Harris, Linn, 
Skyler, and Sandler comes closest to measuring the Expanded HBM by 
measuring the health motivation, structural elements, cues to action, as well as 
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ways to measure the four original constructs of perceived severity, susceptibility, 
benefits, and barriers or costs.  Three experts working in the diabetes field, two 
nurse researchers, and thirteen individuals with type 2 diabetes evaluated the 
original version of the scale for face validity.  The reliability of the original scale 
used to measure health beliefs was not reported (Harris & Linn, 1985).   
Initially, 71 items were generated from HBM theoretical research and 
previously used scales (Becker, Haefner, Kasl, et al., 1977; Becker & Janz, 1985; 
Becker, Maiman, & Kirscht, 1977; Maiman, Becker, & Kirscht, 1977; Rosenstock, 
1966; Rosenstock, 1978).  In subsequent research, the DHBS was rigorously 
tested for reliability and validity (Harris, et al., 1987). 
Test-retest reliability was employed to select items.  The developers 
retained items that had a .35 test-retest correlation (intra-class R’s) and items 
with moderate variance (≤ .40 standard deviations).  Of the original 71 items, 38 
items were retained.  Data was collected from a sample of 280 men at Miami 
Veterans Administration Medical Center and factor analysis was used to verify 
the dimensions the scale was designed to measure.   Seven factors were the 
obtained from the 38 items.  The factor susceptibility consisting of eight items 
accounted for 8.6% with 0.83 test-retest reliability.  The treatment beneficial 
factor consisting of eight items accounted for 7.3% of the variance with 0.51 test-
retest reliability.  The severity factor included five items accounting for 6.7% of 
the variance with 0.74 test-retest reliability.  The structural element factor, which 
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measured patient understanding and family support, consisted of five items 
accounting for 5.5% of the variance.  Test-retest reliability was 0.81.  The 
psychological barrier factor consisting of four items accounting for 5.5 variance 
with 0.78 test-retest reliability.  This factor pertained to the perceived 
psychological obstacles or costs involved in following the prescribed diabetes 
treatment.  The health motivation factor consisting of four items accounted for 
4.3% of the variance with 0.49 test-retest reliability.  Factor scores were inter-
correlated and found to be relatively independent and intra-class correlation were 
used to calculate test-retest reliabilities.  
Predictive validity was determined by using step wise multiple regression 
analysis with type of diabetes co-varied to predict compliance.  The best 
predictor of compliance was the lack of psychological barriers.  The structural 
elements factor and the susceptibility factor added significantly (p < 0.05; p<0.03, 
respectively) to predicting compliance.  All seven factors were able to predict 
compliance accounting for 15% of the total variance.  
Multiple aggression analyzes was also used to predict metabolic control 
from the seven DHBS factor scores.  Metabolic control was a composite score 
from four laboratory values, hemoglobin A1c, fasting blood sugar, 24-hour urine, 
and fasting triglycerides.  Health belief factors predicted control of diabetes better 
than compliance, accounting for 23% of the variance.  The best predictor of 
metabolic control was perceived severity, followed by treatment beneficial, 
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susceptibility, and lack of psychological barriers.  Metabolic control is the 
objective of compliance and therefore reflects the goals of comprehensive self-
care training programs.  
Several limitations of the DHBS persist.  The dimension of self-efficacy 
was not part of the HBM but has since been added to improve the predictive and 
explanatory powers of the expanded model.  In addition, current HBM literature 
suggests that diabetes self-care is affected by environmental barriers as well as 
psychological barriers.  Individuals with diabetes vary in terms of the number of 
barriers that affect them and their sensitivity to each barrier.  
Previous scales designed to measure perceived barriers to diabetes self-
care (Ary, et al., 1983; Davis, et al., 1987; Schafer, et al., 1983) have confirmed 
the significant influence that barriers have on self-care behaviors.  Most HBM 
scales are limited by the number of barriers they measure and their inability to 
differentiate the level of severity of each barrier.  The Environmental Barriers to 
Adherence Scale (EBAS) developed by Irvine, Saunders, Blank, and Carter 
(1990) at the University of Virginia, addresses 60 barriers across the four major 
areas of diabetes self-care (diet, exercise, blood glucose testing, and 
medication).  The scale is able to differentiate how intensely each barrier affects 
the person. 
The scale has been rigorously tested for reliability and validity.  Test-retest 
for the total scale was 0.80 (p < 0.001).  Test-retest scores for each subscale 
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ranged from 0.59 for both medication and exercise to 0.74 for glucose testing 
and diet barriers.  A high Cronbach alpha was obtained for the total scale (0.94).  
The coefficients for diet (0.91), exercise (0.86), glucose testing (0.86), and 
medication (0.84, also indicated high internal consistency. Validity was assessed 
by four measures.  Content validity was made by having five diabetes 
professionals review the scale.  Concurrent validity was assessed by correlating 
the scale with two barrier scales, the Barriers to diabetes Adherence Scale 
(BAS), and the diabetes-Care Profile Barriers (DCP-BAS) subscale (Davis, et al., 
1987; Schafter, et al., 1983).  The correlations (r = 0.63) with the BAS and 
(r=0.51) the DCP-BAS subscale reflected a moderate level of concurrent validity.  
Statistical conclusion validity was determined by correlating the EBAS with a 
reliable measure of self-care behavior, the Diabetes Self-Care Behavior (DSCB) 
scale (Wilson, Ary, et al., 1986).  The DSCB is a 24-item self-report scale that 
measures levels of adherence for diet, exercise, medication (oral and insulin), 
glucose testing, alcohol consumption, foot care, and carrying diabetes 
identification.  Correlations ranged from r = -0.33 to –0.52 (p < 0.05) reflecting the 
negative relationship between barriers and adherence behaviors.  The total 
EBAS scale was also found to be correlated with Hemoglobin A1c (r=0.28, 
p<.001).  The scale was found to have discriminate validity.  Each of the EBAS 
subscales (diet, exercise, medication, and glucose testing) correlated well with 
corresponding measures of self-care behavior and less well with non-
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corresponding self-care behavior (foot care, alcohol consumption, carrying 
diabetes identification).  Correlations between the SCBS and the total EBAS 
scores ranged from r=0.73 to r=0.86. 
The external validity of the EBAS is limited due to its validation with mainly 
a type 2 diabetes population.  The self-report nature of the scale and the 
validation with other self-reported adherence measures can be biased; therefore, 
future validation with other measures of self-care behaviors would be beneficial. 
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Comprehensive Diabetes Self-Care Management Training 
For many years, diabetes education has been viewed as an important part 
of diabetes care.  Since the discovery of insulin in the 1920s, leaders in the 
diabetes field have recognized the important role diabetes education plays in the 
patient's ability to manage the disease.  Over the years, diabetes education has 
been the focus of hundreds of research studies.  Most of the earlier research that 
focused on knowledge acquisition reported that depending on the combination of 
education interventions most showed beneficial effects.  Brown (1988) examined 
the effects of diabetes education in a meta-analysis study of 47 studies 
conducted from 1954 to 1986.  Overall, Brown found that the mean unweighted 
effect size was .91 (SD - 0.75) and the weighted mean effect size for controlled 
studies was .33 (SD - 0.01).  The strongest evidence of beneficial effects of 
diabetes education was the large weighted mean effect size of 0.84 calculated 
from the 13 studies that reported using glycosylated hemoglobin as the 
dependent variable.  
In the 1970s, new techniques became available to assess the metabolic 
control of diabetes. Glycosylated hemoglobin (GHB), a form of hemoglobin that 
reflects the average blood glucose concentration over a three-month period, 
gave researchers and clinicians a tangible, reliable measure of glycemic control 
(Gabbay, et al., 1977; Koenig, et al., 1976).  Technological advances in blood 
glucose monitoring allowed patients to perform glucose testing and make 
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management decisions at home.  These new techniques allowed researchers to 
measure the metabolic outcomes of diabetes education efforts. 
In a similar meta-analysis of diabetes education, Padgett (1988) and her 
colleagues examined 93 studies conducted from 1976 to 1986.  Overall, the 
unweighted mean effect size of 0.51 provided more support for the positive 
effects of diabetes education.  The authors were quick to point out that many of 
the studies were of poor quality and suffered weak study designs and numerous 
methodological problems.  Brown criticized numerous studies attempting to 
measure knowledge scores with instruments that had not been tested for 
reliability or validity.  Internal validity was a problem in several studies included in 
the meta-analysis that failed to examine the effects of high attrition rates.  Two 
earlier studies (Mulhauser, et al., 1983; Paulozzi, Norman, McMahon, & Connel, 
1984) attempted to measure the effects of diabetes education on metabolic 
control but without the use of a control.  The possibility that the improvement 
found could be a result of something besides the education intervention could not 
be ruled out.  
Although the results of the DCCT were promising, the practical 
considerations of implementing intensive management and comprehensive 
education programs in today's health care climate have been difficult to 
overcome.  With the introduction of prospective payment and managed care, 
many health care providers are faced with disincentives to provide diabetes 
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education.  In the 1980s, a Federal survey (Leicher, 1986) found less than 10% 
of the hospitals had structured diabetes self-care management training 
programs.  Coonrod et al. (1994) found only 35% of the diabetes population 
reported having attended any diabetes classes or education programs.  The 
major impediments to receiving adequate diabetes education are lack of 
physician referral and inadequate reimbursement for education services.  
Whereas the effectiveness of diabetes self-management training or education to 
improve metabolic control controversy still exists, there is a danger that those 
pressed to reduce costs may choose to agree with those studies that favor their 
own biases.  Will the number with severe knowledge deficits grow higher than the 
already high 50-80% levels previously reported (Coonrod, Betschart, & Harris, 
1994; Watkins, et al., 1967; Williams, et al., 1967)? 
Despite the plethora of studies that have attempted to answer the question 
of whether diabetes education effectively improves metabolic control, the results 
are still inconclusive.  Early studies examining the relationship between diabetes 
education and metabolic control were largely cross-sectional, correlational, or 
causal-comparative allowing no causal inferences to be made.  Little attention 
was paid to having adequate power to detect a difference if one truly existed.  
Sample sizes used were generally too small to detect realistic effect sizes that 
may actually exist between usual care and other educational interventions.  Due 
to ethical considerations, educational interventions could not be compared with a 
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no education control group.  In addition, most studies were criticized for 
employing weak research designs that lacked random selection and assignment, 
proper comparison with a control group, and inadequate control of extraneous 
factors that could influence glycemic control. 
Educational interventions varied in composition and comprehensiveness 
among studies making it difficult to arrive at any conclusions about whether 
diabetes education was effective or not (Clement, 1995).  Prompted by these 
concerns, Congress established the National Diabetes Advisory Board in 1983 to 
attempt to structure diabetes education and develop standards.  Educational 
programs that meet the national standards receive recognition from the American 
Diabetes Association.  ADA approved programs follow a goal-oriented approach 
that has been found to be highly successful at improving metabolic control 
(Assal, et al., 1985).  The goal-approach assumes that the patient is able to 
define or set goals and has the commitment and know-how to achieve the goals 
defined.  The goals of diabetes self-management education are to help the 
patient acquire the skills and knowledge to manage the day-to-day issues of 
diabetes, handle crises, and prevent diabetes-related complications.  The 
individual with diabetes must learn to test his or her own blood sugars, interpret 
the results, and balance their diet, exercise and medication.  Key elements of 
ADA comprehensive diabetes self-care management training include: an 
assessment of their educational needs; diabetes teaching individually tailored to 
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address the needs identified in the assessment; and a follow-up assessment to 
identify deficiencies and plan strategies to meet the patient's goals (Street, et al., 
1993).  ADA recognized programs follow standards for structure, process, and 
outcomes. 
Obviously, not all persons with diabetes are willing or able to perform the 
self-care behaviors needed to achieve good metabolic control.  Benefits of 
diabetes education may be minimal or non-existent if patients are not motivated 
or unable to make improvements in self-care.  Is it fair to determine the 
effectiveness of all diabetes self-care management training programs on 
metabolic control when some of these programs do not include metabolic control 
in their objectives?  In one of the few prospective studies that used a random, 
controlled design, Bloomgarden, et al. (1987) attempted to compare an 
educational intervention group with a usual-care group.  The education 
intervention utilized a traditional didactic approach that stated metabolic control 
was not one of the program's objectives.  The sample size a priori seemed 
adequate but failed to take into account the high rate of attrition expected in a 
long-term trial.  After randomization of 749 type 1 patients, 30% of the 
experimental group, and 26% of the control group refused to participate, 
jeopardizing the intent of randomization.  Only 71 out of 165 subjects in the 
experimental group completed seven out of nine educational sessions.   
Bloomgarden was unable to detect a significant difference in metabolic control 
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between the experimental group and the control group.  Mulhauser and Berger 
(1993) criticized the study for its unstructured, didactic educational approach and 
its lack of information on the insulin treatment used.  They cautioned that 
diabetes education cannot compensate for deficiencies of inappropriate insulin 
treatment regimens.   
Another controlled study conducted by Korhonen, et al., (1983), failed to 
demonstrate the impact of diabetes education on metabolic control using didactic 
educational methods.  Their sample size was small (N = 72)  and therefore the 
power was too low to detect significant differences between the experimental 
group receiving the 8 - 12 hours diabetes education intervention and a control 
receiving .5 hours of basic education.  Their study was also criticized for 
inadequate insulin therapy confounding the results.  The study did not measure 
glycosylated hemoglobin which is considered essential when attempting to 
measure metabolic control. 
In contrast, long-term prospective studies that incorporated behavioral 
change strategies demonstrated improvement in metabolic outcome (Delamater, 
et al., 1991; Hartwell, Kaplan, & Wallace, 1986; Kaplan, et al., 1987; Laitinen, et 
al., 1993; Raz, Soskolne, & Stein, 1988; Wooldridge, et al., 1992).  In a large-
scale randomized, controlled clinical trial, Mazzuca et al. (1984) found a 
significant difference between the experimental group receiving comprehensive 
diabetes education and a control group receiving routine education.  They 
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studied the effects of education on knowledge, skills and self-care behaviors on a 
study population of predominantly elderly black women with non-insulin treated 
type 2 diabetes.  Garrard et al. (1990) found, using a quasi-experimental design, 
a statistically significant improvement in Hgb A1c values from pre- to post-
intervention in the experimental group receiving a five-day comprehensive 
diabetes self-care management training program.  Because of their weaker 
design, these improvements in metabolic outcome can only be associated with 
the treatment rather than caused by the intervention.  
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Continuous Glucose Monitoring 
A new glucose monitoring device approved by the FDA in 1999, the 
Continuous Glucose Monitoring System (CGMS) developed by MiniMed Inc., 
provides a novel minimally invasive technique that continually measures glucose 
levels using a miniscule (0.5ul) sample of dermal interstitial fluid.  The 
Continuous glucose monitoring system records tissue glucose levels at five 
minute intervals for up to 3 days.  Information provided from the continuous 
glucose monitoring system CGMS) has helped identify patient-specific patterns 
of glucose control. Previous studies have shown that dermal interstitial glucose 
measurements by the CGMS closely correlate to capillary glucose meter 
measurements and venous blood laboratory values (Jansson, Fowelin, Smith & 
Lonnroth, 1988; Service, O’Brien, Wise, Ness & LeBlanc, 1997; Bolinder, 
Hagstrom-Toft, Ungerstedt &Arner, 1997).   
Although capillary self-monitoring of blood glucose (SMBG) levels has 
been a mainstay in intensive management of diabetes, the true variations in 
blood glucose levels may not be detected by conventional SMBG recording. The 
glucose sensor data in conjunction with frequent SMBG measures can be helpful 
to identify glucose excursions including asymptomatic hypoglycemia.  The 
information obtained from the sensor can facilitate decisions concerning diabetes 
management and provide evaluation of treatment options.  The sensor may also 
be used to help patients see directly the glycemic effects of food intake and 
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exercise and may motivate or act as cues to facilitate behavior change.  A pilot 
study using the MiniMed continuous glucose monitoring system in nine poorly 
controlled type 1 subjects (mean HgbA1c 9.9%) showed a reduction of mean 
HgbA1c to 8.8 % in a 5 week period (Bolinder, Hagstrom-Toft, Ungerstedt & 
Arner, 1997). 
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Implications for Future Research 
A prospective study design is needed to assess the role of health beliefs, 
and the conditions under which they may be modified to improve the health-
related outcome.  The real promise of the Expanded Health Belief Model lies in 
its usefulness not only to explain and predict behavior but to apply this 
understanding to develop different intervention strategies to change these beliefs 
in order to direct their behavior towards the right direction.  Certain variables in 
the model can be modified to produce the desired outcome.  Some HBM 
variables have already been successfully manipulated to improve health-related 
actions.  For example, action can be triggered by appropriate communications 
such as reminder postcards, follow-up phone calls, lab reports, and mass media 
campaigns. New technologies such as the continuous sensor can be employed 
as cues to action by showing patients the effects of their diabetes therapies.  
Barriers can be minimized by addressing the salient issues of the individual 
involved such as cost of the treatment, insurance coverage, fear of adverse 
reactions, or complexity of the regimen.  By knowing the perception of the 
individual, the practitioner may dispel any misconceptions, and improve the 
persons’ understanding of the efficacy and relevant issues relative to the 
advocated health action.  The scheme of the Health Belief Model developed by 
Becker (1974) has been revised to illustrate the mutable variables that affect 
diabetes self-care (Figure 4).  The highlighted variables reflect the variables that 
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have potential for improvement from diabetes education intervention.  Knowledge 
of the disease, perceived susceptibility, and seriousness of the disease, 
perceived threat of the disease, perceived benefits minus barriers, as well as 
modifying factors such as attitudes, beliefs, skills, self-efficacy, and cues to 
action can be modified to improve the likelihood of diabetes self-care 
management. 
In summary, the literature suggests that most diabetes education 
interventions have positive effects on knowledge; but in order for diabetes 
education to effectively improve metabolic control it must be able to motivate and 
enable the patient to adopt self-care behaviors.  In order to overcome many of 
the obstacles encountered in previous studies, several conditions must be met.  
First, a prospective randomized, controlled trial is necessary to assure that 
demographic, psychosocial, and clinical factors have an equal chance of being in 
the experimental or control group.  Additional follow-up studies are needed to 
examine the long-term effects of diabetes education on glycemic control, 
complication rates, and other important outcomes such as costs associated with 
increased health care utilization, disability, and quality-of-life issues.  
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Figure 4.   
The Health Belief Model as Predictor of Diabetes Self-care Behavior  
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 86 
Chapter Three: Methods 
This chapter describes the methods to be used in this study.  It includes 
the purpose of the study, the hypothesis, research questions, and the research 
plan consisting of the population and sample, instrumentation, procedures, data 
collection and analysis. 
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Purpose of the Study 
The purpose of this study was to determine if persons with diabetes 
participating in an ADA diabetes self-management education with intensive 
follow-up care achieve better metabolic control than the standard follow-up care. 
The intensive follow-up group differs from the standard follow-up group by 
utilizing a MiniMed continuous glucose sensor. This study sought evidence as to 
whether the data obtained from the sensor could lead to improved HgbA1c 
values by facilitating understanding of patient specific patterns of glucose control 
and in facilitating appropriate changes in diabetes management. 
The specific aims of this investigation were: 
1. To determine whether there was a statistically significant difference in 
mean Hgb. A1c values over time (week 1, week 12, and week 24) for the 
intensive follow-up group (SFG) compared to a standard follow-up control 
group (IFG). 
2. To determine if there were statistically significant changes in mean scores 
for health beliefs measured by the Revised Diabetes Health Belief 
Questionnaire subscales (perceived barriers, perceived severity, 
perceived susceptibility, perceived benefits, cues to action, health 
motivation, perceived self-efficacy ability, and structural elements) over 
time (from week 1 to week 24) for the intensive follow-up group compared 
to the standard follow-up control group.  
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3. To assess whether persons with diabetes who participated in the intensive 
follow-up group had any significant differences in diabetes self-care 
practice scores compared to the standard follow-up control group. 
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Hypothesis 
This prospective study compared the effectiveness of an intensive follow-
up group compared with standard care follow-up of participants of an ADA 
diabetes self-management education program on metabolic control, diabetes 
self-care behaviors and health beliefs.  The randomized pretest-posttest control 
group design tested the following null hypothesis: 
Ho: There is no significant difference in mean glycosylated hemoglobin 
(HgbA1c) value over time (week 1, week 12, and week 24) for participants of a 
ADA diabetes self-management education program assigned to the intensive 
follow-up group  (Utilizing the MiniMed sensor) compared to a standard follow-up 
control group. 
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Research Questions 
This investigation also attempted to answer the following questions: 
1. Is there any significant difference in mean glycosylated hemoglobin 
values over time (week 1, week 12, and week 24) between those 
participants of the ADA diabetes self- management education 
(DSME) randomly assigned to the intensive follow-up group or the 
standard follow-up control group? 
2. Are there any significant profile differences in mean Health Belief 
Model subscale scores (perceived barriers, severity, susceptibility, 
benefits, self-efficacy, cues to action, motivation and structural 
elements) between the DSME participants assigned the intensive 
follow-up and the standard follow-up control group over time?  
3. Is the difference between the week 1 and the week 24 mean 
perceived barrier scores of the intensive follow-up group 
significantly different compared to the standard follow-up control 
group? 
4. Is the difference between the week 1 and the week 24 mean 
perceived benefits score of the intensive follow-up group 
significantly different compared to the standard follow-up control 
group? 
5. Is the difference between the week 1 and the week 24 mean 
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perceived self-care ability scores of the intensive follow-up group 
significantly different compared to the standard follow-up control 
group? 
6. Is the difference between the week 1 and the week 24 mean 
perceived severity scores of the intensive follow-up group 
significantly different compared to the standard follow-up control 
group? 
7. Is there a significant difference between the week 1 and the week 
24 mean perceived susceptibility scores of DSME participants 
randomly assigned to the intensive follow-up group compared to 
the standard follow-up control group? 
8. Is there a significant difference between the week 1 and the week 
24 mean perceived cues to action scores of DMSE participants 
randomly assigned to the intensive follow-up group compared to 
the standard follow-up control group? 
9. Is there a significant difference between the week 1 and the week 
24 mean structural elements scores of DMSE participants randomly 
assigned to the intensive follow-up group compared to the standard 
follow-up control group? 
10. Is there a significant difference between the week 1 and the week 
24 mean diabetes self-care practice scores of DSME participants 
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randomly assigned to the intensive follow-up group compared to 
the standard follow-up control group? 
This study seeks evidence as to whether type 2 diabetes participants of an 
ADA diabetes self- management education program randomly assigned to the 
intensive follow-up group have any significant differences in their HgbA1c values, 
health beliefs, and diabetes self-care behaviors over time compared to a 
standard follow-up group.  The intensive follow-up group differs from the 
standard follow-up group by utilizing a continuous glucose sensor to determine 
blood glucose patterns and responses to exercise, medications, food intake, and 
other daily activities.  
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Research Plan 
Population and Sample 
The sample was recruited from a diabetes population receiving care within 
the Tampa Bay area.  The area has an ethnically diverse population.  Numerous 
cultures and socio-economic backgrounds are represented, such as Anglo-
Americans and persons of other European heritage, African-Americans, Asians, 
Hispanics, and Native Americans.  The Tampa Bay area is comprised of both 
urban and rural communities.  The study population was limited to literate 
English-speaking Adults ages 18 or older with type 2 diabetes.  The study is 
further limited to consenting adults referred to the University Community Hospital 
by their physicians. Participants had to be referred to the program by the 
physicians who had evaluated their health status and determined that they were 
medically stable and able to participate in all diabetes self-care activities.  
Persons with medical problems that impair their ability to perform diabetes self-
care management were ineligible for the study.  The case manager during the 
initial assessment validated the health status of persons referred to the study.   
Pertinent medical information was documented on the baseline evaluation form 
(see Appendix 1).  Any physical and mental impairments that limit participation in 
diabetes self-care were discussed with the referring physician who determined 
whether the person was able to participate in the study.  Other exclusion criteria 
for the study are listed in Table 1. 
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The recruitment strategies included advertising in newsletters  published 
by the University Community Hospital.  Letters and flyers were mailed to Tampa 
area physicians and persons with diabetes interested in attending DSME.   
Persons with diabetes who were on existing mailing lists also were sent flyers 
about the study, including how to be referred by a physician.  Flyers also were 
distributed at the USF Medical Clinics, University Square Mall and Citrus Park 
Mall Health Source Centers, and at diabetes special events such as University 
Community Hospital annual Sugarfest and at diabetes fundraiser events (see 
Appendix 2).  Both physicians and patients were made aware of the purpose and 
design of the study.  During the initial assessment, patient informed consent 
forms were signed prior to random assignment (see Appendix 3).  The study was 
reviewed and approved by the University of South Florida Institutional Research 
Board and the University Community Hospital Research Committee.  
 
 95 
Table 1. 
Exclusion Criteria  
? Persons with type 1 diabetes , gestational diabetes, or secondary 
diabetes 
? Pregnant women 
? Patients with concomitant conditions or in poor health that impairs 
ability to participate in self-care management activities or limits life 
expectancy as determined by their physician 
? Persons with diabetes who have participated in other diabetes self- 
management education programs within last year  
? Persons with diabetes who are unwilling to attend scheduled 
sessions over a six-month period  
? Persons with diabetes who have any form or history of 
hemoglobinopathy or hemolytic process that could interfere with 
reliable assessment of Hgb A1c    
? Persons with diabetes with HgbA1c less than 7.0% or greater than 
13.0% 
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Enrollment continued until a minimum of 159 participants completed the 
program to achieve adequate power (0.80) at a 0.05 alpha level.  A priori sample 
size was based on minimum sample size calculations for a 2-group repeated 
measures design (Vonesh & Chinchilli, 1997) for a maximum correlation of .90 
with a minimum standardized difference (T/s) of 0.5 (see Table 2). The control 
group size of 78 allowed for a 30% attrition rate and the intervention group size of 
81, a 35% attrition rate.  Self-addressed reminder cards were completed.  Prior to 
appointments, reminder cards were mailed or reminder phone calls were made to 
help minimize attrition.  
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Table 2.   
 
Minimum Sample Sizes per Group for Testing the Hypothesis of Equal Group 
Effects in a Two Group RM Design  
 
 
Number of  
groups 
 
 
Number of 
treatments 
(time) 
 
 
Maximum 
correlation 
 
 
Standardized difference:  T/s 
 
 
 
 
 
 
 
0.50
 
0.75
 
1.00 
 
1.25 
 
1.50 
 
2.00
 
2 
 
2 
 
0.0
0.1
0.3
0.5
0.7
0.9
 
32
35
41
48
54
60
 
14
16
19
21
24
27
 
9 
10 
13 
14 
15 
16 
 
7 
7 
8 
9 
10 
11 
 
5 
6 
6 
7 
8 
8 
 
4
4
4
5
5
5
 
 
 
 
3 
 
0.0
0.1
0.3
0.5
0.7
0.9
 
21
26
34
41
51
59
 
10
13
15
19
23
27
 
7 
8 
10 
12 
14 
16 
 
5 
6 
7 
8 
10 
11 
 
4 
5 
5 
6 
7 
8 
 
4
4
4
4
5
5
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Table 2 (continued).   
 
 
Number of  
groups 
 
 
Number of 
treatments 
(time) 
 
 
Maximum 
correlation 
 
 
Standardized difference:  T/s 
 
 
 
 
4 
 
0.0
0.1
0.3
0.5
0.7
0.9
 
16
21
30
40
49
59
 
8
10
14
18
22
26
 
6 
7 
9 
11 
14 
16 
 
5 
5 
6 
7 
8 
11 
 
4 
5 
5 
6 
7 
8 
 
5
5
5
5
5
5
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
0.0
0.1
0.3
0.5
0.7
0.9
 
13
18
28
38
48
58
 
6
8
13
17
22
26
 
6 
6 
8 
11 
13 
16 
 
6 
6 
6 
8 
9 
11 
 
6 
6 
6 
6 
7 
8 
 
6
6
6
6
6
6
 
 
 
 
6 
 
0.0
0.1
0.3
0.5
0.7
0.9
 
11
16
27
37
48
58
 
5
8
12
17
21
26
 
7 
7 
8 
11 
13 
16 
 
7 
7 
7 
7 
9 
11 
 
7 
7 
7 
7 
7 
8 
 
7
7
7
7
7
7
Note.  Adapted from Rochon (1991, Table 3). 
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Procedures 
Subjects with diabetes who were willing to participate and meet eligibility 
requirements signed the informed consent and completed the initial Revised 
Health Belief Questionnaire.  A complete diabetes assessment (following 
American Diabetes Association guidelines) and initial evaluation forms were 
completed by the case manager (see Appendix 1 for initial evaluation and initial 
assessment forms). To reduce selection bias, both the interviewing case 
manager and participants were not aware of group assignment at the time of the 
initial assessment.  To minimize selection bias, a program assistant not involved 
in patient assessment or teaching randomly assigned patients to an intervention 
or control group.  In the initial diabetes assessment a variety of demographic, 
psychosocial, and clinical information was compiled including: the patient's 
medical history; present health status; previous education; health services 
utilization; diabetes knowledge; skills; attitudes; social and financial support 
systems; barriers to learning; self-care; and associated medical conditions or risk 
factors.  
During the initial visit, patients completed the Revised Diabetes Health 
Belief Questionnaire (see Appendix 4), comprised of the DHBS, EBAS, and 
DSES (Harris, et al., 1987; Hess, Davis, & Van Harrison, 1986; Irvine, 1996).  
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Each scale was tested rigorously and found to be valid and reliable.  Content 
validity was examined during a pilot test, and reliability was confirmed with the 
target diabetes population.  The case manager scored the various subscales of 
the questionnaire and recorded them on the initial evaluation form.  The program 
assistant placed all forms in medical records.  To reduce potential for investigator 
bias, testing information was recorded separately and filed in medical records 
until compiled for data analysis.   
Physiological Instrumentation 
The primary variable selected to measure diabetes control is glycosylated 
hemoglobin or Hgb A1c.  The Hgb A1c has been substantiated in the literature as 
a reliable biochemical test able to quantify the average glycemic levels for an 8-
12-week period.  Glycosylated Hgb is also a useful surrogate marker for 
development of diabetes-related complications (Gabbay, et al., 1977; Koenig, et 
al., 1976).  The Hgb A1c employed a capillary blood glucose sample analyzed 
using a Micro Optical Detection method (A1cNow, Metrika, Inc, Sunnyvale, Ca). 
The normal range of the assay is 4.3 to 5.9. Comparisons with a National 
Glycohemoglobin Standardization Program (NGSP) certified reference method 
showed a within-laboratory precision of 5%.  Capillary-drawn blood and venous-
drawn blood have shown to be equivalent (R2 = 0.89).  Cagliero, Levina, and 
Nathan (1999) found that immediate capillary HgbA1c testing provided accurate 
and reliable results in office based settings. The capillary blood volume 
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requirement for the test is 10 micro-liters obtained by a standard lancet 
technique.  The analytical method is able to detect abnormal hemoglobin (e.g. 
sickle cell, anemia, polythysemia), interfering substances (e.g. bilirubin, 
coumadin) and nonviable samples. 
A pilot test was initiated by the Diabetes Treatment Center at University 
Community Hospital in August 1996 to analyze the feasibility of using capillary 
Hemoglobin A1c measurements, pre-participation and post-participation in a 
diabetes self-management outpatient program.  Thirty volunteer participants who 
were tested prior to the program also were re-tested three months after 
completing the diabetes self-management program.  The mean Hgb A1c before 
the program was 9.26% compared to the mean Hgb A1c of 7.52% three months 
after completion of the program (Figure 5).  Ten capillary-drawn samples were 
compared with simultaneously venous-drawn sample analyzed by the central lab 
method, which uses electrophoresis.  A coefficient of variation of .997 was found 
between the two methods.  The inter-rater Kappa coefficient was .97.
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Figure 5.   
Pilot Study Results  
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Psychosocial Instrumentation 
The revised Expanded Health Belief Model Questionnaire (EHBMQ) was 
designed from three established diabetes-specific instruments; the Diabetes 
Health Belief Scale (DHBS) (Harris, et al., 1987); the Environmental Barriers to 
Adherence Scale (EBAS) (Irvine, Saunders, Blank, & Carter, 1990); and the 
Diabetes Self-Efficacy Scale (DSES) (Crabtree, 1987).  The scales selected had 
undergone rigorous reliability and validity testing.  The DHBS was developed and 
validated by Harris, et al. (1987).  Test items were generated from the HBM 
literature and previously developed scales.  Test-retest correlates on a sample of 
30 men were used to determine item reliability.  Items with greater than 0.35 test-
retest correlation and standard deviations of 0.40 were retained.  A factor 
analysis was conducted on a larger sample of 280 male veterans, 7 interpretable 
factors representing the 7 dimensions of the HBM (severity, susceptibility, 
predictive psychological barriers, treatment beneficial, cues to action, health 
motivation, and structural elements) were found providing evidence of construct 
validity.  Convergent validity was established with a tested sample of 120 men. 
The developers found that health beliefs accounted for 15% of the total variance 
in compliance to diabetes self-care and 23% of the total variance in diabetes 
control.  The EBAS was added to the questionnaire to overcome one of the major 
limitations of the DHBS.  The scale only measures psychological barriers.  In 
addition, Irvine et al. (1990) overcame other shortcomings of previous scales by 
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increasing the number of barriers measured and being able to differentiate the 
sensitivity of each individual to the barriers.  The EBAS was rigorously tested for 
reliability and validity using 214 individuals with type 1 and type 2 diabetes.  The 
test-retest reliability for the total scale was 0.80 (p < 0.001).  Test-retest reliability 
scores on the subclass were 0.59 for medication barriers, 0.59 for exercise 
barriers, 0.74 for glucose testing barriers, and 0.74 for diet barriers (p < 0.001 for 
each subscale).  Cronbach’s alpha for the total scale was 0.94, with subscales 
ranging from 0.84 to 0.94, indicating high internal consistency. 
Content validity was established by having a panel of five diabetes experts 
review the scale for representativeness.  Evidence of concurrent validity was 
established through the correlation with two other barrier scales, the Barriers to 
Adherence Scale (BAS) developed by Glasgow, McCaul and Schafer (1986), and 
the Diabetes Care Profile – Barriers to Adherence Subscale (DCP-BAS) 
developed by Davis, Hess, Van Harrison and Hiss (1987).  Moderate correlation 
were found ranging from r = 0.34 to 0.62 for the BAS and r = 0.30 to 0.51 for the 
DCP-BAS.  
Convergent validity was determined by the scale’s correlation with self-
care behavior, measured by the diabetes self-care behavior (DSCB) scale.  Self-
care behaviors included in the scale were diet, exercise, medication, glucose 
testing, alcohol consumption, foot care, and carrying diabetes identification.  The 
EBAS correlated well with each corresponding adherence behavior (diet, 
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exercise, medication, and glucose testing), and less well with non-corresponding 
behaviors (foot care, alcohol use, and carrying identification).  Correlation with 
corresponding adherence behaviors ranged from r = -0.33 to -0.52 (p < 0.05), 
reflecting a consistent negative relationships between behaviors.  In addition, 
Hgb A1c was found to be correlated with the total EBAS (r = 0.28, p < 0.001).   
The EHBMQ also includes a diabetes self-efficacy subscale; a ten-item 
subscale was devised from the self-efficacy theoretical literature (Bandura, 
1977a; 1977b), and the Diabetes Self-Efficacy Scale (DSES) developed by 
Crabtree (1987) in collaboration with Bandura.  The DSES work was tested on 
143 persons with type 1 and type 2 diabetes yielding internal consistency for the 
total scale (standardized alpha = 0.71).  Using the DSES, Crabtree found 25% to 
33% of the variance in diabetes self-care behaviors could be explained by self-
efficacy (after controlling for the effects of age, sex, marital status, types of 
diabetes, severity, and number of complications) providing evidence of construct 
validity.  
The revised Expanded Health Belief Model Questionnaire comprised of 
the three established diabetes-specific health belief scales was designed to 
measure the following aspects of the model: 
? Perceived susceptibility which measures the person with diabetes 
perceptions of their own risk of developing diabetes or its complications, 
and measures the perceived threat of becoming ill or having a condition 
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become worse from diabetes. Perceived severity is a person’s perception 
of the consequences of diabetes and its associated complications (pain, 
death, disability) and how much interference in their lives they perceive 
are due to diabetes.  
? Perceived benefits measure beliefs regarding the effectiveness of 
diabetes self-management in reducing the threat of diabetes and its 
complications.  It also measures the person’s faith in curative powers of 
the physician and that the recommended action or intervention by their 
physician will result in a reduction in the health threat.  
? Perceived barriers measures psychological and situational obstacles that 
would have to be overcome in order for a person to follow the 
recommended diabetes regimen.  It measures the potential negative 
aspects of the diabetes treatment perceived by the person. 
? Cues to action assess the symptoms or motivating factors such as health 
messages that are likely to lead to seeking medical care or follow positive 
health behaviors.  
? Structural elements assess modifying factors such as a person’s locus of 
control, social support, and understanding of diabetes and the treatment 
regimen.  
? Health motivation measures general health motivation or concern for one’s 
own health.  
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? Perceived self-efficacy measures a person’s own assessment of their 
ability to perform diabetes self-care or engage in diabetes-specific health 
behaviors. Each item in the questionnaire was assigned to one of the eight 
subscales designed to measure the dimension.  Responses follow a 
common 4-point Likert scale.  The higher the scores within each subscale, 
the greater the influence of the belief or concept.   
Content validity of the revised EHBMQ was strengthened by use of 
established reliable and valid scales, a thorough literature review, personal 
diabetes education experience, and the use of a panel of experts, eight certified 
diabetes educators, four HBM research experts, and one statistical measurement 
expert.  The diabetes experts evaluated the instrument with regards to diabetes 
self-care management, while the HBM experts evaluated the items in terms of 
the representative of the dimensions of the EHBM.  The statistical measurement 
expert reviewed the scales for overall measurement design.  
During pilot-testing of the revised questionnaire, ten individuals with 
diabetes who previously participated in diabetes self-care management training 
were asked to complete the questionnaire on two separate occasions,10-14 days 
apart.  Comments about the questionnaire items were encouraged.  Overall, the 
questionnaire was found to be easy to understand and to administer, taking 
between 10 and 20 minutes to complete.  Feedback from the individuals 
indicated that the wording and reading level were appropriate for the target 
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population.  The SMOG readability formula applied to the revised questionnaire 
indicated an 8th grade level.  The SMOG is generally reliable within 1.5 grade 
levels (McLaughlin, 1969). Concurrent validity is if the HBM factors are logically 
associated with metabolic control.  Lower barrier scores, higher severity, 
susceptibility benefits, self-efficacy, cues to action, health motivation, and 
structural element scores are expected to account for improved Hgb A1c values.  
Expanded Health Belief Model Questionnaire Reliability and Validity 
Results 
Although previous studies established the validity and reliability of the 
health belief subscales used to make up the revised Expanded Health Belief 
Model Questionnaire (EHBMQ), the instrument was pilot tested in the type 2 
diabetes target population. Ten patients were asked to comment on all aspects of 
the questionnaire: time it takes to complete, ease of format, any questions that 
were unclear or ambiguous. During pilot testing, questions that were ambiguous 
or difficult for the target group to understand were modified. The instrument was 
examined by a panel of diabetes experts for content validity, ease of use and 
SMOG testing to confirm an 8th-grade reading level. Reliability was re-confirmed 
by test-retest measurement using ten additional patients with type 2 diabetes; the 
revised questionnaire was administered twice within 10 to14 days to confirm test-
retest reliability. Statistical analysis of the revised questionnaire was performed 
using SAS procedures (SAS Institute, Cary, NC). Table 3 shows which questions 
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are included in each scale, the range of possible scores, and the interpretation of 
the score. 
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Table 3:   
Revised Diabetes Health Belief Model Questionnaire Formulae  
Scale name 
Subscale 
name Scale equationa 
Range of 
possible 
scores 
on scale Interpretation of score 
Perceived 
susceptibility --- 
Σ9, 11, 19, 21, 
23, 32, 35, 39, 43 9-36 >18 considered high 
Perceived treatment 
benefits --- 
Σ5, 6, 7, 8, 10, 
13, 17, 18, 31, 40 10-40 >20 considered high 
Perceived severity --- 
Σ16, 20, 22, 25, 
26, 36, 38, 41 8-32 >16 considered high 
Cues-to-action --- 
Σ15, 29, 37, 42, 
44, 45 6-24 >12 considered high 
Perceived barriersb --- 
Σ4, 14, 57, 60, 
63, 66 65-260 >126 considered high 
Perceived barriers Medication Σ57.1-57.15 15-60 >30 considered high 
Perceived barriers Diet Σ60.1-60.15 15-60 >30 considered high 
Perceived barriers Exercise Σ63.1-63.16 16-64 >32 considered high 
Perceived barriers Monitoring Σ66.1-66.17 17-68 >34 considered high 
 111 
Table 3 (continued). 
Scale name 
Subscale 
name Scale equationa 
Range of 
possible 
scores 
on scale Interpretation of score 
Structural elements 
(understanding, social 
support) 
 --- Σ3, 12, 24, 34 4-16 >8 considered high 
Motivation --- 
Σ1, 2, 27, 28, 30, 
33 6-24 >10 considered high 
Self-efficacy --- 
Σ46, 47, 48, 49, 
50, 51, 52, 53, 54 9-36 >18 considered high 
Note:  The range of scores per question is 1 to 4. Missing item scores 1 (Not at all) on all scales 
except for Perceived Barriers questions 57 (15-60), 60 (15-60), 63 (16-64), and 66 (17-68) 
aQuestion numbers. 
bPerceived Barriers subscales: The following subscales are calculated and represent one 
"question" in the Perceived Barriers scale: Medication (Q57), Diet (Q60), Exercise (Q63), 
Monitoring (Q66). 
 
The results of the ANOVA confirmed good test-retest reliability for each 
Health Belief subscale (see Table 4).  In Table 4, each row represents an 
ANOVA model.  In the model, the score on the scale or subscale is the 
dependent variable, and the two independent variables introduced into the model 
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are patient identification number (“patient” in the Table 4), and time (1 or 2).  The 
F-test value and the p-value on the F-test are reported.  If the F-test is large 
enough so as to generate a small enough p-value, then the ANOVA model is 
considered to fit well enough to allow interpretation of the mean square values for 
each covariate.  All F-tests had an associated p-value of <0.05, so all models 
were interpreted.  The patient mean square p-values were all <0.05, which would 
be expected.  This suggests that patient identification explained a significant 
amount of variability in the model.  If the instrument is reliable, the time covariate 
should not explain a significant amount of variability in the model.  In other words, 
it should not matter when the patient completes the instrument, the results should 
be similar.  The time covariate was highly non-significant in all models, 
suggesting this was the case. The correlation coefficients ranged from 0.65 for 
the perceived severity scale to 0.91 for the treatment benefit subscale. 
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Table 4.   
Reliability of Health Belief Scales and Subscales  
    
Reliability of Scale from Time 1 to Time 
2 (ANOVA) 
(n=10) 
Correlation 
Coefficient from 
Time 1 to Time 2
(n=10) 
Scale Name 
Subscale 
Name 
F Test 
value 
p-value 
on F 
test 
Patient 
Mean 
Square
p-value 
Time 
Mean 
Square 
p-value r 
r-
squared 
Perceived 
susceptibility --- 12.15 0.0004 0.0003 0.2339 0.86 0.74
Perceived 
treatment 
benefits --- 17.10 0.0001   <.0001 0.2259 0.91 0.83
Perceived 
severity --- 3.15 0.0493 0.0381 0.8321 0.65 0.43
Cues-to-action --- 12.54 0.0004 0.0003 0.5911 0.88 0.78
Perceived 
barriersa --- 7.46 0.0029 0.0022 0.3452 0.79 0.62
Perceived 
barriers Medication 21.38
 
<.0001   <.0001 0.6618 0.93 0.87
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Table 4 (continued). 
    
Reliability of Scale from Time 1 to Time 
2 (ANOVA) 
(n=10) 
Correlation 
Coefficient from 
Time 1 to Time 2
(n=10) 
Scale Name 
Subscale 
Name 
F Test 
value 
p-value 
on F 
test 
Patient 
Mean 
Square
p-value 
Time 
Mean 
Square 
p-value r 
r-
squared 
Perceived 
barriers Diet 5.35 0.0094 0.0071 0.5765 0.71 0.51
Perceived 
barriers Exercise 7.16 0.0034 0.0025 0.8777 0.81 0.66
Perceived 
barriers Monitoring 10.61 0.0008 0.0006 0.1965 0.85 0.72
Structural 
elements 
(understanding, 
social support) --- 10.29 0.0009 0.0006 0.5203 0.84 0.70
Motivation --- 5.03 0.0116 0.0087 0.7577 0.73 0.54
Self-efficacy --- 12.14 0.0004 0.0003 0.7804 0.87 0.75
aPerceived Barriers subscales: The following subscales are calculated and represent one 
"question" in the Perceived Barriers scale: Medication (Q57), Diet (Q60), Exercise (Q63), 
Monitoring (Q66). 
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Cronbach Alpha procedures were employed to test the questions and 
subscale scores at each time period (see Table 5)  
 
Table 5.   
Cronbach Alpha Results for Health Belief Scales and Subscales at Times 1 and 
2  
    
Cronbach Alpha for Scale
Time 1 
(n=10) 
Cronbach Alpha for Scale
Time 2 
(n=10) 
Scale name 
Subscale 
name Raw 
Standard
-ized Raw 
Standard-
ized 
Perceived susceptibility --- 0.82 0.81 0.87 0.85
Perceived treatment 
benefits --- 0.72 0.77 0.86 0.88
Perceived severity --- 0.20 0.33 0.68 0.66
Cues-to-action --- 0.59 0.60 0.72 0.73
Perceived barriersa --- 0.45 0.54 0.56 0.68
Perceived barriers Medication 0.77 b 0.68 b 
Perceived barriers Diet 0.87 b 0.78 b 
Perceived barriers Exercise 0.62 b 0.81 b 
Perceived barriers Monitoring 0.73 b 0.54 b 
Structural elements 
(understanding, social 
support) --- 0.42 0.53 0.57 0.64
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Table 5 (continued). 
    
Cronbach Alpha for Scale
Time 1 
(n=10) 
Cronbach Alpha for Scale
Time 2 
(n=10) 
Scale name 
Subscale 
name Raw 
Standard
-ized Raw 
Standard-
ized 
Motivation --- -0.04 0.06 0.55 0.62
Self-Efficacy --- 0.87 0.88 0.84 0.86
aPerceived Barriers subscales: The following subscales are calculated and represent one 
"question" in the Perceived Barriers scale: Medication (Q57), Diet (Q60), Exercise (Q63), 
Monitoring (Q66). 
bNot calculable due to lack of variance on several questions. 
 
In Table 4, p-value on the F-test for each subscale showed significance 
indicating that the difference between time one and two were due to individual 
differences rather than time differences. All time mean square p-values were not 
significant.  Time two standardized Cronbach alpha values ranged from 0.62 for 
motivation scale to 0.87 for perceived treatment benefits (see Table 5). The 
Cronbach alpha results for individual questions are in Appendix 11 
Perceived self-efficacy measures a person’s own assessment of their 
ability to perform diabetes self-care or engage in diabetes-specific health 
behavior. The 4-point Likert subscale scores range from 9 (low self-efficacy 
score) to 36 (highest score); the mean self-efficacy score for all participants was 
30.31. The control and intensive groups mean at baseline was similar: 30.20 
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compared to 30.41 reflecting moderately high self-efficacy scores before 
intervention.  All nine questions of the subscale had high alpha values 0.85 or 
higher. The overall standardized Cronbach alpha score was 0.88 at time one, 
and 0.86 at time two.   
The perceived susceptibility subscale measures the person’s perception of 
his or her own risks associated with diabetes. The scale scores range from 9 to 
36 (lowest  to highest). The mean for all participants at baseline was 27.94.  Both 
groups had similar high mean susceptibility scores at baseline.  The Cronbach 
alpha for each of the nine test items was 0.746 or higher. The overall 
standardized Cronbach alpha for the subscale was. 0.81 at time one and 0.85 at 
time two. 
The perceived benefits subscale measures the diabetic’s belief in the 
effectiveness of the diabetes treatment regimen and their faith in their physician’s 
recommendations to reduce the threats posed by diabetes and its complications.  
The scale ranges from 9 (lowest score) to 36 (the highest). The mean for all 
participants at baseline reflected a high mean score of 36.32.  The groups 
showed no pre-intervention differences. The Cronbach alpha for the nine test 
questions were 0.746 or above.  The overall standardized Cronbach alpha for the 
subscale was 0.77 at time one and 0.88 at time two. 
The severity subscale measures a person’s perception of the burdens and 
consequences (e.g. pain, death, disability) associated with diabetes. The 
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subscale ranges from 8 to 32 (lowest to highest score).  The overall mean at 
baseline was 25.46.  Both control and intensive groups had similar high mean 
scores 25.52 and 25.40, respectively.  The Cronbach alphas for the eight test 
items were 0.542 or above. The overall standardized Cronbach alpha for the 
subscale was 0.33 at time one, and 0.66 at time two. 
The cues-to-action subscale assesses the person’s response to 
symptoms and modifying factors such as health messages that are likely to result 
in obtaining medical care or engaging in positive health behaviors.  The subscale 
ranges 6 to 24 (low to high).  The overall mean was 17.88 -- both groups had 
similarly high mean scores at baseline: 18.23 for the control and 17.51 for the 
intensive group.  The Cronbach alphas for the six items were 0.66 or higher.  The 
overall standardized Cronbach alpha for the subscale was 0.60 at time one, and 
0.73 at time two.  
The structural element subscale assesses the modifying factors such as a 
person’s locus of control, social support, and understanding of diabetes and the 
treatment regimen.  The subscale ranges from 4 to 16 (lowest to highest).  The 
overall mean was 10.88, with no significant pre-intervention differences.  The 
Cronbach alphas for the four test items ranged from 0.33 to 0.74.  The overall 
standardized Cronbach alpha subscale was 0.53 at time one and 0.64 at time 
two. 
The motivation subscale measures a person’s concern for his or her own 
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health.  The subscale ranges from 6 to 24 (low to high).  The overall mean was 
high (18.01) as well as both control and intensive group, (17.84, 18.20, 
respectively). The Cronbach alphas for the six test items were 0.48 or above.  
The overall standardized Cronbach alpha was 0.62. 
The barriers subscale measures perceived psychological and situational 
obstacles to overcome for a person to carry out the recommended diabetes 
regimen.  The scale measures barriers to each pertinent diabetes treatment area, 
medications, diet, exercise and monitoring.  The scale ranges from 65 to 260 
(lowest to highest).  The mean for all participants was 94.74.  Both the control 
and intensive group had similar mean scores 93.41 compared with 96.15, 
respectively.  The Cronbach alphas for the six test items (note that these 
questions have multiple parts) were 0.60 or higher.  The overall subscale 
standardized Cronbach alpha was 0.54 at time one and 0.68 at time two. 
The Diabetes Self-Care Practice Assessment was designed to measure 
diabetes self-care skills, knowledge, and adherence to each major diabetes 
regimen.  The patient and diabetes educator who is responsible for the area of 
diabetes self-care education scores this scale.  The health professional uses 
multiple tools such as 24-hour diet recall, food, blood glucose logs, and 
computerized glucometer memory data, (Appendix 5) written knowledge tests, 
and skill checks to rate individuals understanding and performance levels.  
The Diabetes Self-Care Practice Assessment (see Table 6) is used to 
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assess patient’s ability to understand and carry out specific diabetes self- care 
behaviors.  The diabetes self-care assessment also helps ensure fidelity of 
program implementation and that educational objectives are met.  Diabetes 
Educators are trained in the use of the instruments and scoring to ensure 
reliability and fidelity of implementation.
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Table 6.   
Diabetes Self-care Practice Assessment   
 
Date 
 
Date 
 
Date 
 
Date 
 
Objectives 
 
Objectives 
 
 
Learning and skill objectives 
 
Met 
(1)a 
 
Unmet 
(0)b 
 
 
Learning and skill 
objectives 
 
Met (1)a 
 
Unmet 
(0)b 
Diabetes overview understanding 
Able to state what diabetes is 
Able to state type of diabetes 
(Range 0-2) 
Subtotal 
 
  Exercise and physical activity 
Able to state how exercise 
affects blood sugar 
Able to adjust food intake or 
medication for exercise 
Able to state precautions to 
take when exercising or when 
not to exercise 
Able to plan snacks for 
exercise when needed 
Able to follow personal 
exercise plan 
(Range 0-5) 
Subtotal 
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Table 6 (continued). 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
Objectives 
 
Objectives 
 
Met 
(1)a 
 
Unmet 
(0)b 
 
Met (1)a 
 
Unmet 
(0)b 
Nutrition 
Able to state reason for meal 
planning 
Eats meals/snacks at regularly 
scheduled times 
States reason for reaching or 
maintaining desirable weight 
Able to state rationale for eating 
less fat 
Able to identify fat in food 
Able to describe own personal meal 
plan 
Able to use meal plan 
Able to use meal plan when eating 
out 
Able to describe foods that are 
carbohydrates 
 
 
 
 
 
Medication 
Able to state medication type 
and dose 
Able to describe when it 
should be taken and its effects 
on blood glucose 
Able to describe side effects/ 
precautions 
(range 0-4) 
Subtotal 
 
(for insulin users only, add to 
above) 
Able to describe onset, peak 
and duration of insulin taken 
Able to determine 
when low blood sugars are 
more likely to occur 
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Table 6 (continued). 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
Objectives 
 
Objectives 
 
Met 
(1)a 
 
Unmet 
(0)b 
 
Met (1)a 
 
Unmet 
(0)b 
Able to use labels to determine 
which foods fit meal plan 
Able to explain benefits of fiber and 
list foods high in fiber 
(range 0-11) 
Subtotal 
 
  Describe proper handling and 
how to store insulin 
Able to correctly administer 
insulin 
(range 0-8) 
Subtotal 
  
Urine ketone testing (insulin users 
only) 
Able to describe when to test for 
ketone and able to take appropriate 
action for positive ketones 
(range 0-1) 
Subtotal 
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Table 6 (continued). 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
Objectives 
 
Objectives 
 
Met 
(1)a 
 
Unmet 
(0)b 
 
Met (1)a 
 
Unmet 
(0)b 
Behavioral change 
Able to set diabetic care goals 
Able to problem-solve and identify 
strategies to achieve goals 
(range 0-2) 
Subtotal 
 
Hypoglycemia 
Able to state what hypoglycemia is 
and possible symptoms 
Able to state correctly ways to 
prevent/and treat low BS 
States purpose of glucagon and 
has family/significant other able to 
give glucagon 
 
  Blood glucose monitoring 
Demonstrates ability to test 
blood glucose 
Able to properly maintain 
meter and strips 
Able to state reason for blood 
glucose monitoring and record 
keeping 
Demonstrates via log that 
BS’s are recorded at 
times/frequency 
recommended for their 
diabetes type/situation 
Able to state normal blood 
sugar range and target range 
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Table 6 (continued). 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
Objectives 
 
Objectives 
 
Met 
(1)a 
 
Unmet 
(0)b 
 
Met (1)a 
 
Unmet 
(0)b 
Wears or carries diabetes 
identification 
(range 0-5) 
Subtotal 
  Able to adjust 
food/medication/or activity 
based on results 
Able to obtain meter supplies 
Able to describe Hbg A1c or 
glycated hemoglobin test, its 
purpose and their personal 
value and goal 
(range 0-10) 
Subtotal 
  
Hyperglycemia 
Able to state what hyperglycemia is 
and possible symptoms 
Able to state courses of action 
(range 0-2) 
Subtotal 
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Table 6 (continued). 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
Objectives 
 
Objectives 
 
Met 
(1)a 
 
Unmet 
(0)b 
 
Met (1)a 
 
Unmet 
(0)b 
Complications 
States awareness of potential 
complications: 
Heart/symptoms 
Nerves/symptoms 
Eyes/symptoms 
Kidney/symptoms 
Circulation/peripheral 
vascular/symptoms 
Amputations/symptoms 
Sexual 
dysfunction/pregnancy 
Able to discuss how to prevent or 
delay complications 
(range 0-8) 
Subtotal 
 
 
 
 
Personal health 
Has regular eye exams (min 
yearly) 
Has regular dental care (min 
yearly) 
Has regular physical exams or 
doctor visits/medical care (min 
yearly) 
Has awareness of community 
and health professional 
resources (e.g. support 
groups, Endo’s, ADA, etc.) 
Able to inspect feet 
Does not go barefoot 
Able to trim toenails properly 
or goes regularly to podiatrist 
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Table 6 (continued). 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
 
Learning and skill objectives 
 
Date 
 
Date 
 
Objectives 
 
Objectives 
 
Met 
(1)a 
 
Unmet 
(0)b 
 
Met (1)a 
 
Unmet 
(0)b 
   Able to state effects of 
smoking on circulation 
Able to state effects of alcohol 
on BS 
(range 0-9) 
Subtotal 
  
TOTAL SCORE   
aIndicates patient met learning or skills objective. 
bIndicates patient was not able to met learning or skills objective 
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The participant completes behavioral goals at week one.  Progress toward 
goals will be assessed at 12 weeks. Participants rate their progress on a scale of 
one to ten.  Educational needs are reassessed based on individual’s needs 
(Appendix 6).   
The ADA Diabetes Self-Care Management Training Program 
All participants received comprehensive diabetes self-care management 
education over the first 12-week trial period (for schedules see Appendix 6).  The 
diabetes self-care management training program is American Diabetes 
Association (ADA) approved and meets all national standards of structure, 
process, and outcome for diabetes education.  The ADA-approved diabetes self-
care management training consists of an interdisciplinary package of diabetes 
modalities comprising all aspects of diabetes management including social, 
medical, nutritional, and exercise management.  A team of certified diabetes 
educators that includes a nurse, a dietitian and an exercise specialist is 
deployed.  The aspects of care are provided to persons with diabetes through a 
case management system that individually assesses the needs of the patient or 
client.  Education sessions focus on areas needing more attention.  Each session 
has standardized curricula, objectives, and evaluation.   
The program objectives are based on three critical components: 
1. Optimal and intensive blood glucose monitoring and treatment; 
2. Behavioral change, and 
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3. Diabetes education which includes the person with diabetes, their 
families, and significant others.  
The ADA-approved curriculum and materials used in this study were 
adapted from Life with Diabetes: A Series of Teaching Outlines, by the American 
Diabetes Association (1997b).  The guide was developed to assist health 
professionals in the education of patients with diabetes mellitus in the required 
content areas.  The guide also provides a supplementary section that addresses 
other diabetes information.  Each outline includes a statement of purpose, 
prerequisites that should be known before participation in the session, materials 
needed, recommended teaching methods, a content outline, evaluation and 
documentation plan, and suggested readings related to each topic. 
The Diabetes Self-Care Practice Assessment was designed for diabetes 
educators to rate persons with diabetes on the understanding of diabetes self-
care, and then actual performance of self-care observed by the diabetes 
educator or obtained from glucometer memory data.  This assessment based on 
the Living with Diabetes curriculum documents progress toward behavioral and 
educational goals and whether curriculum objectives are met (see Table 6). 
A variety of teaching strategies were employed in the program.  Their 
selection was based on an assessment of the patient's age, medical status, 
educational level, physical and emotional disabilities, and readiness to learn.  
Teaching took place in the well-equipped classroom, the exercise room, or a 
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counselor's office.  Flip charts and poster size educational charts were used to 
illustrate key concepts during sessions. Each patient received a folder that 
included a patient educational manual, a meal planning pamphlet, monitoring log 
books, and other handouts to supplement the core patient education materials.  
Portable VCRs, overhead projectors, blackboards and whiteboards, and food 
models are some of the educational tools used to enhance learning.  The patient 
is asked personally, or by way of questionnaire, what they are most interested in 
learning and any perceived barriers to learning.  The instructors incorporate this 
information into their lesson plans.  For a listing of various handouts, tapes, 
posters, and book titles used, see Appendix 7.  Printed materials are written at 
between the 6th- and 8th-grade reading level.  Pictograms, food models, and large 
print are used frequently for those with vision problems.  Skills are taught using a 
variety of techniques including verbal instruction, demonstration, problem-
solving, and empowerment training. 
In 1993, the national standards for diabetes self-management education 
programs were revised by an American Diabetes Association (ADA) Task Force 
(made up of various diabetes organizations and representatives) to reflect recent 
research and current health care trends.  The purpose of the standards was to 
provide a guide for the establishment and maintenance of quality diabetes self-
management education.  The term self-management training replaced previous 
traditional terms such as patient education and self-management and is “to refer 
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to the process whereby individuals learn to manage their diabetes” (ADA, 
1998a).  For a program to receive ADA recognition, it must meet all of the 
national standards.  Diabetes self-care training programs must meet stringent 
standards for structure, process, and outcome evaluation.  The structure 
guidelines delineated the human and natural resources needed including the 
professional staff requirements, and space and budget requirements.  The 
structural standards ensure that the curricula meet specific criteria.  The 
standards ensure that ADA-approved programs provide instruction in the content 
areas that are relevant to the program’s target diabetes population.  
The content areas included in the revised standards are: 
1.  Diabetes overview 
2. Stress and psychosocial adjustment 
3. Family involvement and social support  
4. Nutrition  
5. Exercise and activity  
6. Medications  
7. Monitoring and use of results  
8. Relationships among nutrition, exercise, medication, and blood 
glucose levels 
9.  Prevention, detection, and treatment of chronic complications  
10.  Prevention, detection, and treatment of acute complications  
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11.  Foot, skin, and dental care  
12. Behavioral change strategies, goal setting, risk factor reduction, 
and problem-solving  
13. Benefits, risks, and management options for improving glucose 
control 
14. Preconception care -pregnancy and gestational diabetes  
15. Use of health care systems and community resources  
 
The standards acknowledge the uniqueness of both the community as a 
whole and the individual with diabetes.  The standards require a community 
needs assessment be done to define the target population and whether the 
program is designed to meet the needs of this population.  In addition, an 
individual assessment for each participant in the program is required to identify 
personal educational needs.  The individualized assessment takes into account a 
person’s age, disease processes, culture, and lifestyle.  The assessment 
includes: relevant medical history, present health status, health services or 
resource utilization, risk factors, diabetes knowledge and skills, cultural 
influences, health beliefs and attitudes, health behavior and goals, support 
systems, barriers to learning, and socioeconomic factors (see Appendix 4).  
Through this assessment, individual perceptions of susceptibility and 
seriousness of diabetes and its complications can be determined.  Pre-program 
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assessment gathers information about the individual’s beliefs, attitudes, 
knowledge, and skill levels, as well as the individual’s environment and their 
social and physical situations to which the person must function.  During the 
initial orientation session, the revised Health Belief Model Questionnaire and the 
Diabetes Needs Assessment are completed.  Based on this information, 
individual program education plans and intervention strategies are designed to 
focus on those perceptions that need to be changed and those skills and 
knowledge levels needing improvement.  Barriers to learning and barriers to 
treatment modalities are assessed to help patients develop problem-solving and 
coping skills that overcome barriers.  
In the first education session, the diabetes educator attempts to provide 
information about diabetes, its pathophysiology, the risk factors for the disease, 
and who is susceptible to the disease.  The instructor also gives an overview of 
the benefits of various treatment modalities. During the needs assessment, the 
diabetes educators identify individuals who score poorly on perceived 
susceptibility, severity of diabetes or benefits, and attempt during the initial 
education to modify these beliefs.  The educator would emphasize that diabetes 
is a serious disease with short- and long-term complications.  The educator 
would describe the various diabetes-related complications such as nephropathy, 
retinopathy, and peripheral neuropathy.  The educator would also explain the 
relationship of hyperglycemia to other conditions such as cardiovascular disease.  
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Symptoms associated with high and low blood sugar are described.  Abnormal 
blood sugars can act as cues to action.  When persons with diabetes recognize 
the symptoms they can act to manage their blood glucose levels.  Acute 
complications such as diabetes ketoacidosis (DKA) and hyperosmolar coma are 
described; the risk associated with these complications and actions to take to 
prevent their occurrence are described.  Costs of these complications in terms of 
illness, pain, financial burdens from hospitalizations, increased medical care, 
disability or loss or work, and the benefits of prevention are discussed. 
For those who have low scores on perceived benefits of care, the 
educator can emphasize the immediate and long-term rewards for controlling 
diabetes.  Avoiding pain, financial expense, and other problems due to poor 
management are stressed.  Benefits of increased sense of well being, feeling 
good, and having the energy to enjoy life are emphasized 
The ADA program recognizes the importance of identifying barriers to 
specific self-management behaviors.  During the assessment, the educator 
focuses on uncovering specific barriers (e.g. financial cost, convenience, 
complexity of regimen, lack of support) to each area of diabetes management.  
The nurse educator may focus on barriers to medical treatment; the dietitian may 
focus on barriers to following a meal plan; while the exercise specialist may work 
with the patient on barriers to exercise. 
For those identified as having low perceived self-care abilities, focus is 
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placed on developing skills and self-confidence.   To foster self-confidence the 
diabetes educators instructs the patient on the correct self-care skills then allows 
the participants to return the demonstration.  Use of glucose monitoring and log 
books act to reinforce the behavior but also allows the diabetes educator to 
provide feedback and reinforcement to facilitate the participant’s self-efficacy.  
The program not only focuses on increasing knowledge of self-care activities, but 
provides time for practicing these skills.  ADA programs use empowerment such 
as goal setting techniques and contracting to enhance self-efficacy.  A matrix of 
the educational sessions and the applications of the Expanded Health Belief 
Model concepts are illustrated in Table 7. 
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Table 7.   
Matrix of the Educational Sessions and Applications of the Expanded Health 
Belief Model Concepts  
Education/session/ 
content area 
Instructor Health Belief Model application 
Orientation 
Case Manager — 
CDE 
? Baseline attitudes, beliefs, knowledge 
of diabetes self-care skills 
assessment, and adherence.  (Hgb 
A1c) 
Overview of diabetes 
Certified Diabetes 
Educator (CDE) 
Nurse/Dietitian 
? Seriousness of diabetes.  
? Susceptibility to diabetes, and its 
complications. 
? Benefits of treatment, and diabetes 
control including self-efficacy by 
patient able to identify chronic 
complications, symptom recognition, 
and self-care behaviors that will 
prevent complications 
 
 
 
 
 137 
Table 7 (continued). 
Education/session/ 
content area 
Instructor Health Belief Model application 
Medications CDE/Nurse 
? Benefits of medications.  
? Barriers to medication regimen. 
? Strategies to overcome barriers of 
medication regimen:  timing, action, 
and side-effects (for insulin users — 
skills are checked, proper methods 
demonstrated, and practiced to 
improve self-confidence.  
? Self-efficacy enhanced through 
understanding the timing action, side-
effects, and administration of 
medications (insulin: demonstrate 
abilities, and proper administering of 
insulin). 
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Table 7 (continued). 
Education/session/ 
content area 
Instructor Health Belief Model application 
Nutrition Dietitian 
? Importance of nutrition in controlling 
blood sugar.  
? Benefits of timing/scheduling of 
meals, carbohydrate consistency and 
balance of meals. 
? Barriers to nutrition management 
identified and strategies discussed.  
? Self-efficacy enhanced by 
participation in meal planning food 
records.  
? Feedback and reinforcement acts to 
enhance and elicit family support and 
ensure an understanding of glycemic 
effects of food. 
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Table 7 (continued). 
Education/session/ 
content area 
Instructor Health Belief Model application 
Behavior goal setting CDE/Dietitian 
? Importance of behavior change.  
? Barriers to behavioral change.  
? Self-efficacy enhanced through small 
steps achieved toward goals, 
measured objectives, problem 
solving/coping skills to prevent 
relapse. 
? Discuss personal incentives and 
rewards.  
? Demonstrate commitment to change 
through written contract.  
Exercise 
CDE/Exercise 
Physiologist 
? Enhance understanding of the effects 
of exercise on blood sugar control 
and general health. 
? Benefits of exercise. 
? Barriers of exercise discussed and 
strategies to overcome. 
 
 
 140 
Table 7 (continued). 
Education/session/ 
content area 
Instructor Health Belief Model application 
  
? Enhanced self-efficacy through 
exercise practicum (practice on 
treadmill, stationary bike). 
? Teach how to monitor pulse, heart 
rate (cues to action) and encourage 
family and social support. 
? Self-behavioral goals development for 
exercise. 
Monitoring 
CDE/Nurse/ 
Exercise 
Physiologist/ 
Dietitian 
? Importance/benefits of glucose 
monitoring and Hgb A1c testing.  
? Barriers to monitoring discussed and 
strategies to overcome.  
? Practicum to perform glucose 
monitoring and logging results to 
enhance self-efficacy.  
? Blood sugar values/symptoms (cues 
to action). 
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Table 7 (continued). 
Education/session/ 
content area 
Instructor Health Belief Model application 
Acute hypoglycemia/ 
hyperglycemia 
management 
Complications 
Chronic 
Complications/foot care 
CDE/Nurse 
? Importance of prevention of 
complications. 
? Benefits of self-management. 
? Self-efficacy enhanced by patient able 
to demonstrate proper foot care, list 
ways to treat low/high blood sugars.  
? Evaluate glucose monitoring log and 
enhance patient problem solving skills 
to raise and lower blood sugar values. 
? Barriers discussed/strategies 
discussed. 
? Self-behavioral goals developed.  
? Recognize signs/symptoms of 
complications (cues to action). 
? Discuss the tests and the 
assessments available for detecting 
and preventing complications.  
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Table 7 (continued). 
Education/session/ 
content area 
Instructor Health Belief Model application 
Diet and exercise follow-
up 
 
? Barriers discussed for exercise/meal 
planning/food logs discussed/problem 
solving strategies for special situation 
discussed/exercise 
practicum/demonstrate skills learned, 
heart rate. 
? Reinforcement by educators and cues 
to action. 
Stress/sick days rules 
disaster plan, special 
situations 
 
? Progress of behavioral goals 
assessed for meal planing/exercise. 
? Importance of stress management. 
? Problem solving: travel, special 
situations, disaster, sick days. 
? Reassessment of Hgb A1c, beliefs, 
attitudes, adherence. 
 
To ensure fidelity of implementation, all diabetes educators were certified 
diabetes educators with a minimum six months teaching experience using the 
Life with Diabetes curriculum.  All diabetes educators had completed yearly 
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diabetes self-care training competencies and had documentation in their 
employee record files.  The diabetes educators who participated in the research 
study were trained during staff meetings on the use and interpretation of scores 
obtained from the EHBMQ.  
Because the investigator and diabetes educators may represent 
“passionate workers” who want to see the ADA program succeed, efforts to 
minimize investigator bias were made.  Instructors were randomly audio-taped to 
ensure equal treatment of participants.  Taping of educational sessions also 
ensured that key diabetes content areas were being delivered uniformly.  The 
diabetes self-care practice assessment completed served to document that the 
objectives of the curriculum were being met.  Each participant completed a 
program satisfaction survey that evaluates educator performance and overall 
satisfaction with the program (see Appendix 7).  
A potential weakness of the EHBMQ assessment is social desirability 
bias.  Social desirability bias is where patients report levels of self-care that they 
want health care providers to believe they perform rather than actual 
performance.  To offset this potential bias, other measures of self-management 
were obtained and compared.  Patients were asked to maintain diaries of self-
care behaviors (food records, blood glucose monitoring records).  Using patients’ 
food records, glucose monitoring records, exercise records, the diabetes 
educators rated patient’s understanding of diabetes and actual performance on 
 144 
the diabetes self-care practice assessment.  
This diabetes program is taught in small group and one-to-one counseling 
sessions that reduce the complexity, duration of sessions, and amount of 
behavior change expected in each step through tailoring the sessions and 
behavioral goals to each person.  Emphasis is placed on behavioral objectives 
that the client believes that he/she can achieve.  The ultimate goal of diabetes 
education is to enable patients to achieve optimal control of their disease through 
personal involvement, motivation, and better understanding of diabetes and its 
effects on their health and well-being.  
Intensive Follow-up Care  
After completing ADA comprehensive self-care training, study participants 
were randomly assigned to standard follow-up care or intensive follow-up care.  
Standard follow-up care participants were mailed reminder letters to return to the 
Diabetes Care Institute 12 weeks from initial HgbA1c value to obtain follow-up 
HgbA1c values.  Behavioral goals status, and educational needs were reviewed 
with patients by certified diabetes educators and documented on the Behavioral 
Change Goals form (Appendix 7) and Education Assessment form (Appendix 8).  
(See also Appendix 9 for Division of Nursing Standards/Policies/Procedures.)  
Outcome data are entered into the computer to summarize HgbA1c, education 
and behavioral goal outcomes. Pre-test/ post-test percent improvement and 
patient satisfaction survey results are also collected to evaluate the education 
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program.  
The intensive follow-up care group differs from standard follow-up care by 
utilizing the MiniMed continuous glucose sensor to provide a more 
comprehensive glucose pattern analysis to evaluate the effects of food, exercise, 
and medications on patient’s blood glucose levels. All participants were 
scheduled to return for their 12th week follow-up that consisted of HgbA1c and 
assessment of educational and behavioral goals. Those participants randomized 
to the intensive follow-up group also were placed on the continuous glucose 
monitor system.  
The trained diabetes educator placed a MiniMed continuous sensor on the 
intensive follow-up patient and they were instructed in its use.  The patient wore 
the device at home for 72 hours.  Patients were instructed to maintain their usual 
daily activities, medications, and check blood glucose levels four times a day 
while wearing the monitor.  Key events were entered into the sensor such as 
eating, taking medication, exercise, using a number code.  Patients were given a 
logbook to record meals, activities, blood glucose test values, and medication 
dose and time. The MiniMed continuous glucose monitoring system (CGMS) is a 
Holter-style sensor that continuously and automatically records glucose levels 
(within 40-400 mg/dl range) in the patient’s subcutaneous tissue fluid, once every 
5 minutes, for 72 hours.  Information collected by the CGMS was downloaded on 
a computer and reviewed by the diabetes care team.  A clinical report identifying 
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patterns of glucose excursions and graphs of the patient’s blood glucose levels 
(approximately 288 blood glucose readings per 24 hours) are generated.  During 
the follow-up appointment with the diabetes team, the computer generated blood 
glucose data and the patient’s logbook were reviewed with the patient and 
therapy effects were explained (for policies and procedures see Appendix 8). 
Both the intensive follow-up group and the standard follow-up groups 
returned at 24 weeks for review of behavioral goals, complete post-intervention 
Health Belief Questionnaires, and HgbA1c determinations. Participants were able 
to discuss any diabetes self-care concerns with the certified diabetes educators.  
Determination of HgbA1c on three occasions pre-education week one, post-
education week 12, and at week 24 follow-up using a random assignment of 
follow-up care allowed examination of the effects of self-care training and 
collection of evidence to concerning the efficacy of intensive follow-up care 
versus standard follow-up care. 
Documentation 
The diabetes educators received training on proper documentation on the 
Diabetes Treatment Assessment and Education Record, the Diabetes Self-care 
Practice Assessment, and the initial evaluation and follow-up evaluation forms.  A 
program assistant filed evaluation forms in the medical records.  During post-
intervention, pre-evaluation Hgb A1c levels and initial EHBMS scores were not 
available for comparison, to minimize investigator bias.  Post-intervention scores 
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were recorded on the follow-up evaluation form and given to the program 
assistant to file in medical records.  The diabetes educator documented each 
session completed by the patient on the diabetes assessment and education 
record.  The date attended, the instructor who taught the session, and the 
content areas covered were recorded.  As each objective of the Life with 
Diabetes curriculum was met, the diabetes educator documented the diabetes 
self-care practice assessment, the date, and the score obtained. 
Data Collection and Analysis 
Baseline clinical and demographic data were collected and documentation 
was kept in the participant’s medical record.  Descriptive statistics were used to 
describe the study population (see Table 8).  Statistical analysis was performed 
using the SAS (1979) statistical program.  Characteristics of the study groups 
were compared for any pre-intervention differences.  Chi-square analysis was 
used for nominal or ordinal variables such as gender, race, and education.  T-
tests were used for interval or ratio variables, such as pre-Hgb. A1c, and EHBMQ 
scale scores.  Tukey or Bonferroni post-hoc procedures were to be used as 
appropriate if differences were found.  An analysis of variance (ANOVA) for 
repeated measures tested whether the groups differed in mean Hgb. A1c over 
time.  The “between” variable was the group variable (control vs. intervention 
group) and the “within” factors are the various occasions Hgb. A1c was measured.  
If an overall difference was found between the mean Hgb. A1c over time, Tukey 
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or Bonferroni post-hoc procedures were to be applied.  Tukey procedures are 
preferred if the sphericity assumption is met. The F statistic obtained in the 
repeated measure analysis was correlated using the average of the Huynh and 
Feldt and Greenhouse-Geisser epsilon (S) estimators to maintain alpha close to 
the level of significance.  
 
Table 8.   
Characteristics of Study Population Before Education Intervention  
Characteristic 
Female (%) 
Race (%): White Anglo-American or of European heritage 
Black African-American 
Hispanic 
Other-Pacific Islander 
Native Americans 
Asian 
 
Education (%): Did not complete or less than high school 
High school graduate or higher 
Age (yr.): 
Hgb A1c (%) 
Years since diabetes diagnosis (%) 
Less than 1yr 
1 yr-5yr 
Over 5 yr. 
 
Physician Type (%): Endo 
 Other 
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Table 8 (continued). 
Characteristic 
Treatment Type (%): Insulin, oral medications, diet-controlled ,              
 Insulin and oral diabetes medications 
Expanded Health belief Model Subscale Mean Scores 
Perceived Susceptibility Score 
Perceived Severity Score 
Perceived Benefits Score 
Perceived Barriers Score 
Perceived Self-Efficacy Score 
Health motivation Score 
Cues to Action Score 
Structural Elements Score 
 
The use of random assignment to the intensive follow-up or control group 
strengthens the design’s ability to control systematic error such as selection bias. 
The repeated measure design reduces the within group variability among 
participants due to individual differences such as duration of disease, severity of 
disease, motivation, education level and social background.
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Summary 
In summary, an ADA-recognized comprehensive diabetes program 
incorporates several components of the Expanded Health Belief Model to 
enhance patient adherence to the diabetes self-care regimen and thereby 
improve glycemic control.  The intensive follow-up intervention is designed to 
evaluate blood glucose patterns and determine the effects of diabetes therapy on 
blood glucose. If persons receiving intensive follow-up achieve significantly better 
outcomes, a new standard for disease management will have received important 
evidence.  DSME leads to lower Hgb A1c levels by increasing the patient’s 
understanding of diabetes and its treatment, and by improving attitudes and 
beliefs that foster adherence to the diabetes regimen.  The program fosters self-
efficacy by providing reinforcement and performance of self-care skills.  Patient 
logs are kept of diet, exercise, glucose monitoring and medication schedules, 
and reviewed with instructors for feedback and reinforcement.  Families and 
significant others are encouraged to participate in the sessions.  Patients are 
encouraged to set self-management goals with guidance from the educator. 
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Chapter Four: Results 
Introduction 
In this chapter, the population characteristics, comparisons between those 
who completed the study with those dropped from the study, and the results of 
the analysis of a randomized repeated measure statistical design are presented.
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Participant Characteristics 
Overall, 159 participants were randomized, 80 to the standard follow-up 
group (SFG) and 79 to the intensive follow-up group (IFG) after signing the 
consent form and blocking for insulin use.  A random number was assigned and 
group assignment was unknown to educators and participants.  To reduce 
selection bias, a program assistant not involved in the assessment or education 
of participants, sent out follow-up notices and entered HgbA1c and behavioral 
scores into the outcome data files.  Baseline data were collected during the initial 
visit and recorded on the diabetes assessment and education record and initial 
evaluation form.  Participants also completed the Revised Diabetes Health Belief 
Model Questionnaire during this initial assessment and evaluation. All data were 
stored confidentially in the patient’s medical record and computer databases. 
Characteristics of the study population were analyzed for pre-intervention 
differences (see Tables 9 and 10).  The two groups were compared on the 
categorical covariates using chi-square analysis and the continuous variables 
using T-tests.  The groups were not significantly different at baseline for the 
categorical variables: treatment type, ethnicity, education level, type of physician, 
and duration of diabetes. The control and the intensive groups had similar 
distributions for the four treatment types: diet; pills; pills and insulin and insulin 
only indicating the randomization blocking for insulin led to a similar distribution.  
At baseline, the gender covariate showed that more women (N=88) participated 
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in the study then men (N=71).  More women than men were randomized to the 
control than the intensive group (37 women in the control compared to 43 men, 
and 51 women were assigned to intensive group compared to 28 men, chi-
square test value was 5.3902, p-value 0.0203). 
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Table 9.   
Baseline Characteristics by Treatment Group: Categorical Covariates  
    Group       
    Control group Intensive group       
  Level N % N % 
P-
valuea 
Total 
N 
% of 
Total 
All   80 100.00% 79 100.00% --- 159 100.00%
Treatment 
type Diet 8 10.00% 9 11.39% 17 10.69%
  Pills 50 62.50% 44 55.70% 94 59.12%
  
Pills and 
insulin 13 16.25% 18 22.78% 31 19.50%
  Insulin 9 11.25% 7 8.86% 16 10.06%
  Unknown 0 0.00% 1 1.27%
0.6461
1 0.63%
Sex Female 37 46.25% 51 64.56% 88 55.35%
  Male 43 53.75% 28 35.44%
0.0203
71 44.65%
Ethnicity White 48 60.00% 50 63.29% 98 61.64%
  Black 20 25.00% 14 17.72% 34 21.38%
  Hispanic 8 10.00% 13 16.46% 21 13.21%
  Other 2 2.50% 1 1.27% 3 1.85%
  Unknown 2 2.50% 1 1.27%
0.5661
3 1.89%
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Table 9 (continued). 
    Group       
    Control group Intensive group       
  Level N % N % 
P-
valuea 
Total 
N 
% of 
Total 
Highest 
level of 
education 
Grade 
School 1 1.25% 4 5.06% 5 3.14%
  
High 
School 27 33.75% 30 37.97% 57 35.85%
  College 47 58.75% 41 51.90% 88 55.35%
  Unknown 5 6.25% 4 5.06%
0.4804
9 5.66%
Type of 
doctor 
Endo-
crinologist 26 32.50% 30 37.97% 56 35.22%
  
Primary 
care 53 66.25% 49 62.03% 102 64.15%
  Unknown 1 1.25% 0 0.00%
0.4876
1 0.63%
Duration 
of 
diabetes <1 year 42 52.50% 38 48.10% 80 50.31%
  1-5 years 5 6.25% 9 11.39% 14 8.81%
  
>= 5 
years 32 40.00% 27 34.18% 59 37.11%
  Unknown 1 1.25% 5 6.33%
0.2189
6 3.77%
aChi-squared test.
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Table 10.   
Baseline Age, Health Belief Scores, and Hemoglobin (HgbA1c) by Group.  
    Group    
    Control Intensive All 
T-test P-
valuea 
All N 80 79 159 --- 
Age N 75 74 149
  Mean 53.13 52.35 52.74
  St. dev. 10.71 11.32 10.99
0.6656 
Self-efficacy score N 79 75 154
  Mean 30.2 30.41 30.31
  St. dev. 4.9 4.77 4.82
0.7872 
Susceptibility 
score N 79 75 154
  Mean 28.05 27.81 27.94
  St. dev. 5.77 5.48 5.61
0.7941 
Benefits score N 79 75 154
  Mean 36.09 36.57 36.32
  St. dev. 4.27 3.75 4.02
0.4559 
Severity score N 79 75 154
  Mean 25.52 25.4 25.46
  St. dev. 4.11 3.97 4.03
0.8554 
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Table 10 (continued). 
    Group     
    Control Intensive All 
T-test P-
valuea 
Cue-to-action 
score N 79 75 154
  Mean 18.23 17.51 17.88
  St. dev. 4.16 3.74 3.97 0.2609 
Structural score N 78 75 153
  Mean 10.81 10.95 10.88
  St. dev. 3.4 3.74 3.56 0.8102 
Motivation score N 79 75 154
  Mean 17.84 18.2 18.01
  St. dev. 2.36 3.01 3.14 0.4732 
Barriers score N 79 75 154
  Mean 17.84 18.2 18.01
  St. dev. 3.26 3.01 3.14 0.4802 
HgbA1c N 80 79 159
  Mean 8.5 8.5 8.5
  St. dev. 1.3 1.3 1.3 0.9056 
aT-test assumes equal variance between groups. 
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T-test procedures applied to the continuous variables age, HgbA1c, and 
Health Belief subscale scores at baseline showed no significant pre-intervention 
differences (see Table 10).  Box-plots and stem-leaf plots for all continuous 
variables are in Appendix 10.  The continuous variables for the study sample 
were normally distributed except for HgbA1c, which was skewed.  This skewness 
was due to the exclusion criteria for HgbA1c (participant’s HgbA1c must be 7 or 
greater to participate).  The mean age of the study participants was 52.74 years. 
At baseline the two groups were similar.  The control mean age of 53.13 years 
compared to the intensive group mean age of 52.35 years (p=0.6656, ns).  The 
mean HgbA1c value for all subjects at baseline was 8.5%. The two groups had 
similar means at baseline, the control mean HgbA1c value was 8.49% compared 
to the intensive group mean HgbA1c value of 8.52% (p=0.9056, ns). 
The two groups had similar means for the eight dimensions of the EHBMQ 
variables (self-efficacy, susceptibility, severity, treatment benefits, cues to action, 
structural elements, motivation, and barriers).  T-tests showed similar group 
means for the control and intensive group at baseline (see Table 10).  The 
univariate plots for the continuous variables had normal distributions (Appendix 
10).  However, treatment benefit showed for both groups a similarly high mean 
score trend at baseline. The box plot was evenly distributed despite being 
skewed toward the upper range.  
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Drop Out versus Completers 
Overall, 82 patients completed all phases of the study, and 77 dropped out 
or did not have complete data for the primary variable, HgbA1c or the secondary 
EHBMQ variables at week 24.  These individuals are referred to as “dropouts,” 
although they may have provided incomplete data that were kept for the analysis. 
Thirty-seven participants assigned to the control group compared to 45 in the 
intensive follow-up group provided complete data for the study (see Figure 6).  
Overall, those who completed the study were not different than those who 
dropped out (see Table 11 and Table 12).  The only difference that was 
statistically significant was for age, in that the dropouts (mean age 49.89) were 
slightly younger than those who completed the study (mean age 55.49). 
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Figure 6.   
Loss to Follow-Up  
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Table 11.   
Characteristics of Completers vs. Dropouts:  Categorical Covariates  
    Complete Dropped Out       
  Level N 
% of 
Complet-
ers N 
% of 
Dropouts N 
% of 
Total 
P-
valuea 
All   82 100.00% 77 100.00% 159 100.00% --- 
Group Control 37 45.12% 43 55.84% 80 50.31% 
  Intensive 45 54.88% 34 44.16% 79 49.69% 
0.1766
Treatment 
type Diet 9 10.98% 8 10.39% 17 10.69% 
  Pills 49 59.76% 45 58.44% 94 59.12% 
  
Pills and 
insulin 14 17.07% 17 22.08% 31 19.50% 
  Insulin 10 12.20% 6 7.79% 16 10.06% 
  Unknown 0 0.00% 1 1.30% 1 0.63% 
0.6691
Sex Female 48 58.54% 40 51.95% 88 55.35% 
  Male 34 41.46% 37 48.05% 71 44.65% 
0.4036
Ethnicity White 53 64.63% 45 58.44% 98 61.64% 
  Black 19 23.17% 15 19.48% 34 21.38% 
  Hispanic 9 10.98% 12 15.58% 21 13.21% 
  Other 1 1.22% 2 2.60% 3 1.89% 
  Unknown 0 0.00% 3 3.90% 3 1.89% 
0.3158
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Table 11 (continued). 
    Complete Dropped Out       
  Level N 
% of 
Complet-
ers N 
% of 
Dropouts N 
% of 
Total 
P-
valuea 
Highest 
level of 
education 
Grade 
School 1 1.22% 4 5.19% 5 3.14% 
  
High 
School 34 41.46% 23 29.87% 57 35.85% 
  College 44 53.66% 44 57.14% 88 55.35% 
  Unknown 3 3.66% 6 7.79% 9 5.66% 
0.1894
Type of 
doctor 
Endo-
crinologist 30 36.59% 26 33.77% 56 35.22% 
  
Primary 
care 52 63.41% 50 64.94% 102 64.15% 
  Unknown 0 0.00% 1 1.30% 1 0.63% 
0.5574
Duration 
of 
diabetes <1 year 40 48.78% 40 51.95% 80 50.31% 
  1-5 years 8 9.76% 6 7.79% 14 8.81% 
  
>= 5 
years 33 40.24% 26 33.77% 59 37.11% 
  Unknown 1 1.22% 5 6.49% 6 3.77% 
0.3044
aChi-squared test.
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Table 12.   
Characteristics of Completers vs. Dropouts: Continuous Covariates at Baseline  
    Completed
Dropped 
Out All 
T-test P-
valuea 
All N 82 77 159 --- 
Age N 76 73 149
  Mean 55.49 49.89 52.74
  St. dev. 10.04 11.27 10.99 0.0017 
Self-efficacy 
score N 82 72 154
  Mean 30.54 30.04 30.31
  St. dev. 4.53 5.15 4.82 0.5268 
Susceptibility 
score N 82 72 154
  Mean 28.04 27.82 27.94
  St. dev. 5.31 5.98 5.61 0.8116 
Benefits score N 82 72 154
  Mean 36.72 35.88 36.32
  St. dev. 3.49 4.53 4.02 0.1939 
Severity score N 82 72 154
  Mean 25.65 25.25 25.46
  St. dev. 3.68 4.42 4.03 0.5444 
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Table 12 (continued). 
    Completed
Dropped 
Out All
T-test P-
valuea 
Cue-to-action 
score N 82 72 154
  Mean 18.11 17.61 17.88
  St. dev. 4 3.95 3.97 0.4383 
Structural score N 82 71 153
  Mean 11.12 10.59 10.88
  St. dev. 3.93 3.08 3.56 0.3598 
Motivation score N 82 72 154
  Mean 18.2 17.81 18.01
  St. dev. 3.59 2.54 3.14 0.4441 
Barriers score N 82 72 154
  Mean 94.02 95.56 94.74
  St. dev. 23.06 25.15 23.99 0.6941 
HgbA1c N 82 77 159
  Mean 8.5 8.5 8.5
  St. dev. 1.3 1.2 1.3 0.9859 
aT-test assumes equal variance between groups. 
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The drop out rate for the control group was 53.75% compared to the 
43.04% for the intensive follow-up group. The overall distributions of completers 
compared to dropouts on the categorical covariates treatment type, sex, 
ethnicity, education, physician type, disease duration were not significantly 
different. ( value >0.05).  There were no significant differences between the 
completers compared to the dropouts for the continuous health belief and 
HgbA1c covariates. Characteristics of completers compared with dropouts by 
treatment group are described  in Table 13. There were no significant differences 
found for the categorical covariates in the control group. Fewer diet-controlled 
patients in the standard follow-up group completed the study (8.11%) control 
compared with intensive follow-up group (13.33%). Participants treated with 
insulin had different participation rates.  (SFG, 7/37, 18.92%; IFG 3/45, 6.67%)  
Those completing the study were evenly distributed between groups for 
treatment type. (P value = 0.40 in Table 16).   
More patients followed by primary care physicians (32/43, 74.41%) 
compared to endocrinologist dropped out of the control group (10/43, 23.26%). In 
the intensive follow-up group (18/34) 52.94% dropped out from subjects referred 
by primary care physicians compared to endocrinologist referred (16/34) 47%. 
Those completing the study had similar distribution for physician type. The follow-
up groups had no significant differences (p value = 0.26, ns).   
Patients dropping out of the control had diabetes of shorter duration (less 
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than 1 year 25/43, 58.14%; 1-5 year, 4/43, 9.30%) compared with patients with 
diabetes over 5 years (13/43. 30.23%)? In the intensive group (44.12%, 15/34 < 
1yr, 2/34, 5.88% for 1-5 year duration) more dropped out had diabetes for a 
shorter duration while only 38.24% (13/34) dropped out who had diabetes over 5 
years.  
Dropouts were slightly younger (mean age 49.89) than those completing 
the study (mean age 55.49).   The mean ages of those completing the study 
were similar (SFG mean 55.37; IFG mean 55.59) with younger participants 
dropping out in both groups.  Time commitments may be partially responsible for 
this trend secondary to hours the Diabetes Care Institute was open. Office hours 
were offered from 7:30 AM until 6:00 PM.   
More diet-controlled patients dropped out in the control group (5/43, 
11.63% compared to the IFG (3/34 8.82%).     Eight out of forty-five participants 
assigned to an intensive follow-up group treated with diet and pills completed the 
study compared six out of thirty-seven in the standard follow-up group.    More 
women completed the study (15 / 37, 40.54%) than dropped out (22/43.51.16%).  
More African-Americans completed the study in the intensive group (11/43, 
25.58%) than those assigned the control (9/37, 24.32%).  Hispanics dropped out 
more in the intensive group (9/34, 26.47%) than the control (3/43. 7%).  
 More college level participants completed the study in the intensive 
follow-up group (24/45, 53.33%) compared to the control. (20/37, 54.05%).  A 
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similar distribution was found for those completed the study for high school level 
or below 43.23% for the control and 42.22% for the intensive group.  The 
difference between groups may be due to the unknown levels, two in the IFG and 
1 in the control. (P value = 0.03). The small cell numbers may effect the 
interpretation of the p value but there seems to be some potential for attrition 
bias.  The main study continuous variables did not seem to be affected by the 
attrition. 
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Table 13.   
Characteristics of Completers vs. Dropouts by Treatment Group: Categorical 
Covariates  
    Control Group   
    Complete Dropped Out   
  Level N 
% of 
Complet-
ers N 
% of 
Dropouts
P-
valuea 
All   37 100.00% 43 100.00% --- 
Treatment type Diet 3 8.11% 5 11.63%
  Pills 21 56.76% 29 67.44%
  
Pills and 
insulin 6 16.22% 7 16.28%
  Insulin 7 18.92% 2 4.65%
  Unknown 0 0.00% 0 0.00%
0.2395 
Sex Female 15 40.54% 22 51.16%
  Male 22 59.46% 21 48.84%
0.3421 
Ethnicity White 23 62.16% 25 58.14%
  Black 9 24.32% 11 25.58%
  Hispanic 5 13.51% 3 6.98%
  Other 0 0.00% 2 4.65%
  Unknown 0 0.00% 2 4.65%
0.3597 
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Table 13 (continued). 
    Control Group   
    Complete Dropped Out   
  Level N 
% of 
Complet-
ers N 
% of 
Dropouts
P-
valuea 
Highest level of 
education 
Grade 
School 1 2.70% 0 0.00%
  
High 
School 15 40.54% 12 27.91%
  College 20 54.05% 27 62.79%
  Unknown 1 2.70% 4 9.30%
0.2901 
Type of doctor 
Endo-
crinologist 16 43.24% 10 23.26%
  
Primary 
care 21 56.76% 32 74.42%
  Unknown 0 0.00% 1 2.33%
0.1199 
Duration of 
diabetes <1 year 17 45.95% 25 58.14%
  1-5 years 1 2.70% 4 9.30%
  
>= 5 
years 19 51.35% 13 30.23%
  Unknown 0 0.00% 1 2.33%
0.1698 
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Table 13 (continued). 
    Intensive Group   
    Complete Dropped Out   
  Level N 
% of 
Complet-
ers N 
% of 
Dropouts
P-
valuea 
All   45 100.00% 34 100.00% --- 
Treatment 
type Diet 6 13.33% 3 8.82%
  Pills 28 62.22% 16 47.06%
  
Pills and 
insulin 8 17.78% 10 29.41%
  Insulin 3 6.67% 4 11.76%
  Unknown 0 0.00% 1 2.94%
0.3812 
Sex Female 33 73.33% 18 52.94%
  Male 12 26.67% 16 47.06%
0.0606 
Ethnicity White 30 66.67% 20 58.82%
  Black 10 22.22% 4 11.76%
  Hispanic 4 8.89% 9 26.47%
  Other 1 2.22% 0 0.00%
  Unknown 0 0.00% 1 2.94%
0.1307 
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Table 13 (continued). 
    Intensive Group   
    Complete Dropped Out   
  Level N 
% of 
Complet-
ers N 
% of 
Dropouts
P-
valuea 
Highest level 
of education 
Grade 
School 0 0.00% 4 11.76%
  
High 
School 19 42.22% 11 32.35%
  College 24 53.33% 17 50.00%
  Unknown 2 4.44% 2 5.88%
0.1160 
Type of doctor 
Endo-
crinologist 14 31.11% 16 47.06%
  
Primary 
care 31 68.89% 18 52.94%
  Unknown 0 0.00% 0 0.00%
0.1481 
Duration of 
diabetes <1 year 23 51.11% 15 44.12%
  1-5 years 7 15.56% 2 5.88%
  
>= 5 
years 14 31.11% 13 38.24%
  Unknown 1 2.22% 4 11.76%
0.1822 
aChi-squared test. 
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Table 14.   
Characteristics of Completers vs. Dropouts by Treatment Group: Continuous 
Covariates  
    Control  
    Completed
Dropped 
Out 
T-test P-
valuea 
All N 37 43 --- 
Age N 35 40
  Mean 55.37 51.18
  St. dev. 10.96 10.23
0.0907 
Self-efficacy 
score N 37 42
  Mean 29.92 30.45
  St. dev. 4.49 5.28
0.6323 
Susceptibility 
score N 37 42
  Mean 29.11 27.12
  St. dev. 5.19 6.15
0.1272 
Benefits score N 37 42
  Mean 36.73 35.52
  St. dev. 3.82 4.6
0.2122 
Severity score N 37 42
  Mean 26.65 24.52
  St. dev. 3.11 4.63
0.0209 
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Table 14 (continued). 
    Control   
    Completed
Dropped 
Out 
T-test P-
valuea 
Cue-to-action 
score N 37 42
  Mean 18.70 17.81
  St. dev. 3.77 4.48 0.3446 
Structural score N 37 41
  Mean 11.38 10.29
  St. dev. 4.29 2.27 0.1609 
Motivation score N 37 42
  Mean 18.27 17.45
  St. dev. 3.83 2.65 0.2691 
Barriers score N 37 30
  Mean 91.30 95.97
  St. dev. 18.92 27.22 0.4206 
HgbA1c N 37 37
  Mean 8.6 8.6
  St. dev. 1.3 1.2 0.5326 
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Table 14 (continued). 
    Intensive   
    Completed
Dropped 
Out 
T-test P-
valuea 
All N 45 34 --- 
Age N 41 33
  Mean 55.59 48.33
  St. dev. 9.32 12.40
0.0054 
Self-efficacy 
score N 45 30
  Mean 31.04 29.47
  St. dev. 4.56 4.99
0.1618 
Susceptibility 
score N 45 30
  Mean 27.16 28.80
  St. dev. 5.3 5.69
0.2050 
Benefits score N 45 30
  Mean 36.71 36.37
  St. dev. 3.23 4.46
0.6992 
Severity score N 45 30
  Mean 24.82 26.27
  St. dev. 3.93 3.95
0.1237 
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Table 14 (continued). 
    Intensive   
    Completed
Dropped 
Out 
T-test P-
valuea 
Cue-to-action 
score N 45 30
  Mean 17.62 17.33
  St. dev. 4.15 3.09
0.7458 
Structural score N 45 30
  Mean 10.91 11.00
  St. dev. 3.65 3.93
0.9204 
Motivation score N 45 30
  Mean 18.13 18.3
  St. dev. 3.42 2.34
0.8163 
Barriers score N 45 30
  Mean 96.27 95.97
  St. dev. 25.97 27.22
0.9618 
HgbA1c N 45 34
  Mean 8.4 8.6
  St. dev. 1.4 1.2
0.5412 
aT-test assumes equal variance between groups. 
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To examine the effect on the differences between treatment groups 
imposed by the dropouts, the baseline characteristics were reanalyzed using only 
those 82 individuals for whom there were complete data.  These results are 
shown in Table 15 and Table 16. 
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Table 15.   
Baseline Characteristics by Treatment Group for Those with Complete Follow-up: 
Categorical Covariates  
    Group       
    Control group Intensive group       
  Level N % N % 
P-
valuea 
Total 
N 
% of 
Total 
All   37 100.00% 45 100.00%   82 100.00%
Treatment 
type Diet 3 8.11% 6 13.33% 9 10.98%
  Pills 21 56.76% 28 62.22% 49 59.76%
  
Pills and 
insulin 6 16.22% 8 17.78% 14 17.07%
  Insulin 7 18.92% 3 6.67% 10 12.20%
  Unknown 0 0.00% 0 0.00%
0.3713
0 58.54%
Sex Female 15 40.54% 33 73.33% 48 41.46%
  Male 22 59.46% 12 26.67%
0.0027
34 64.63%
Ethnicity White 23 62.16% 30 66.67% 53 23.17%
  Black 9 24.32% 10 22.22% 19 10.98%
  Hispanic 5 13.51% 4 8.89% 9 1.22%
  Other 0 0.00% 1 2.22% 1 1.22%
  Unknown 0 0.00% 0 0.00%
0.7243
0 0.00%
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Table 15 (continued). 
    Group       
    Control group Intensive group       
  Level N % N % 
P-
valuea 
Total 
N 
% of 
Total 
Highest 
level of 
education 
Grade 
School 1 2.70% 0 0.00% 1 1.22%
  
High 
School 15 40.54% 19 42.22% 34 41.46%
  College 20 54.05% 24 53.33% 44 53.66%
  Unknown 1 2.70% 2 4.44%
0.7054
3 3.66%
Type of 
doctor 
Endo-
crinologist 16 43.24% 14 31.11% 30 36.59%
  
Primary 
care 21 56.76% 31 68.89% 52 63.41%
  Unknown 0 0.00% 0 0.00%
0.2564
0 0.00%
Duration 
of 
diabetes <1 year 17 45.95% 23 51.11% 40 48.78%
  1-5 years 1 2.70% 7 15.56% 8 9.76%
  
>= 5 
years 19 51.35% 14 31.11% 33 40.24%
  Unknown 0 0.00% 1 2.22%
0.0921
1 1.22%
aChi-squared test.
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Table 16.   
Baseline Characteristics by Treatment Group for Those with Complete Follow-up: 
Continuous Covariates  
    Group     
    Control Intensive All 
T-test P-
valuea 
All N 37 45 82 --- 
Age N 35 41 76
  Mean 55.37 55.59 55.49
  St. dev. 10.96 9.32 10.04 0.9270 
Self-efficacy score N 37 45 82
  Mean 29.92 31.04 30.54
  St. dev. 4.49 4.56 4.53 0.2658 
Susceptibility 
score N 37 45 82
  Mean 29.11 27.16 28.04
  St. dev. 5.19 5.3 5.31 0.0976 
Benefits score N 37 45 82
  Mean 36.73 36.71 36.72
  St. dev. 3.82 3.23 3.49 0.9810 
Severity score N 37 45 82
  Mean 26.65 24.82 25.65
  St. dev. 3.11 3.93 3.68 0.0242 
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Table 16 (continued). 
    Group     
    Control Intensive All 
T-test P-
valuea 
Cue-to-action 
score N 37 45 82
  Mean 18.7 17.62 18.11
  St. dev. 3.77 4.15 4 0.2254 
Structural score N 37 45 82
  Mean 11.38 10.91 11.12
  St. dev. 4.29 3.65 3.93 0.5955 
Motivation score N 37 45 82
  Mean 18.27 18.13 18.2
  St. dev. 3.83 3.42 3.59 0.6304 
Barriers score N 37 45 82
  Mean 91.3 96.227 94.02
  St. dev. 18.92 25.97 23.06 0.3345 
HgbA1c N 37 45 82
  Mean 8.6 8.4 8.5
  St. dev. 1.3 1.4 1.3 0.6184 
aT-test assumes equal variance between groups. 
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Of those 82 individuals on which data were complete, there were 
significant gender differences between the control group and the intensive group 
(more women in the intensive group, p=0.0027).   Education (higher education in 
the intensive group, p=0.0340), and duration of diabetes (shorter duration in the 
intensive group, p=0.0020) were different.   Also, baseline severity scores were 
higher in the control group (26.65) compared to the intensive group (24.82, 
p=0.0242). 
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Research Question 1 results 
The primary objective of this study was to determine if persons with type 2 
diabetes participating in an ADA diabetes self-management education randomly 
assigned to an intensive follow-up group employing the continuous sensor would 
achieve lower mean HgbA1c values indicating better metabolic control than 
controls receiving standard control.  A randomized, repeated measure design 
was employed to test the null hypothesis that there is no significant difference in 
mean HgbA1c values over time (week 1, week 2, and week 24), for participants 
of a ADA DSME randomly assigned to the intensive follow-up group compared to 
the standard follow-up group.  Twelve weeks from their initial assessment of 
HgbA1c and after completing the diabetes self-management education patients 
were scheduled to return for follow-up.  Both groups were first informed by letter 
from the program assistant the date their HgbA1c and behavioral and outcome 
follow-up was scheduled.  The letter was sent well in advance of the scheduled 
time and place of their appointment.  Those with a scheduling conflict were 
instructed to call immediately so that their schedule needs could be met. Those 
who were randomly assigned to the intensive group also received a letter that 
they had been assigned to the intensive group and given the number to schedule 
their appointment for follow-up employing the sensor.  A complete description of 
the MiniMed continuous glucose monitor sensor, and the time and effort required, 
were described in the letter and discussed on the phone on scheduling. The 
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MiniMed CGMS used in this study was loaned to the center as a courtesy. The 
principle investigator, the diabetes educators and the Diabetes Care Institute had 
no affiliated with MiniMed and received no payment or incentives to use their 
product in this research.  MiniMed did not solicit the center to conduct this 
research.  MniMed had no involvement or control of the study .They implied no 
obligations for their donation of the sensors used in this research.  The sensor 
was previously discussed at the initial enrollment prior and during the informed 
consent process. The primary response variable, the HgbA1c value, was 
measured using the same capillary NGSP certified micro-optical detection assay, 
A1cNow at week 1, week 12 and week 24 (see Figure 7).  The mean HgbA1c 
values for the control were compared to the intensive follow-up group using a 
SAS ANOVA GLM procedure for repeated measures (see Appendix12 for 
ANOVA Summaries and SAS output).   The results used Tukey and Bonferroni 
adjustments for multiple comparisons. The data analysis conducted found no 
significant statistical difference between the groups (see Table 17).   
The first arm of intervention reflected the largest drop of the mean 
HgbA1c.  The overall mean HgbA1c value of 8.5% dropped to 7.1% at week 12.  
The mean baseline HgbA1c values for the control  (8.6, N=80) and intensive 
group (8.5,N=79 ) showed no pre-intervention differences, the F value was 0.16, 
p= 0.6880.  At week twelve the standard follow-up group mean HgbA1c was not 
significantly different than the intensive group . ( F> 0.00, p= 0.9776.  At twenty-
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four weeks, HgbA1c means reflected no significant differences between the 
control and intensive follow-up groups (F > 0.02, p= 0.8798).  Tukey and 
Bonferroni corrections showed no significant differences between mean HgbA1c 
levels in each group at week 1, week 12, or week 24. 
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Table 17.   
Results from Repeated Measures ANOVA Analysis of Hemoglobin at Weeks 1, 
12, and 24, Control vs. Intensive.  
    
Week 
1 
Week 
12 
Successc at Week 
12, Y/N (%) 
Week 
24 
Successc at Week 
24, Y/N (%) 
Control N 80 62 27/35 (43.55%) 50 29/21 (54.72%) 
  Mean 8.49 7.18 --- 6.93 --- 
  Std Dev 1.26 1.29 --- 1.40 --- 
Intensive N 79 60 33/27 (55.00%) 53 
29/24 
(58.00%) 
  Mean 8.52 7.16 --- 7.00 --- 
  StDev 1.28 1.40 --- 1.34 --- 
F Valuea   0.16 0.00 --- 0.02 --- 
p-valuea Unadjusted 0.6880 0.9776 --- 0.8798 --- 
  
Tukey 
Groupingb NSD NSD --- NSD --- 
  
Bonferroni 
Groupingb NSD NSD --- NSD --- 
Note:  Considered in ANOVA - Control, N=48; Intensive, N=53 
aRepeated measures ANOVA. 
bNo significant differences between groups. 
cSuccess = Hemoglobin at 7% or less. 
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Table 17 also includes the proportion of participants who successfully 
lowered their HgbA1c to the ADA standard of 7% or less. At week 12, 55% of the 
intensive group and 44% of the control members were successful.  At week 24, 
58% of the intensive and 55% of the control group members were successful.  A 
1.0% lowering of HgbA1c is clinically significant to lower complications and costs 
of care. Overall, the mean HgbA1c value dropped 1.6%. 
 
Figure 7.   
Mean Hemoglobin at Weeks 1, 12, and 24 by Group  
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An annual follow-up visit was conducted with 51 of the participants.  Table 
18 shows their Hgb1ac measures at this follow-up. 
 
Table 18.  
Hemoglobin (Hgb1ac) at 1-year Follow-up  
    Group     
    Control Intensive All 
T-test P-
valuea 
Hgb1ac at annual 
follow-up N 27 24 51 --- 
  Mean 6.78 7.15 6.95
  St. dev. 1.70 1.41 1.28
0.3028 
aT-test assumes equal variance between groups. 
.
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Research Questions 2-11 results 
A profile analysis was employed utilizing a repeated ANOVA to compare 
the mean Health Belief subscale scores for both groups for the eight major 
constructs of the expanded health belief model (self-efficacy, treatment benefits, 
susceptibility, severity, cues to action, structural elements, motivation and 
barriers pre- and post-intervention). A comparison of pre-intervention mean 
scores illustrates that the two groups were similar at baseline (see Figure 8).  At 
week 24, study participants completed the revised expanded Health Belief 
Questionnaire for the second time to measure post-intervention beliefs (see 
Figure 9).  Both groups showed a similar response pattern.  As previously 
reported there were no pre-intervention differences.  Figure 10 shows the 
differences at each time by group, and Figure 11 shows the overall profiles at 
weeks 1 and 24 by group.  There were no significant EHBMQ subscale mean 
score differences found between the control group and the intensive group at 
week 24, with the exception of perceived severity scores. The mean for the 
control was higher (27.05) than for the intensive follow-up group (p value 0.03).  
Tukey’s Studentized range test confirmed differences between the groups at 
week 24.  When applying the GLM procedure to the mean score differences from 
week1 to week 24, no differences were found between groups.  The persons in 
the control group with lower severity scores tended to drop out more which may 
have inflated the severity mean scores. The GLM procedure summary is 
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summarized in Appendix 12. 
 
Figure 8.   
Baseline Health Belief Profiles by Group  
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Figure 9.   
Week 24 Health Belief Profiles by Group  
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Figure 10.   
Health Belief Profiles in Differences from Baseline to Week 24 by Group  
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Figure 11.   
Health Belief Profiles at Weeks 1 and 24 by Group  
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There was no significant difference between groups from week 1 to week 
24 in mean barrier scores.  The baseline mean for the control group went down 
from 96.15 to 90.60  at 24 weeks.  The intensive follow-up group mean remained 
fairly constant going from 93.4 to 94.1. The overall mean for barriers was 94.74.  
The scale ranged from lowest score of 65 to highest score 260.  The mean score 
for all participants in both groups were low at baseline and after intervention.   
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The mean differences from week 1 to week 24 showed treatment benefit 
scores increased slightly in both groups (SFG 36.7 to 37.2; IFG 36.7 to 37.2); 
however, no significant differences were found between groups. The scale range 
for treatment benefits was lowest score 9 to highest score 36.  Both groups 
showed high treatment benefit scores before and after intervention. 
No significant differences were found between groups in the mean self-
efficacy scores from week 1 to week 24.  The difference from week 1 to week 24 
showed a larger improvement in the SFG (30.21-33.15)) compared to the IFG 
(31.04 -30.74).  The scale ranged from 9 (lowest) to 36 (highest).  Both groups 
showed a slight increase in mean scores at 24 weeks.  Both pre-intervention and 
post-intervention self-efficacy scores reflected high self-efficacy beliefs. 
There was a significant difference at week 24 for the mean severity scores 
between the control and the intensive follow-up group.  The mean severity score 
increased from 25.4 to 27.3 for the control; whereas, the intensive follow-up 
group declined from 25.5 to 25.0.  The scale ranged from 8 to 32.  The mean 
severity scores reflected high values for both groups before and after 
intervention. 
There was no significant difference between groups in mean susceptibility 
scores from week 1 to week 24.  The control group means baseline score 
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increased from 27.8 to 28.9 at 24 weeks.  The intensive follow-up group means 
score went from 28.1 to 27.8. The scale ranged from 9 to 36.  Both group means 
indicated high-perceived susceptibility scores before and after intervention. Cue 
to action mean scores for the control group remained high going from baseline 
18.2 to 18.9 at week 24.  The intensive follow-up group increased from 17.5 to 
17.6 at week 24. 
Both groups showed improvement in structural element scores from 
baseline to 24 weeks. The control increased from 10.9 to 12.8.  The intensive 
follow-up group increased from 10.9 to 12.1.  There was no significant difference 
between groups. The scale ranged from 4 to 16.  Both groups had high scores 
pre-and post intervention. Mean motivation scores for both groups were similar.  
The mean scores remained high at baseline and at week 24.  (SFG 18.2 to 18.5; 
IFG 18.8 to 18.3) 
At week 12, both groups completed the diabetes self -care practice 
assessment (PCA) designed to measure diabetes self-care skills, knowledge, 
and adherence to each aspect of the diabetes regimen.  Both the diabetes 
educator and the patient rated the tool.  For example, when rating diet knowledge 
and compliance, the dietitian CDE, took into account the patient’s ability to 
understand nutrition concepts covered by the curriculum, but also reviewed food 
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recalls and records. The rater also utilized the patient and family self-reports: pre- 
and post-test; behavioral goal evaluations (Appendix 6), and when appropriate, 
observation of actual skills.  Reading nutrition labels and selecting appropriate 
amounts of carbohydrates in a lunch meal served are examples of ways the 
educator observed and rated patient performance (see Table 3, Table 4).  The 
diabetes Self-Care Practice Assessment designed to meet the objectives of the 
Life with Diabetes curriculum was used to assure the fidelity of the program.  
Both groups had similar mean scores at 12 weeks.  The mean of all persons 
completing the PCA was 95.5%’ the control group mean was 95.7% (N=55) 
compared to the intensive group mean score 95.4%.
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Chapter Five: Discussion 
This chapter includes: a summary of results; limitations; conclusions; 
implications for diabetes education, clinical practice, and glycemic control; and  
lessons learned and recommendations for future research. 
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Summary 
This study sought evidence as to whether type 2 adults who participate in 
ADA approved DSME randomly assigned to an intensive follow-up would have 
significant differences in HgbA1c values, health belief and behavior scores 
compared to those assigned to the standard follow-up over time. 
A repeated measure ANOVA analysis showed a statistically significant 
reduction in mean HgbA1c at each time period from week 1 to week 12 (SFG 
8.6-7.1, N=79; IFG 8.5-7.1, N=80) and from week 12 to week 24 (SFG 7.1 to 6.9, 
N=48; IFG 7.1-7.0, N=53).  There were no significant differences found between 
the groups (F=0.17 Pr>f ). 
The 8 major constructs of the expanded health belief model (self-efficacy, 
treatment benefits, susceptibility, severity, cues to action, structural elements, 
motivation and barriers) were measured at baseline and at the six month (24 
week) follow-up using the revised expanded health belief model questionnaire. A 
repeated ANOVA profile analysis found no significant differences in health belief 
scores between the groups except for perceived severity (p value 0.03).   The 
mean severity scores for the standard follow-up group was higher (27.05) than 
for the intensive follow-up group (25.00) at week 24. Both groups had similar high 
scores at baseline. The follow-up intervention using the CGMS had resulted in a 
slight lowering of the patient’s perception of their severity; however, both groups 
perceived severity scored remained high.  T-Test results comparing those who 
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completed study (N=82, mean severity score=25.65) compared to those dropped 
from the study (N=77, mean 25.25) showed no difference in mean severity (Pr >t 
0.5444).   There is a statistical difference (p-value=0.02) when comparing the 
standard follow-up group mean scores at week 24 with the intensive group.  The 
intensive follow-up group mean declined slightly from 26.27 to 24.82. The SFG 
slightly increased from 24.52 to 26.64.  
Both groups had high means scores that improved from baseline to six 
month for treatment benefits, self-efficacy, cues- to- action and structural 
elements.  Barrier mean scores for the SFG slightly decreased (96.1 to 90.0) 
where as the IFG remained fairly constant (93.4 to 94.1). Both groups had similar 
low mean scores before and after intervention (p-value > 0.05). Mean 
susceptibility scores slightly increased in the SFG (27.8-28.9) compared to the 
IFG lowering after intervention (28.1-27.8). Both groups had high mean scores 
pre- and post intervention. Motivation mean scores for both groups were constant 
remaining high before and after intervention.  
Mean barrier scores were similar for both groups with the mean scores 
improving in the SFG from baseline to post intervention (96.15-90.62) whereas 
the IFG remained fairly constant (93.40-94.08). The mean barrier scores 
reflected a low level of barriers before and after study interventions.  Mean 
motivation scores remained consistently high before and after intervention with 
no differences found between groups.  Cues to action scores remained 
 199 
consistently high from baseline to the six- month follow-up visit with no difference 
found between groups. 
The diabetes self-care practice score measures the patient’s 
understanding and ability to carry out specific diabetes self-care behaviors.   Both 
groups had similar high mean diabetes self-care practice scores (SFG=95.7, 
IFG=95.4). The diabetes self-care practice assessment developed from the ADA 
approved “Life with Diabetes “curriculum objectives helped ensure the fidelity of 
the education program.   
At baseline, the control and the intensive follow-up groups had similar 
distributions of the categorical variables: treatment type, ethnicity, education 
level, and type of physician and duration of diabetes. At baseline, the intensive 
follow-up group had slightly more women than men (IFG N=51; SFG N=37). This 
slight gender difference had no known impact on the primary variable under 
study. There is no conclusive evidence that suggest that HgbA1c or health belief 
scores would be different due to gender. The United Kingdom Prospective Study 
(1999) they found no differences in HgbA1c based on gender. 
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Limitations 
The control and intensive follow-up group had similar distributions at 
baseline for the continuous variables: age; week 1 HgbA1c values; and the 8 
Health Belief Model subscales.  The randomization worked well at evenly 
distributing the variables for a small sample size.  The univariate SAS procedure 
was utilized to test the variables for normal distributions see Appendix 10).  A 
normal distribution was confirmed for the variables: self-efficacy, susceptibility, 
severity,  cues to action, structural elements, motivation, barriers and age.  The 
box plot for treatment benefits showed equal distribution: however, a ceiling 
effect towards the top of the scale indicated that those who make the effort to 
attend diabetes classes are people who perceive that education offers a high 
benefit.  This finding is not unexpected since the exclusion criterion limits the 
study to participants willing to participate in diabetes education. The finding of 
this study therefore may not be generalized to all diabetes patients.  Patients 
unwilling or unable to attend diabetes classes may be different  
Due to the exclusion of patients with HgbA1c values less than 7%, the plot 
of the HgbA1c values reflected the upper half of the bell –shaped curve.  At lower 
HgbA1c levels a significant clinical difference due to effects of treatment would 
be difficult to measure without prohibitive sample sizes.  From the pilot study and 
outcome data prior to the study we expected a drop in HgbA1c at 3 months but 
these outcomes not being obtained in a controlled study could only be 
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considered an estimate.  During the years 2000-2004, the center’s outcome data 
for the years corresponding to the study showed a 1.14 to 2.27 percent reduction 
in mean HgbA1c levels per year (500 - 829 patients per year) for those who 
returned for follow-up.  
The results of this study cannot be generalized to all type 2 patients. This 
study is delimited to sample of healthy type 2 adult volunteers referred to an 
outpatient ADA approved DSME employing an empowerment goal oriented 
approach. Other diabetes populations may have different results. The study 
results showed that participants of this study had high perceived health beliefs 
and were highly motivated prior to the DSME and follow-up intervention. 
Although at six months there were slight improvement in mean health belief 
scores there no statistical difference found between the groups or differences 
over time except for perceived severity..  
Patients not attending DMSE or those who did not complete the education 
interventions may be different and have different outcomes. The participants in 
this study do not characterize all persons with type 2 who may seek or are in 
need of diabetes education. 
 The DSME offered at the Diabetes Care Institute of University Community 
Hospital is an outpatient program providing services in the Tampa Bay area other 
types of programs in other geographic locations may be different.  There is a 
potential for investigator bias because the investigator and Diabetes Educators 
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may represent “passionate” workers. Use of a Standardized curriculum, audio-
taping, peer-evaluations and competencies, and employing the patient care 
assessment helped ensure the fidelity of the program.  The investigator and 
Diabetes Educators were blinded to the group assignment.  The program 
assistant not involved in the education entered the data.  Data was filed in 
medical records and databases until compiled for data analysis.   
  . Both groups had similar improvements in HgbA1 over time.  The 1.4 
percent HgbA1c reductions achieved in the education arm of the study was 
higher than expected.. This larger than expected drop in the HgbA1c made it 
more difficult to see significant changes between groups during the intervention 
phase.  The smaller effect size of the intervention would be difficult to detect in 
this sample size These findings provide further evidence that DSME meeting the 
national standards and follow-up interventions help achieve and maintain better 
glycemic control.  Longer-term prospective studies are needed to determine 
whether these improvements can be sustained.   
Several meta-analysis studies (Norris et. al., 2002, Brown et. al., 1992; 
Padgett et. al., 1998) confirmed a beneficial effect of DSME on knowledge, 
improved diabetes self-care behaviors and improved metabolic control.   Brown 
(2002) stated that previous DSME studies showed an early moderate effect size 
on HgbA1c with a peak at 1 to 6 months. Similar results were found in this study.  
Participants in this study showed a continual reduction of HgbA1c from 12 weeks 
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to 24 weeks. The study follow-up period was limited to six months and therefore 
the long- term effects are not known. One-year follow-up data was available on 
early participants that showed a trend for the HgbA1c lowering to be sustained.  
Future studies are needed to confirm this observation.  Mean outcome data for 
all patients participating in DSME also showed that patients returning in one year 
sustained HgbA1c improvements.  
Brown found that benefits on psychological outcomes improved more after 
6 months. In this short-term study the expanded health belief model was not 
particularly helpful in determining changes in psychosocial outcomes. The groups 
showed no statistical differences in their Health belief scores except for severity. 
A highly motivated volunteer sample does not represent a cross-section of the 
diabetes population. Studies with other sample populations with less motivation 
or who score low initially on health beliefs may need to be explored to determine  
the utility of the model.  In light of the study findings of no significant differences 
perhaps Diabetes Educators need to explore other theoretical models and 
frameworks that would be more useful. The behavioral and health belief 
outcomes measured in this study by the revised diabetes expanded health belief 
model questionnaire may be different than those measured with other 
instruments. Even though structural element questions in the EHBM 
questionnaire involved social support this study was limited by its lack of direct 
tracking of family involvement. 
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     One hundred and fifty-nine participants had baseline HgbA1c values..  Fifty-
six had missing HgbA1c values at week 24.   Forty-three out of the fifty six were 
lost to follow-up (unable to contact by phone or mailings).  Nine relocated out of 
the Tampa Bay Area.  Four patients withdrew due to time constraints.  One 
reason given for patient’s missing the 3 -month follow-up was that their physician 
ordered HgA1c and other labs prior to their 12-week follow-up.  Of the remaining 
103 who had an HgbA1c at week 24, twenty-three did not complete the second 
EHBM questionnaire.  82 0f the 159 had all primary and secondary variables at 
the end of the study period.  Those that completed the study were similar to 
those who dropped out for all variables except  those completing the study were 
slighter older, the mean age 55 compared to 50.  The time required for follow-up 
was limited to working hours 7:30 to 6pm, which may have been a factor for 
younger working adults. The final baseline data analysis showed that the 
younger participants who dropped out were evenly distributed between the 
groups.  
Initially, the sample size was estimated for 159 participants to achieve adequate 
power (0.80) at a 0.05 alpha level.  The control group size was planned for 78 
patients to allow for a 30% attrition rate.  The intensive follow-up group sample 
size was planned for 81 subjects to allow for a 35% attrition rate. Despite use of 
reminder letters, repeated phone calls and offering flexible follow-up times the 
attrition rate was higher than anticipated.  Overall 35% (56/159) of patients did 
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not return for the HgbA1c determination at week 24.  After dropping from the 
analysis those with incomplete data, 82 patients had all primary and secondary 
variables.  In the standard follow-up group fifty-four percent dropped out 
compared to forty-three percent of the intensive group.  The higher then 
expected attrition and the significant lowering of the HgA1c following DSME 
made it difficult to detect small mean difference in HgbA1 between the follow-up 
groups.  The expected reduction in HgbA1c is less as patients obtain HgbA1c 
goals.  The mean HgbA1c value for both follow-up groups were at the ADA goal 
of seven percent or less (SFG 6.9,,IFG 7.0). The proposed Hypothesis that the 
CGMS follow-up group would do better was not substantiated by the study 
results. The conclusions drawn that no differences exists between the groups 
should be interpreted with caution due to the loss of power to detect small 
differences between the groups. This new technology utilized in the intensive 
follow-up group resulted in similar reductions in HgbA1c as the standard follow-
up. There was no statistically significant difference found between from the 
groups. Fifty-four percent of the patients in the standard follow-up group 
achieved the ADA goal for HgbA1 (7% or less) compared to 58% in the intensive 
follow-up group.  In light of these findings of no added benefit, the standard 
follow-up is recommended over the intensive since it is less time consuming and 
more cost- effective.    
The HgbA1c lowering effects of the CGMS reported in previous studies 
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were mainly attributed to changes in medical management.  Several studies 
reported effective lowering of HgbA1 when the sensor was used to adjust 
diabetes therapy. (Bode et al., 1999; Ludvigsson &Hanas, 2003 ;). 
This study controlled for medical management changes in order to 
examine the effects of DSME and the follow-up interventions on the HgA1c 
outcomes.  Those with recent medical changes were excluded in this study. 
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Conclusions 
This study provides evidence that DSME programs that meet national 
standards effectively help type 2 adults improve their HgbA1 outcomes.  Mean 
HgbA1 levels significantly dropped from week1 to week 12 following the DSME 
and from week 12 to week 24 following the follow-up intervention.  There were 
 No statistically  differences found between the SFG and the IFG.  There were no 
statistically significant differences in mean Health belief scores and PCA scores 
between groups except for mean severity scores.  Those in the IFG had 
significantly lower mean severity scores than the standard group.  
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Implications for Diabetes Education, Clinical Practice, and Glycemic Control 
DSME should be offered to all persons with type 2 diabetes regardless of 
age, duration of diabetes or type of treatment.  Diabetes Self-management. 
Education is needed to acquire the necessary knowledge, skills, and attitudes to 
perform self-care behaviors that foster good metabolic control.   
Follow-up interventions with certified diabetes educators were effective in 
measuring clinical improvement through point of care HgbA1c measurement and 
to Identify whether patients were successful in achieving their diabetes self-
management goals.  Those unsuccessful in obtaining the ADA goal need further 
evaluation of their barriers to control. The Certified Diabetes educator worked 
collaboratively with the patient to identify the barriers and help patients form 
strategies to help overcome these barriers. This collaborative relationship 
resulted in improvement regardless of the type of intervention. 
Norris (2002) concluded from his meta-analysis examining the effects of 
DSME that patients in these studies showed improved A1C results after DSME 
and these reductions in HgbA1 levels were sustained with regular provider or 
professional contact.  Patients not followed by health professionals regularly had 
relapses in their HgbA1 improvements. 
Recently, the American Association of Diabetes Educators (AADE, 2003) 
recommended that seven scientific-based diabetes self care behaviors (being 
active, eating healthy, medication, monitoring, problem-solving, lowering risks for  
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and living with diabetes) should be outcomes measured by DSME programs.  
The AADE suggested that DSME programs evaluate a continuum of outcome 
measures from immediate outcomes (tests, observation of skills) to intermediate 
outcomes (lab test, self-report of goal progress, behavioral and health belief 
measurements) to post intermediate outcomes (clinical improvement measures) 
to long term outcomes.  These new recommendations pose considerable 
challenges for education programs that often lack the financial support and 
reimbursement needed to carry out these goals.  The paradigm of responsibility 
or improved diabetes outcomes is shifting again from provider to patient to a 
shared responsibility.  Diabetes goals need to be formed by the patient with the 
active guidance of the health providers for them to achieve the desired effects.  
Evaluation of outcomes is necessary to determine which type of interventions is 
best for which populations.  Questions regarding how often follow-up 
interventions should be offered and for what duration to prevent relapse need to 
be answered.  
At present the CGMS has received poor reimbursement for use in type 2 
patients.  Due to the costs of these new technological interventions and the 
highly successful DSME outcomes utilization of the sensor for educational and 
behavioral changes alone are not supported. Further research is needed to 
determine which type 2 patients would benefit when medical therapy adjustments 
are included in the intervention..   
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The study findings support current recommendations that patients should 
first receive DSME.  A basic level of knowledge is necessary in order to carry out 
diabetes self-care skills and behaviors that lead to better clinical and 
psychological outcomes.  Further studies are needed to determine which patient 
characteristics are contributing to the successful and unsuccessful HgbA1c 
outcomes.
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Implications for Public Health 
According to the recent National Health and Nutrition Examination Survey 
(NHANES III) and data from the American Association of Clinical 
Endocrinologists (AACE) survey, the majority of persons with type 2 diabetes 
have failed to reach A1C goals. The NHANES survey (2000) reported only 37% 
reached goal levels, whereas the AACE survey (2005) reported only 33% 
reached the AACE preferred A1C goal of 6.5%. In light of the culminating 
evidence that intensive diabetes management lowers the burden and cost of 
diabetes Public Health policies are needed to assure that diabetes education is 
affordable and accessible to the public. Public Health initiatives are needed to 
continue the legislative efforts for adequate DMSE insurance coverage and 
reimbursement for diabetes supplies.  The passage of the Balanced Budget Act 
in 1997 acknowledged the importance of DSME and led changes in the Medicare 
coverage of Diabetes.  Prior to this legislation, persons with diabetes could only 
receive DSME within one year of their diagnosis or if they had 2 consecutive 
HgbA1c values over 8.5% or other new onset diabetes micro-vascular 
complication.  Patients had to already present with major renal and retinal 
problems to qualify.  Studies on the cost and healthcare utilization of Diabetes 
have shown that waiting until diabetes complications set in are considerably 
more costly.  Although this legislation improved the Medicare guidelines it still 
does not do enough to prevent the diabetes prevalence from growing. The 
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Center for Disease Control (2005) estimates 20.8 million has diabetes and 
another 54 million have insulin resistance of prediabetes.  Epidemiological 
studies suggest that the diabetes epidemic is largely due to the person’s diet and 
lifestyle (Schulze & Hu, 2005). Medicare recognizes prediabetes and metabolic 
syndrome but still denies DSME and even minimal Medical Nutritional Therapy 
coverage to these patients. 
In the light of the  high success rate (55% SFG, 58%) of patients who 
Attended DSME public health policies are needed to adapt the ADA DMSE to 
state and federal funded programs.    Public Health policy needs to foster the 
various agencies to work towards the common goal.  Presently, ADA and AADE 
are recommending 3 sets of goals. First, primary prevention needs to address 
the obesity and prediabetes population. These high risks patients need education 
to help them make difficult lifestyle changes such as diet and exercise. 
Secondary prevention focuses on those with the disease controlling the disease 
to prevent complications. Tertiary prevention goals are to prevent morbidity and  
mortality from the diabetes related complications.  
Although the CGMS has important clinical applications for physicians in 
medical therapy, policies regarding its use as an education intervention are not 
warranted due to the option of a follow-up intervention with the CDE that is as 
effective and less costly.  
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Lessons Learned and Recommendations for Future Research 
Long–term prospective DSME outcome trials have had problems with high 
attrition rates. In addition, the health benefits attributable from education are 
difficult to measure separately from other therapies.  These issues make it 
difficult to draw reliable conclusions about the effectiveness of DSME and follow-
up interventions. 
In part this is due to ethical concerns about use of a control group that 
withholds beneficial therapies.  In order to detect small effect sizes, impractical 
sample sizes and needed.  
Increase in awareness and funding for educational outcome research is 
needed.  A coalition made up of members from the American Diabetes 
Association, Foundation for Accountability, The Health Care Finance 
Administration, the National Diabetes Quality Improvement Alliance, the 
American Academy of Family Physicians, The American College of Physicians 
and the Veterans Administration formed to develop an evidence-based 
consensus for outcome measurement goals.  These endeavors have lead to the 
development of standards for DMSE and diabetes care. Outcome measures will 
continue to help evolve to answer the questions as to what is best practice. 
ADA approved DSME programs need to measure both clinical and 
psychosocial outcomes in order to determine how effective they are in 
empowering the patient to achieve their goals. Follow-up interventions are a 
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critical time to focus on progress made by patients toward their goals and to help 
patients overcome the barriers they encounter.  Numerous studies have provided 
evidence that psychosocial outcomes are important to measure because they 
affect clinical outcomes (Peyrot &Rubin, 1999, DCCT, 1996; Schafer, McCaul & 
Glasgow, 1986; Peyrot & Rubin 1995).  
Focus studies are needed to determine why patients do not follow-up and 
ways to increase return rates.  Further studies are needed to determine cost-
effective ways to follow-up on patients, and at what interval are necessary to 
achieve and sustain diabetes self-care goals and behaviors.  Follow-up 
intervention outcome measures are needed to assess the patient’s progress to 
their goals, measure their behavioral change and develop strategies to overcome 
any barriers encountered.  Follow-up with the diabetes educators helped 
reinforce patient’s motivation and efforts toward their goals.  Previous studies 
have found that patient’s did better when they communicated regularly with 
health professionals than when left on their own (Brown, 1992; Norris, 2002). 
The drop out rate was higher than planned for estimated sample size.  As 
a result the loss in sample size resulted in a loss of power to detect small 
differences in groups.  Since both groups showed significant drops in HgbA1c 
1.6%, only very large samples could detect a difference between the groups if 
one truly exist.  Although unable to provide evidence that the intensive follow-up 
was more effective, the study did indicate that HgbA1c values could improve 
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significantly from both education and follow-up interventions.  The lower HgbA1c 
levels achieved in this study reflects a clinically significant difference, for every 
1% lowering of the HgbA1c a 35% reduction of microvascular complication has 
been shown in type 2 population. 
The International Diabetes Center (2001) reported have that medical 
management can account for 0.5-4% lowering of HgA1c.  This study controlled 
for medical management effects by limiting sample to those who have had no 
recent change in medications.  
 In light of the study findings, it is recommended that those who have not 
had DSME be offered training regardless of age, duration of the disease  and 
other factors.  Exploratory regression model research is needed to find out what 
elements of the ADA curriculum accounts for the most improvement in HgbA1c 
outcomes.  There are a number of people who may find attending ten hours of 
DSME and participating in follow-up too time consuming.  By learning more about 
the ADA curriculums essential elements we can meet the needs of those the 
ADA program is not  currently reaching and make it more appealing to those who 
feel the ten hour program is too time consuming.   
Additional studies are needed to determine the type and duration of follow-
up interventions that prevent relapse....Due to time and financial constraints of 
this study the follow-up time period was limited to 24 weeks.  Some patients with 
early enrollment came back for 1-year follow-up.  The lower hgbA1c mean for 
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those with 1 - year follow-up, showed a trend of maintenance of the improved 
HgbA1c. N=51, 6.95: SFG N=27, HgA1c mean 6.78; IFG N=24 mean HgbA1c 
7.15).   Future studies are needed to determine if long-term effects can be 
maintained and what type and frequency of intervention is needed to obtain and 
sustain diabetes goals. 
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Appendix 1:  Assessment and Education Records and Baseline Evaluation Form 
Assessment and Education Records 
BASELINE EVALUATION FORM 
IDENTIFYING INFORMATION 
Date of Evaluation: _____/_____/_____  
(mm/dd/yy) 
 
Patient's Physician type: ________ (1) Endocrinologist 
________ (2) Primary Care/Other 
 
Patient Surname:  
 
Patient's ID/SS Number:  
 
Date of Birth: ____/_____/______ 
(mm/dd/yy) 
If age <35> 70, patient is ineligible 
Gender: ______ (1) Male  
______ (2) Female 
Race: ______ (1) White 
______ (2) Black  
______ (3) Hispanic   
______ (4) Other.   Please specify: ____________ 
Education: ______ (1)  Less than high school education 
______ (2)  Graduated high school or higher 
education 
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PERTINENT MEDICAL HISTORY 
Type of Diabetes: 
 
_______Type I (ineligible)  
_______Type II-non-insulin  
_______Type II-insulin  
_______Secondary diabetes  (ineligible) 
History of Gestational 
diabetes 
 
________ (ineligible) 
Duration since Diabetes 
Diagnosis:    
 
________ (years) 
History of any 
hemoglobinopathy or 
hemolytic process:  
 
________ (1) Yes  (If yes, ineligible) 
________ (2)  No 
 
________ Height (cm)  
 
________ Weight (Kg)      ________ BMI 
 
Other illnesses (check all 
that apply):  
 
________ Heart Disease 
________ Lung  
________ Cancer 
________ Hypertension   
________ Stroke 
________ Alzheimer’s 
________ Other Specify _____________________ 
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DOCUMENTED DIABETES COMPLICATIONS 
Eyes  ________ Yes  
________ No 
Specify: 
Amputation ________ Yes  
________ No 
Specify: 
Kidney ________ Yes  
________ No 
Specify: 
Nerves ________ Yes  
________ No 
Specify: 
Circulation ________ Yes  
________ No 
Specify: 
ER Visits ________ Yes  
________ No 
Specify: 
Hospitalization within 
last 2 years 
________ Yes  
________ No 
Specify: 
Vision Impaired ________ Yes (ineligible) 
________ No 
Specify: 
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Mobility Impaired 
 
________ Yes (ineligible) 
________ No 
Specify: 
On dialysis ________ Yes (ineligible) 
________ No 
Specify: 
Medical Clearance for 
Exercise 
________ Yes (ineligible) 
________ No 
Specify: 
TYPE OF TREATMENT FOR DIABETES 
_____ (1) Diet only.   Specify type 
__________________________________ 
_____ (2) Diet and oral 
hypoglycemic agent 
(OHA) pills.   
 
Specify type/amount  
 
_____ (3) Oral hypoglycemic 
agents (Diabetic pills) 
only.   
 
Specify type/amount  
 
_____ (4) More than 2 doses of 
OHA's pills or more than 
1 brand of OHA pills/day 
and diet. 
 
Specify type 
__________________________________ 
______(5) Insulin Therapy  Specify 
__________________________________ 
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_____ (5) Date started on OHA     ___/____/____  
(mm/dd/yy) 
 
_____ (6) Date started on insulin ___/____/____  
(mm/dd/yy) 
 
_____ (7) Date of last diabetes 
medicine change 
___/____/____  
(mm/dd/yy) 
 
Glycosylated Hemoglobin Value:  ______  %  and date  
___/____/____  
(mm/dd/yy) 
 
Expanded HBMQ  Scales: Date ____/____/____ 
 (mm/dd/yy) 
 
Expanded HBM Subscales Mean Scores 
Severity _____________ 
Susceptibility    _____________ 
Benefits _____________ 
Barriers _____________ 
Health Motivation _____________ 
Self-efficacy _____________ 
Cues to Action _____________ 
Structural Elements _____________ 
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For returning controls (8 week)  
Hgb A1c _______%  
Date ___/___/___ 
 (mm/dd/yy) 
 
Last appointment with physician who 
manages your diabetes     
 
Date ___/___/___ 
 (mm/dd/yy) 
Any changes in medical management 
over past 8 weeks? 
 
________ Yes  
________ No 
Specify: 
Date ___/___/___ 
 (mm/dd/yy) 
 
Have you changed any aspect of your 
diabetes management over the past 8 
weeks? 
 
________ Yes  
________ No 
Specify: 
Date ___/___/___ 
 (mm/dd/yy) 
 
Previous Diabetes Education  
 
________ Yes  
________ No 
Specify: 
Date ___/___/___ 
 (mm/dd/yy) 
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Appendix 2:  Sample Flyer for Advertising Program 
 
 Purpose of Study 
 
To determ
ine if persons w
ith type 
2 diabetes participating in 
diabetes self-m
anagem
ent 
training assigned to an intensive 
follow
-up group achieve better 
diabetes control than those 
assigned to the standard follow
-
up group.  
 A
 finger stick H
em
oglobin A
1c 
w
ill be perform
ed to assess blood 
glucose control and eligibility for 
the study (> 7.0 < 13). 
 H
em
oglobin A
1c is a 
m
easurem
ent of long-term
 blood 
glucose control that assesses 
how
 your blood glucose control 
has been over the past 8-12 
w
eeks.  Previous studies have 
show
n that by keeping H
gbA
1c 
level near norm
al can prevent or 
delay com
plications of diabetes 
such as blindness, nerve dam
age, 
kidney disease, and am
putations. 
 
W
ho C
an Participate? 
 
• 
People age 18-70 w
ith a diagnosis of 
D
iabetes M
ellitus,  Type 2 
• 
People w
ho have not attended a 
diabetes education program
 in 
the past year 
• 
People w
illing to attend 
approxim
ately 10-14 hours of 
education sessions over a 24 
w
eek period 
• 
People w
ho are physically able to 
care for their diabetes. 
• 
People w
illing to use a glucose 
m
onitor and or sensor  
 Proposed B
enefits of Participating in 
Study: 
 • 
Im
proved blood glucose control 
• 
D
ecreased risk of diabetes 
com
plications 
• 
Learning new
 skills for diabetes 
m
anagem
ent 
• 
Your H
em
oglobin A
1c level w
ill be 
tested.  
 
Education W
ill C
over  
 
• 
M
eal planning 
• 
Exercise 
• 
M
edication 
• 
B
ehavioral change 
• 
C
oping w
ith diabetes/stress 
m
anagem
ent 
• 
Prevention of com
plications 
• 
B
lood glucose m
onitoring 
• 
Special situation  
• 
Trouble shooting 
• 
C
onvenient scheduling 
• 
D
iabetes Education and supplies 
covered by m
ost insurance 
• 
Sm
all group and individualized 
counseling 
• 
N
o charge for follow
-up B
lood 
glucose m
onitoring, H
gbA
1c 
and  follow
-up sessions. 
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FO
R
 M
O
R
E IN
FO
R
M
A
TIO
N
 
 
C
all Jodee M
eisenhelder-
Sm
ith, R
D
 
@
 
The D
iabetes C
are Institute 
@
 
U
niversity C
om
m
unity 
H
ospital 
813-615-7751 
      
D
IA
B
ETES C
A
R
E 
IN
STITU
TE 
3100 E
A
S
T FLE
TC
H
E
R
 
A
V
E
N
U
E
 
TA
M
P
A
, FLO
R
ID
A
 
33613-4688 
 
   
N
eed H
elp 
M
anaging Your 
D
iabetes? 
    
Volunteers A
re 
N
eeded to 
Participate in the 
D
iabetes C
are 
Institute’s R
esearch 
Study
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Appendix 3:  Informed Consent Form 
 
INFORMED CONSENT FORM (ADULT) 
Study Title: The Effects of ADA Comprehensive Diabetes Self-Management 
Training and Continuous Glucose Monitoring on Diabetes Health Beliefs, 
Behaviors and Metabolic Control 
 
Protocol No. 
 
Sponsor: 
 
Primary Investigator: Jodee Meisenhelder-Smith, MNS, CNS, 
CDE, RD, LD 
 
Institution (s): University of South Florida 
University Community Hospital, 
Diabetes Care Institute  
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Introduction: 
 
You are being invited to participate because you have Type 2 Diabetes Mellitus .  
The study will focus on reducing Hemoglobin A1c  levels, a measurement of blood 
glucose that assesses how your blood glucose control has been over the past 8 
– 12 weeks.  Previous studies have shown that by keeping Hgb A1c levels near 
normal, diabetes complications can be delayed or prevented.  
 
Purpose: 
 
The primary purpose is to determine if persons with Type 2 diabetes  
participating in   ADA diabetes self-care management training program who have 
intensive follow-up achieve better control over their blood glucose levels than 
those receiving standard follow-up. 
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INFORMED CONSENT FORM 
 
Adult Informed Consent 
Diabetes Care Institute @ 
University Community Hospital and/or 
University of South Florida 
 
Information for People Who Take Part in Research Studies 
 
The following information is being presented to help you decide whether or not 
you want to be a part of a research study. Please read carefully. Anything you do 
not understand, ask the doctor. 
 
Title of Study:  The Effects of ADA Comprehensive Diabetes Self- 
Management Training and Continuous Glucose 
Monitoring on  Diabetes Health Beliefs, Behaviors and 
Metabolic Control. 
 
Primary Investigator:  Jodee Meisenhelder-Smith, MNS, CNS, CDE, RD, LD 
 
Study Location(s):  Diabetes Care Institute @ University 
Community Hospital.  
Appendix 3:  (Continued) 
265 
 
General Information about the Research Study 
 
The purpose of this research study is to determine if persons with type 2 diabetes 
participating in a diabetes self-care management training program with intensive 
follow-up achieve better control over their blood glucose levels than those in the 
standard follow-up control group. You are being asked to consent to participate 
because the study will focus on reducing hemoglobin A1c values which show the 
average blood sugar over the past three months in adults aged 35-70 with type 2 
diabetes.   
 
In order to test the effectiveness of the diabetes education, you will be randomly 
selected to receive one of two or more different treatment plans.  Randomization 
is similar to a flip of a coin.  Your chances of being put in either or any group is 
about the same.  All participants will receive the education program. 
 
You may want a friend or family member to read the form and talk to the study 
doctor with you. You can also talk to your personal doctor about what you should 
do. Talking things over can help you make the right choice. 
 
The time you will need to spend in this research study will be about: 16 hours.  At 
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the initial visit and after completing the education sessions, you will be asked to 
complete a questionnaire.  The questionnaire takes about 30 minutes to 
complete and will ask questions about your diabetes care and feelings about 
your health and diabetes.  
 
The number of other people that might take part in this study at this local site is: 
approximately 159. 
 
Plan of Treatment 
Your regular medical treatment will not actually be part of the research study 
but will prepare you for the study.  
The experimental treatment that you will receive by taking part in this research 
study is: 
You will be seen as an outpatient at the clinic several times over a 24 
week period.  This program differs from standard care for this disorder in 
the following way(s): Participants will receive 10 hours of education 
sessions with diabetic educators covering such topics as diabetes 
overview, nutrition and exercise guidelines, medications, acute and 
chronic complications, glucose and other monitoring, stress management, 
and behavioral goal setting skills.  During your participation, a capillary 
blood sample will be removed from you and analyzed, and used by the 
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investigators and/or the sponsors.  By signing this consent form, you 
agree to allow the investigators to analyze and use your blood as 
described and for the purpose stated.   
 
Benefits of Being a Part of this Research Study 
We cannot tell whether you will benefit from taking a Diabetes self-care 
management training program because its effects on your disease are not totally 
understood. On the other hand, by taking part in this research study, you may 
increase our overall knowledge of your disease and how to treat future patients.  
In addition, the program is designed to help patients improve their overall glucose 
control and in so doing reduce their risk of diabetic complications.   
 
Risks of Being a Part of this Research Study 
You may have side effects from regular treatment of your disease. This treatment 
would be medication to control blood sugar levels, blood glucose monitoring, and 
diet.  The possible side effects of this regular treatment are listed below along 
with your chances of having them and their seriousness compared to your 
disease. 
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There are no known risks associated with participating in a diabetes self-care 
management training program.  The testing of Hgb A1c and blood sugars requires 
one (1) drop of blood drawn from the subject using standard capillary lancets 
used in every day care of diabetes.   
 
Alternatives of Being Part of this Research Study 
Alternatives of being part of this research study is/are: Routine care.  Another 
alternative is to not participate in this study. 
 
Payment for Being a Part of this Research Study 
You will not receive cash or other gifts for taking part in this research study.  
However, Florida law requires most insurance to cover the cost of diabetes 
education and supplies.  All eligible patients will receive the diabetes self-care 
management training program  
 
Costs of Being a Part of this Research Study 
The diabetes self-care management training program and diabetes supplies such 
as lancets, needles and glucose monitoring strips are covered by the patient’s 
insurance.  Participants in the study will not incur any additional cost for follow-up 
care. Hgb Aic are performed free of charge.   
You will be provided a written list of procedures required because of the research 
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study.  One of the persons in charge of the research will discuss these 
procedures with you, and will assist you in making sure prior to participation that 
your insurance covers your costs for regular diabetes care.  Most costs 
mentioned above are covered by your insurance.   The DTC @ UCH is available 
to help you with insurance coverage information.  You may contact the primary 
investigator, Jodee Meisenhelder-Smith at (813) 632-7751; Beeper (813) 227-
0904. 
 
In Case of Illness or Injury 
Call your referring physician and the primary investigator, Jodee Meisenhelder-
Smith, at 813-632-7751 in the event you get sick or injured while on this research 
study. If you have an emergency, go to the closest emergency room or clinic for 
treatment. 
 
Available Medical Treatment 
This study is being conducted by Jodee Meisenhelder-Smith, MNS, CNS, CDE, 
RD, LD on patients from University Community Hospital.  University Community 
Hospital reviews research studies through its Institutional Review Board but is 
not an investigator in this study and does not supervise or direct the study.  If you 
experience a side effect or injury, and if emergency treatment is required, 
immediately contact Jodee Meisenhelder-Smith at (813) 632-7751, Beeper (813) 
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227-0904. 
 
University of South Florida Injury Statement 
In the event that you sustain an injury or illness as a result of participating in this 
research, please be aware that medical treatment for the injuries or illness may 
not be available from the University of South Florida (USF). USF does not 
maintain an emergency department nor does it provide medical treatment in all 
disciplines of medicine. If you become ill or sustain an injury which you believe is 
related to participation in this research, immediately contact one of the persons 
listed on page 1 of this form, and if emergency care is needed seek emergency 
attention from your nearest local hospital. 
 
If injury results from your participation in research, money damages are not 
automatically available. Money damages are only available to the extent 
specified in Florida statute, 768.28. A copy of this statute is available upon 
request to the Division of Compliance Services USF. This statute provides that 
damages are available only to the extent that negligent conduct of a University 
employee caused your injuries, and are limited by law. If you believe you are 
injured as a result of participation in this research and the negligent conduct of a 
University faculty member, you may notify the USF Self Insurance Programs 
(813) 974-8008, who will investigate the matter. 
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Confidentiality of Your Records 
Your research records will be kept confidential to protect your privacy to the full 
extent of law. However, authorized research investigators, agents of the United 
States Food and Drug Administration, the Department of Health & Human 
Services and the USF Institutional Review Board may inspect your records from 
this research project. Doctors, nurses and others involved with your care will also 
be able to see the research information in your medical record. 
The results of this research study may be published, but they will not include your 
name or any other information that may identify you. 
 
Volunteering to Be Part of this Research Study 
You should only take part in this research study if you want to and not because 
you are afraid of losing medical benefits. If you decide you want to stop taking 
part in the study tell a study monitor as soon as possible. They will want to tell 
you if there are any dangers in stopping treatment. If you decide to stop, any 
other suitable treatment for your disease that may exist will be offered to you. 
You may be removed from the study without your consent for non-compliance 
with the diabetes education sessions.   
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Questions and Contacts 
If you have any questions about this research study, contact the investigator 
listed on the first page at USF/DTC @ UCH at (813) 632-7751, Beeper (813) 
227-0904. 
 
If you have questions about your rights as a person who is taking part in a 
research study, you may contact a member of the Division of Compliance 
Services of the University of South Florida at 813-631-4498. 
 
Your Consent—By signing this form I agree that: 
I have fully read or have had explained to me in my native language this 
informed consent form describing a research project. 
I have had the opportunity to question one of the persons in charge of this 
research and have received satisfactory answers. 
I understand that I am being asked to participate in research. I understand 
the risks and benefits, and I freely give my consent to participate in the 
research project outlined in this form, under the conditions indicated in it. 
I have been given a signed copy of this informed consent form, which is 
mine to keep. 
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_________________________________________________________ 
Signature of Participant Date 
 
Printed Name of Participant  
 
_________________________________________________________ 
Signature of Witness Date 
 
Printed Name of Witness  
 
 
Investigator Statement 
I have carefully explained to the subject the nature of the above protocol. I, 
hereby, certify that to the best of my knowledge the subject signing this consent 
form understands the nature, demands, risks and benefits involved in 
participating in this study and that a medical problem or language or educational 
barrier has not precluded a clear understanding of the participant’s involvement 
in this study. 
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_________________________________________________________ 
Signature of Primary Investigator Date 
 
Printed Name of Primary Investigator  
 
I may contact Jodee Meisenhelder-Smith at (813) 632-7751, Beeper (813) 227-
0904 if I have any further questions or suffer a research related injury. 
I understand that if I become pregnant I should notify the researcher and I should 
not participate in any other diabetes research while on this study. 
_________________________________________________________ 
Signature of Participant Date 
 
Printed Name of Participant  
 
_________________________________________________________ 
Signature of Witness Date 
 
Printed Name of Witness   
 
Appendix 3:  (Continued) 
275 
Institutional Approval of Study and Informed Consent 
The research study and Informed Consent Form were reviewed and approved by 
the University of South Florida Institutional Review Board for the protection of 
human subjects. This approval is valid until the date provided below. The board 
may be contacted at (813) 631-4498. 
 
Approval Consent Form Expiration Date: (Stamp date here.) 
 
 
 
 
Revision Date:_______ 
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Appendix 4:  Study Forms 
REVISED DIABETES HEALTH BELIEF  
AND ENVIRONMENTAL BARRIER SCALE 
 
NAME_________________________DATE___/___/___ 
Directions: We are interested in your responses to the following health-related 
questions.  Circle one of the numbers 1-4 after each question that best 
describes how you feel. 
 
1. How likely are you to take your temperature when you feel sick? 
1. not at all likely 2. somewhat likely 
3. likely 
4. very likely 
 
2. How important do you think it is to get a health checkup even when you feel ok? 
1. not at all important 
2. somewhat important 
3. important 
4. very important 
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3. How much do you feel you understand your treatment for diabetes? 
1. not at all 
2. a little 
3. somewhat  
4. very much 
 
4. How much would you say your diet gets in the way of your daily living? 
1. not at all 
2. a little 
3. somewhat  
4. very much 
 
5. How helpful to you is information about your diet?  
1. not at all  
2. a little  
3. somewhat  
4. very much  
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6. How helpful is testing your own blood sugars at home for diabetes control?  
1. not at all helpful 
2. a little helpful 
3. somewhat helpful 
4. very much helpful 
 
7. To what extent do you believe that exercise can lower your blood sugar 
levels?  
1. not at all 
2. a little 
3. somewhat 
4. very much 
 
8. How helpful is a meal plan for control of your blood sugar levels? ?  
1. not at all helpful 
2. a little helpful 
3. somewhat helpful 
4. very much helpful 
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9. How likely is it that diabetes will shorten your life ?  
1. not at all likely 
2. a little likely 
3. somewhat likely 
4. very much likely 
 
10.  How much do you think your doctor can help you to achieve a longer, 
healthy with your diabetes? 
1 not at all 
2 a little 
3 some 
4 a lot 
 
11. How likely are persons with diabetes to have numbness or tingling in their 
arms or legs? 
1 not at all 
2 somewhat 
3 easily 
4 very likely 
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12.  How much do your family and close friends help you to stay on your diet? 
1 not at all 
2 a little 
3 somewhat 
4 a lot 
 
13.  How helpful would you say an educational program is for persons with 
diabetes? 
1 not at all helpful 
2 a little 
3 somewhat 
4 very much 
 
14.  How much do you worry about what you eat? 
1 not at all 
2 a little 
3 some 
4 a lot 
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15. How likely would symptoms of low blood sugar such as cold sweats, 
weakness, and headache lead you to seek medical help? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
 
16. To what extend do you believe diabetes-related kidney disease interferes 
with your everyday activities? 
1 not at all 
2 a little 
3 somewhat 
4 a lot 
 
17. How much of a problem would you have with your diabetes if you did not 
take your medications? 
1 not at all 
2 a little 
3 somewhat 
4 a lot 
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18. To  what extent do you believe that the benefits of taking care of your 
diabetes is worth the effort? 
1    not at all 
2    a little 
3 somewhat 
4 a lot 
 
19.  To what extent do you worry about future health problems due to your 
diabetes? 
1    not at all worried 
2    somewhat worried 
3    usually 
4    very much 
 
20.  To what extent do you feel your diabetes is a serious disease? 
1    not at all 
2    a little 
3    somewhat 
4    very much 
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21.  Do you think it is likely that poorly managed diabetes will lead to health 
problems affecting the nerves, kidneys, eyes, or heart? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
 
22.  To what extent do diabetes-related skin problems interfere with everyday 
living? 
1 not at all  
2 a little 
3 somewhat 
4 very much 
 
23.  How likely are you to have circulation problems due to your diabetes? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
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24.  How often are special meals prepared for you? 
1 not at all 
2 occasionally 
3 usually 
4 nearly always 
 
25. To what extent do you believe that diabetes treated with a pill or diet is a less 
serious form of diabetes than diabetes treated with insulin? 
1    not at all 
2    a little 
3    somewhat 
4    very much 
  
26. To what extent do you believe poorly managed diabetes will lead to serious 
health problems in the future? 
1    not at all 
2    a little 
3    somewhat 
4    very much 
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27. Compared to other priorities in your life such as family, work, or religion, how 
important your  health? 
1 not at all  
2 a little 
3 somewhat 
4 very important 
 
28. How likely is it that you will take better care of your health in the future? 
1    not at all likely 
2    somewhat likely 
3    likely 
4    very likely    
 
29. If you were having symptoms of high blood sugars (e.g. blurred vision, 
increased thirst or urination), would you be likely to seek medical help? 
1 not at all likely 
2 a little likely 
3 somewhat likely 
4 very likely 
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30. Do you hesitate to tell newly made friends that you have diabetes? 
1 not at all 
2 a little 
3 somewhat 
4 very much 
 
31. How much do you think medical treatment will reduce your chances of 
developing complications from diabetes? 
1 not at all 
2 a little 
3 somewhat 
4 very much 
 
32.  How likely are you to have diabetes-related skin problems.   
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
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33.  How would you rate you health? 
1    poor 
2    fair 
3    good 
4    excellent 
 
34.  To what extent do you feel you have control over your diabetes? 
1    not at all 
2    a little 
3    somewhat 
4    very much 
 
35. How likely is that you will have kidney problems due to your diabetes: 
1 not at all  
2 a little 
3 somewhat 
4 very 
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36. How much would diabetes-related kidney disease get in the way of your 
daily living? 
1 not at all 
2 a little 
3 somewhat 
4 very much 
 
37.  If  you were short of breath, would you be likely to see a doctor? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
 
38.  How much would diabetes-related eye disease get in the way of your daily 
living? 
1 not at all 
2 a little 
3 somewhat 
4 very much 
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39. How likely do you think it is that you will have numbness and tingling in your 
arms and legs due to your diabetes? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
 
40. How much do you think your doctor can help if you have diabetes-related 
tingling and numbness in your arms and legs? 
1 not at all helpful 
2 a little helpful 
3 somewhat helpful 
4 very helpful 
 
41. To what extent would numbness and tingling in your arms or legs get in the 
way of your daily living? 
1 not at all 
2 a little 
3 somewhat 
4 very much 
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42. If you were sick to your stomach would you seek treatment? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
 
43.  How likely do you think it is that you will have sexual problems  (impotence, 
vaginal dryness or yeast infections) due to your diabetes? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
 
44. If you were unable to think concentrate clearly, how likely would you be to 
seek help? 
1 not at all likely 
2 somewhat likely 
3 likely 
4 very likely 
 
 
Appendix 4:  (Continued) 
291 
45.  To what extent do your family and friends remind you to follow your diabetes 
treatment plan (take medications, follow diet, exercise, check blood sugars, 
etc.)? 
1    not at all 
2   sometimes 
3    usually 
4    too much 
 
46. How confident are you in your ability to eat meals at regularly scheduled 
times,  every 4-5 hours? 
1    not at all 
2   a little 
3   somewhat 
4   very  
 
47. How confident are you in your ability to follow a calorie controlled diabetes 
meal  plan? 
1    not at all  
2    a little 
3    somewhat 
4    very  
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48. How confident are you in your ability to read food labels? 
1    not at all  
2    a little 
3    somewhat 
4    very  
 
 
49.  How confident are you in your ability to select healthy foods when eating 
away from home?   
1    not at all 
2    a little 
3    somewhat 
4    very  
 
50. How confident are you in your ability to test your blood sugars daily using a 
home blood sugar meter? 
1    not at all 
2    a little 
3    somewhat 
4    very  
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51. How confident are you in your ability to exercise (e.g. walk, bike, swim) 3-5 
times a week for at least 15-20 minutes at a time? 
1    not at all 
2    a little 
3    somewhat 
4    very  
 
52.  How confident are you in your ability to follow your diabetes treatment plan 
(medication, diet, exercise, home blood sugar monitoring, foot care)? 
1    not at all 
2    a little 
3    somewhat 
4 very 
 
53. How confident are you in your ability to cope with stress and your feelings 
(worry, fear, denial, etc.) about diabetes? 
1    not at all 
2    a little 
3    somewhat 
4 very 
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54. How confident are you in your ability to test your blood sugars and adjust 
your eating, exercise, or medications to improve your blood sugar levels? 
1    not at all 
2    a little 
3    somewhat 
4 very 
 
 
Environmental/Situational Barriers 
 
Answer the questions about your diabetes care YES or NO.  If YES, circle the 
number 1-4 that best describes the extent each barrier affected you (1 not at all 
to 4 very much) over the past 3 months.  
 
55. Do you take pills to control your diabetes? 
YES _____   NO _____ 
 
56. Do you take insulin? 
YES _____   NO _____ 
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57. To what extent did the situations below keep you from taking your diabetes 
medication/s (pills/insulin) as you should? 
 Not at all Very Much
____  time or schedule problems 1 2 3 4 
____  inconvenience (carrying supplies 
with me, finding good place, etc.) 
1 2 3 4 
____  side effects of medication 1 2 3 4 
____  forget to take 1 2 3 4 
____  health problems (e.g. trouble seeing, 
hands shaky) 
1 2 3 4 
____  too sick or weak to care for self 1 2 3 4 
____  too painful 1 2 3 4 
____  too costly 1 2 3 4 
____  being away from home 1 2 3 4 
____  special occasions (e.g. birthdays) 1 2 3 4 
____  feeling depressed or other negative 
emotions (anger, frustration, denial) 
1 2 3 4 
____  do not believe the medication 
ordered is helpful 
1 2 3 4 
____  takes too much of my effort 1 2 3 4 
____  interferes with daily activities 1 2 3 4 
 
58. Have you been given a meal plan or diet to follow?      
YES _____   NO _____ 
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59. Check any that apply to your meal plan 
________ limits added sugar and sweets 
________ calorie controlled 
________ low fat or cholesterol 
________ low salt 
________ protein controlled 
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60. To what extent did the situations below keep you from staying on your 
meal plan over the past 3 months? 
 
 Very Little Very Much
____  time or schedule 1 2 3 4 
____  inconvenience (preparing food, etc.) 1 2 3 4 
____  feeling hungry a lot 1 2 3 4 
____  health problems (e.g. vision, shaky 
hands) 
1 2 3 4 
____  too costly 1 2 3 4 
____  eating away from home 1 2 3 4 
____  special occasions 1 2 3 4 
____  negative emotions, feeling stressed, 
depressed, etc 
1 2 3 4 
____  feeling diet is ineffective in 
controlling my diabetes 
1 2 3 4 
____  too difficult 1 2 3 4 
____  takes too much effort 1 2 3 4 
____  interferes with daily activities 1 2 3 4 
____  too few foods I like that are on my 
diet 
1 2 3 4 
____  no one else eats like I have to 1 2 3 4 
____  rely on others to prepare meals 1 2 3 4 
 
 
61. Has your doctor advised you to exercise? YES _____   NO _____
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62. How often do you exercise for 15 minutes or longer at a time? 
_____ less than once a week 
_____ once a week 
_____ 2-3 times a week 
_____ 4-6 times a week 
_____ daily 
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63. To what extent did the situations below keep you from exercising over the 
past 3 months? 
 Very Little Very Much
____  too busy 1 2 3 4 
____  inconvenience 1 2 3 4 
____  feeling bad during or afterwards 1 2 3 4 
____  health problems 1 2 3 4 
____  too costly 1 2 3 4 
____  away from home 1 2 3 4 
____  special occasions 1 2 3 4 
____  too difficult 1 2 3 4 
____  requires too much effort 1 2 3 4 
____  interferes with other daily activities 1 2 3 4 
____  feeling too tired 1 2 3 4 
____  bad weather 1 2 3 4 
____  fear of low blood sugars 1 2 3 4 
____  too sick 1 2 3 4 
____  hate to exercise alone, no one was 
available 
1 2 3 4 
____  do not like to exercise 1 2 3 4 
 
Do you test your blood sugars with a meter at home YES ____   NO_____ 
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64. Over the past 3 months did you test your blood sugars at home 
_____ less than once a week 
_____ 1-2 times a week 
_____ every other day 
_____ daily 
_____ 2 times a day 
_____ 3 or more times a day 
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65.   To what extent did the situations below keep you from testing your blood 
sugars over the past 3 months? 
 Very Little Very Much
____  too busy 1 2 3 4 
____  never shown how to use a meter 1 2 3 4 
____  too painful 1 2 3 4 
____  problems with health 1 2 3 4 
____  forgot to test 1 2 3 4 
____  too costly 1 2 3 4 
____  away from home 1 2 3 4 
____  too difficult 1 2 3 4 
____  requires too much effort 1 2 3 4 
____  meter not working 1 2 3 4 
____  rely on others to test, no one 
available 
1 2 3 4 
____  blood sugars have been okay lately, 
so no need to test 
1 2 3 4 
____  inconvenient, interferes with other 
activities 
1 2 3 4 
____  testing makes me too nervous or 
frustrated by results 
1 2 3 4 
____  dislike testing 1 2 3 4 
____  I can tell if my blood sugar is high or 
low without testing 
1 2 3 4 
____  ran out of supplies 1 2 3 4 
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Appendix 5:  Follow-up Evaluation Form and Dex Glucometer Monitoring System 
Summary 
 
FOLLOW-UP EVALUATION FORM 
PART I 
Date: ____/____/____  
(mm/dd/yy) 
 
Patient ID#_______________________________________ 
 
Attendance Dates of Program:  ____/____/____ to ____/____/____ 
(mm/dd/yy)  (mm/dd/yy) 
Attended more than 5 hours of sessions:  (1) ______ 
Attended less than 4 hours of sessions:    (2) ______ 
Missed sessions (#) __________________________ 
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Date: ____/____/____  
  (mm/dd/yy) 
 
Post Education:   Expanded  HBM Questionnaire Mean Scores 
Overall Attitudes Scores: _______________ 
Overall Health Motivation Scores: _______________  
Overall Severity Scores _______________ 
Overall Susceptibility Scores _______________ 
Overall Barriers Scores: _______________ 
Overall Benefits Scores: _______________ 
Overall Self-efficacy Scores _______________ 
Overall Cues to Action Scores _______________ 
Overall Structural Elements Scores _______________ 
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PART II 
 
Final Hgb A1c post 8 weeks intervention:  __________ %  Date:  ____/____/____ 
16 week FU ___________ %    (mm/dd/yy) 
__________ Weight (Kg)   Date:  ____/____/____ 
__________ Height (cm)      (mm/dd/yy) 
__________ Body Mass Index (Kg/m2) 
 
Current Type of Therapy  Date Started on Therapy 
 
______ (1) Diet only specify ____________________ ___/___/___ 
   (mm/dd/yy) 
______ (2) Diet and OHA specify ________________ ___/___/___ 
   (mm/dd/yy) 
______ (3) OHA specify _______________________ ___/___/___ 
   (mm/dd/yy) 
______ (4) Insulin specify ______________________ ___/___/___ 
   (mm/dd/yy) 
Appendix 5:  (Continued) 
305 
 
 Any change in type therapy over past 3 months?   No ______   Yes ______ 
If yes, specify ___________________________________________ 
Any hospitalizations or ER visits in last 3 months?  No _____    Yes _____ 
If yes, specify ___________________________________________ 
 
Date of last physician visit (for diabetes management) ____/____/____ 
(mm/dd/yy) 
Patient ID#: ________________________________________ 
 
Part I is completed upon completion of program and placed in patient's file.  
 
Part II is a separate follow-up form used for all patients for 3 months follow-up by 
trained investigator performing Hgb A1c determinations.  Patients are notified of 
follow-up by administrative assistant and asked to refrain from discussing 
whether they attended program or not; and to identify themselves only by ID 
number and showing appointment card.  
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Dex Glucometer Monitoring System Summary 
Summary View 
 
Table 5.  Statistical summary of blood glucose results.  
Summary – mg/dL 
Average 176 mg/dL 
Standard Deviation 123 mg/dL 
Number of Readings 88 
Days Covered 26 
Average Readings per Day 3.3 
Deleted Readings 6 
 
Readings/Range – mg/dL 
 Number Percent 
HI 0 0% 
Very High (300-600) 10 11% 
High (156-299) 30 34% 
Target (65-155) 30 44% 
Low (41-64) 3 3% 
Very Low (10-40) 6 6% 
LO 0 0% 
 
Control Readings 9 
Deleted Control Readings 0 
Lowest Blood Glucose 15 mg/dL 
High Blood Glucose 600 mg/dL 
( ) – Values in parentheses include at least one HI or LO value. 
 
Notes: 
⇒ Indicative of patient compliance and frequency of testing 
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⇒ Provides an overview assessment of general level of glycemic control. 
 
 (WinGlucofacts Help Manual, Bayer Corporation, p. 6.) 
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Appendix 6:  Diabetes Self-management Education Schedule 
DIABETES SELF-MANAGEMENT EDUCATION SCHEDULE 
SESSION TIME TOPIC DISCIPLINE 
SPECIALIST 
Part 1 2 hours Orientation/Case Assessment 
 
Hgb A1c (EHBMQ) 
Case Manager 
 
 
Diabetes Educator
Part 2 1 hour Diabetes Overview/Medication 
 
Nutrition Guidelines 
 
Behavior Goal Setting 
Diabetes Educator
 
Dietitian 
 
Dietitian 
Part 1 2 hours Exercise/Monitoring 
 
 
Exercise Practicum & Glucose 
Monitory Practicum 
Goal Setting 
Exercise 
Specialist 
 
Exercise 
Specialist 
 
Part 2 2 hours Acute Complications 
Hypo/hyperglycemia 
Management 
Chronic Complications/foot 
care/foot exam 
Goal Setting – Glucose 
Monitoring Log 
Diabetes Educator
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SESSION TIME TOPIC DISCIPLINE 
SPECIALIST 
Part 1 1 hour Exercise Follow-up 
 
 
Diet Follow-up/Special Situations 
Food Log Follow-up 
Exercise 
Specialist 
 
Dietitian 
Part 2 2 hours Diabetes and Stress/Sick day 
Rules 
 
Goal Setting/Taking 
Charge/Disaster Plan and 
Travel 
 
Evaluation 
Hgb A1c/Post EHBMQ 
Assessments 
 
Diabetes Educator
 
 
Dietitian 
 
 
 
Case 
Manager/Diabetes 
Educator 
 
Core sessions (part 1 and 2) will be scheduled in week one. Advanced classes in 
areas identified in behavioral goals and follow-up.  Education sessions 
times/dates may vary but all content areas will be covered..  
NOTE: Minimum sessions for maintenance in study are part 1 and part 2 (or 6 
hours).  
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Appendix 7:  Patient Satisfaction Questionnaire 
 
Name  ________________________ 
Date ________________________________ 
DIABETE CARE INSTITUTE 
PATIENT SATISFACTION QUESTIONNAIRE 
 
 
 
 
Excellent 
 
 
 
Very 
Good 
 
 
 
Good 
 
 
 
Fair 
 
 
 
Poor 
 
 
(1) The overall quality of 
the program was 
 
 
 
 
 
 
 
 
 
 
 
(2) The materials used 
were 
 
 
 
 
 
 
 
 
 
 
 
(3) The instructors were 
 
 
 
 
 
 
 
 
 
 
 
(4) The physical facilities 
were 
 
 
 
 
 
 
 
 
 
 
 
Yes 
 
No 
 
Don’t 
Know 
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(5) I participated in setting my diabetes 
management goals 
   
(6) My instructors showed interest in meeting my 
needs 
 
 
 
 
 
 
(7) I understand the information that was 
presented 
 
 
 
 
 
 
(8) I feel better able to manage my diabetes after 
attending this program 
 
 
 
 
 
 
(9) I have used services at this hospital before 
 
 
 
 
 
 
(10) I would recommend these classes to someone 
that I know 
 
 
 
 
 
 
(11) Class time availability was convenient 
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Would you like someone to call you about any concerns that you have about your 
diabetes? ? Yes ? No 
Phone #   
Please list any topics that you would like to hear more about:  
  
  
________________________________________________________________  
  
 
Comments:   
  
  
  
  
 
 
Date:  
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Appendix 8:  Educational Materials 
 
Diabetic Topics™: Patient handouts on major diabetes self-care topics 
designed to supplement the patient education manual and are cartoon 
illustrated.  Topics include: Benefits of exercise, fat busters, 
Hypoglycemia, What is Stress?  Eating out Guidelines, hyperglycemia 
exercise guidelines, sick day rules, making exercise a priority, foot care, 
stress reducers, assertiveness, sweeteners, and fiber.  
 
Education Posters and Flipcharts: Include graphics highlighted with color 
and bold print.  Main points such as: Function of the pancreas, symptoms 
of diabetes, conversion of food into energy, six exchange groups, 
component of an exercise program, sugar and symptoms of stress, oral 
agent action, insulin action, hyperglycemia/ hypoglycemia, blood glucose 
goals, stretchy exercises, nutritional goals, the food you “chews.” 
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Audiovisual Materials:  The following are Diabetes Treatment Centers of 
America approved audiovisual materials.  Individual center purchase of 
materials, once approved, must be cleared through the appropriate RDO. 
? Balance your Act Slides, Prichert and Hall 
? Diabetes Exercise Slides, Prichert and Hall 
? Diabetes Programs in Spanish, Milner-Fennrick 
? Diabetes and Complications: Focus on Living, Oracle Film    and 
Video 
? In Balance, In Control, Boehringer Mannheim, 1987 
? Taking Charge: Living with Diabetes, Oracle Film and Video 
 
Pamphlets 
? Meal Planning with Carbohydrates, American Healthways, Inc 
? Eating Healthy Foods, American Diabetes Association 
? The Exchange List, American Diabetes Association 
? Month of Meals 5, American Diabetes Association 
? A Menu Planner, American Diabetes Association 
? Dining Out Made Simple, Becton Dickinson 
? Exercise and Its Benefits, Becton Dickinson 
? Are You Ready for New Food Labels?, Nabisco Biscuit Co. 
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? *The Sodium Story, American Diabetes Association 
? Living Your Life with Diabetes, Channing L. Bete Co. 
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Appendix 9:  Division of Nursing Standards/Policies/Procedures 
 
TITLE: Continuous Glucose Monitoring 
System (CGMS) 
 
INDEX NO. 
 
APPROVED: 
 
No. Pages 
 
 
 
Signature: 
 
PURPOSE:  
 
To provide guidelines on the use of the Continuous Glucose Monitoring System 
(CGMS), to demonstrate blood glucose trends, and determine patient’s 
responses to exercise, medications, food intake, and stressful situations. 
 
STANDARD: 
 
Tx 3.9 Medication effects on patients are continually monitored. 
 
LEVEL OF RESPONSIBILITY:   
 
RN, CDE to administer procedure of CGMS.
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STANDARD OF PRACTICE:  
 
1. Preplanned outpatient admission for CGMS will be scheduled through 
Diabetes Care Institute (DCI) with prescription from physician. 
 
2. a.  Patient will be able to keep a diary of food, insulin, exercise, and 
hypoglycemic events 
 b.  Patient will wear sensor for three days (72 hrs.) 
c.  Patient will return for sensor download 
 
3. The nurse will integrate data from patient diary sheets on to CGMS data 
sheets.  Physician,  Nurse Practitioner, and/or RN CDE to analyze and 
interpret data for appropriate changes in diabetes management. 
 
DESCRIPTION OF CGMS SENSOR:  
 
• Used by diabetes care professionals to record comprehensive glucose 
profiles and corresponding events, i.e., stress, low blood sugar, food 
intake, insulin and/or oral diabetes agents. 
• CGMS measures three days (72 hrs.) and records glycemic control of 
patient within ranges of 40 mg/dl to 400 mg/dl. 
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• CGMS records sensor signals every five minutes providing 288 glucose 
readings per day. 
 
PROCEDURE:  
 
Equipment: 
 
Continuous Glucose Monitor 
Cable 
Glucose Sensor 
Com-station for Downloading 
Sen-serter 
Belt Clip  
Transparent Dressing Tape 
Patient Blood Glucose Meter 
IV Prep Pads 
“Shower-pak” 
Three (3) Patient Diary Sheets 
MiniMed CGMS Pocket Guidebook 
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CONTINUOUS GLUCOSE MONITORING: INITIATION 
 
I. PRE-INITIATION SET-UP 
 
STEPS  KEY POINTS 
   
1. Gather equipment and 
supplies. 
 
2. Explain procedure to patient 
  
 
   
2.1 CGMS education must be 
thorough or the data will not be 
entered correctly as outlined in 
the instruction manual.3.
 Evaluate all operational 
functions of the sensor prior to 
initiating sensor therapy. 
 
 
4. Describe and demonstrate the 
basic operation techniques to 
the patient. 
a) Entering meter blood 
glucose values into the 
sensor 
b) Selecting “Cal Yes” 
and confirming the 
selection by pressing 
the “ACT” button 
c) Entering events and 
clearing alarms 
 
5. Review with patient the 
MiniMed CGMS Pocket 
Guidebook that covers the   
following topics. 
 
  
 
 
 
 
 
 
 
 
4.1 These are the basic functions of 
the sensor and must be 
demonstrated by the patient to 
assure correct technique for data 
to be accurate and measurable. 
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6. Treat for hypoglycemia if a 
glucose reading is < 60 mg/dl 
or if hypoglycemic symptoms 
occur when < 100 mg/dl.  
Check blood glucose again in 
15 minutes and enter event 
into the sensor.   
 6.1 The CGMS monitor will only 
accept values between 40 mg/dl 
- 400 mg/dl.  If the SMBG value 
is outside of this range, test 
again after treatment and enter 
the value once it is within the 
specified range. 
   
II. SITE SELECTION AND 
PREPARATION 
 
STEPS 
 
1. Abdominal area preferred.  
Keep at least two inches away 
from pump infusion site or 
three inches away from insulin 
injection site. 
 
III. GLUCOSE SENSOR 
INSERTION 
 
STEPS 
 
1. Remove sensor from sterile 
package. 
  
 
 
KEY POINTS 
 
1.1 Avoid areas around scars, 
waistline, underwear lines, and 
within a two inch circle around 
the navel. 
 
 
 
 
 
KEY POINTS  
 
1.1 Sensor must be stored between 
+ 36 degrees to + 75 degrees 
Fahrenheit. 
 
1.2 Warm to room temperature for 
10 minutes before inserting. 
   
2. Load sensor into Sen-serter by 
sliding plug until snug. 
 2.1 Lock Sen-serter to prevent 
premature firing. 
   
3. * Remove clear release paper 
from adhesive pad (around the 
needle) 
* Remove needle guard from 
sensor 
* Unlock Sen-serter 
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4. Hold Sen-serter on insertion 
site.  Press top button on Sen-
serter to insert into sensor 
needle and catheter. 
 
5. To remove sensor from Sen-
serter, slide Sen-serter 
backwards. 
 
 
 
 
 
 
 
5.1 Grasp handle of sensor.  Keep 
Sen-serter “legs” on skin while 
sliding backwards. 
IV. POST SENSOR INSERTION  
 
STEPS 
1. Remove white backing from 
sensor 
  
 
KEY POINTS   
1.1 Hold sensor against skin to 
prevent dislodging. 
   
2. Remove introducer needle by 
gently pulling handle away 
from needle site. 
 2.1 Dispose of needle into 
appropriate sharps receptacle. 
   
3. Check site to verify sensor is 
inserted flush with skin site. 
 
4 Verify that the sensor is 
working after insertion by 
checking the impact signal 
(ISIG) and the voltage counter 
(VCTR).  Press SEL button to 
go to Set Up screen, press 
ACT button.  Press SEL button 
to go to SIGNALS Screen.  
Press ACT button.  The sensor 
will show ISIG value.  Press 
SEL button to view the VCTR 
value.  Press ACT button to 
exit. 
 
 
 
 
5. Secure sensor connection with 
sterile transparent dressing. 
  
 
 
4.1a The sensor is working well if 
ISIG is between 10-100 NA and 
VCTR is between 0.4 v and 1.6 
v. 
 
4.1b If the values are not within the 
acceptable range, 1) check all 
connections, 2) connect the 
cable connector end of the test 
plug to the cable, find the 
“Signals menu and the ISIG 
screen.  The value is between 
24-29 NA, 3) call MiniMed if ISIG 
is not within the acceptable 
range when test plug procedure 
is done. 
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6. Begin initialization.  Press SEL 
button screen to go to Set Up 
screen, press ACT button.  
Press SEL button to go to 
Initialization screen.  Press 
ACT button.  The screen will 
show 60 and it will count down 
to zero. 
 
6.1a The initialization process takes 
60 minutes to complete. 
 
6.1b Do not initialize if the patient’s 
BG is rapidly fluctuating. 
 
6.1c Do not initialize if the patient’s 
BG is greater than 400 mg/dl or 
if it is less than 40 mg/dl. 
 
6.1d Do not Press any button on the 
monitor during initialization 
period.  It will take you out of 
initialization.6.1e Do not 
initialize the same sensor more 
than once. 
 
6.1f If initialization is interrupted, wait 
60 minutes and perform 
calibration. 
   
V. DOWNLOADING CGMS 
DATA 
 
STEPS 
 
1. Download CGMS data per 
MiniMed manual three days 
post insertion. 
 
2. The nurse will integrate data 
from patient diary sheets onto 
CGMS data sheets.  Physician 
and/or Nurse Practitioner, 
and/or RN CDE to analyze and 
interpret data for appropriate 
changes in diabetes 
management. 
 
 
 
  
 
KEY POINTS  
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VI. DOCUMENTATION  
 
STEPS 
   
1. Document per established 
Hospital guidelines. 
 
2. Complete the CGMS Checklist.
  
 
 
2.1 See attached checklist. 
   
VII. DISPOSITION OF DATA 
 
1. One copy of all downloaded 
CGMS data is sent to:  
 Medical Records 
Physician 
Patient. 
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Appendix 10:  Box-plot and Stem-leaf Diagrams of Continuous Variables at 
Baseline 
 
Self-efficacy Score 
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Susceptibility Score 
 
 
Benefits Score 
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Severity Score 
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Cue-to-Action Score 
 
Structural Score 
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Motivation Score 
 
 
Barriers Score 
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Age 
 
 
 
Hemoglobin 
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Appendix 11:  Chronbach Alpha Results for Individual Questions 
 
Time 1 Results 
 
  
    Raw Variables 
(Time 1) 
Standardized 
Variables 
(Time 1) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlati
on with 
Total 
Alpha 
1 Q4 0.502874 
0.381125 
0.233522 
0.514927
0.381125 0.233522 0.514927
2 Q14 0.190814 
0.449102 
0.168631 
0.544623
0.449102 0.168631 0.544623
3 Q57 Total 0.229640 
0.399295 
0.265343 
0.499928
0.399295 0.265343 0.499928
4 Q60 Total 0.363096 
0.327118 
0.477222 
0.392403
0.327118 0.477222 0.392403
5 Q63 Total 0.104887 
0.485328 
0.219408 
0.521487
0.485328 0.219408 0.521487
Perceived 
Barriers 
6 Q66 Total 0.392258 
0.336723 
0.350426 
0.458374
0.336723 0.350426 0.458374
1 Q15 0.094827 0.658094 0.092487 0.644720
2 Q29 -0.086146 0.679209 -0.091699 0.708560
3 Q37 0.552771 0.473090 0.553173 0.451311
4 Q42 0.465137 0.481336 0.518547 0.467663
5 Q44 0.387783 0.522321 0.344425 0.545279
Cues-to-
action 
6 
 
 
Q45 0.695608 0.388105 0.710026 0.373263
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    Raw Variables 
(Time 1) 
Standardized 
Variables 
(Time 1) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlati
on with 
Total 
Alpha 
1 Q60.1 0.372774 0.873468 * * 
2 Q60.2 0.806369 0.847778 * * 
3 Q60.3 0.971435 0.834650 * * 
4 Q60.4 -0.043351 0.879708 * * 
5 Q60.5 -0.043351 0.879708 * * 
6 Q60.6 0.732905 0.856292 * * 
7 Q60.7 0.782255 0.849788 * * 
8 Q60.8 0.569709 0.862583 * * 
9 Q60.9 0.447776 0.871113 * * 
10 Q60.10 0.685610 0.856023 * * 
11 Q60.11 0.837061 0.846007 * * 
12 Q60.12 0.521516 0.865344 * * 
13 Q60.13 * 0.877309 * * 
14 Q60.14 0.347851 0.872892 * * 
Diet 
(Perceived 
Barriers 
Subscale) 
15 Q60.15 * 0.877309 * * 
1 Q63.1 0.598378 0.519273 * * 
2 Q63.2 0.797493 0.492750 * * 
3 Q63.3 0.031722 0.625799 * * 
4 Q63.4 -0.168565 0.675336 * * 
5 Q63.5 * 0.623738 * * 
6 Q63.6 0.400078 0.572950 * * 
7 Q63.7 0.399381 0.579241 * * 
8 Q63.8 0.032141 0.632143 * * 
9 Q63.9 -0.080050 0.661246 * * 
10 Q63.10 0.321599 0.590578 * * 
11 Q63.11 0.672214 0.497040 * * 
12 Q63.12 -0.159826 0.635128 * * 
13 Q63.13 * 0.623738 * * 
14 Q63.14 * 0.623738 * * 
15 Q63.15 0.120241 0.619412 * * 
Exercise 
(Perceived 
Barriers 
Subscale) 
16 
 
 
 
 
 
 
Q63.16 0.228936 0.607263 * * 
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    Raw Variables 
(Time 1) 
Standardized 
Variables 
(Time 1) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlati
on with 
Total 
Alpha 
1 Q57.1 0.784465 0.715648 * * 
2 Q57.2 0.784465 0.715648 * * 
3 Q57.3 0.009432 0.782903 * * 
4 Q57.4 0.740567 0.720844 * * 
5 Q57.5 * 0.777778 * * 
6 Q57.6 * 0.777778 * * 
7 Q57.7 * 0.777778 * * 
8 Q57.8 * 0.777778 * * 
9 Q57.9 0.763763 0.711538 * * 
10 Q57.10 0.784465 0.715648 * * 
11 Q57.11 0.217577 0.779252 * * 
12 Q57.12 0.299674 0.768066 * * 
13 Q57.13 * 0.777778 * * 
14 Q57.14 * 0.777778 * * 
Medication 
(Perceived 
Barriers 
Subscale) 
15 Q57.15 * 0.777778 * * 
1 Q66.1 0.871851 0.618211 * * 
2 Q66.2 * 0.732686 * * 
3 Q66.3 * 0.732686 * * 
4 Q66.4 0.202769 0.726590 * * 
5 Q66.5 0.876038 0.624289 * * 
6 Q66.6 * 0.732686 * * 
7 Q66.7 0.833333 0.650667 * * 
8 Q66.8 * 0.732686 * * 
9 Q66.9 * 0.732686 * * 
10 Q66.10 * 0.732686 * * 
11 Q66.11 * 0.732686 * * 
12 Q66.12 * 0.732686 * * 
13 Q66.13 0.143592 0.734021 * * 
14 Q66.14 * 0.732686 * * 
15 Q66.15 * 0.732686 * * 
16 Q66.16 0.712212 0.663188 * * 
Monitoring 
(Perceived 
Barriers 
Subscale) 
17 
 
 
 
 
 
Q66.17 * 0.732686 * * 
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    Raw Variables 
(Time 1) 
Standardized 
Variables 
(Time 1) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlati
on with 
Total 
Alpha 
1 Q1 0.212733 -0.299296 0.116706 -0.055354
2 Q2 -0.073682 0.042980 -0.152801 0.217014
3 Q27 -0.099504 0.000000 0.018127 0.051745
4 Q28 0.091502 -0.096154 0.254751 -0.221097
5 Q30 -0.097243 0.116667 -0.113094 0.180817
Motivation 
6 Q33 -0.054899 0.031646 0.056152 0.011501
1 Q46 0.685902 0.848733 0.675021 0.862971
2 Q47 0.819845 0.833412 0.814822 0.850469
3 Q48 0.690957 0.854303 0.696928 0.861046
4 Q49 0.726580 0.844226 0.732856 0.857861
5 Q50 0.700765 0.856401 0.710679 0.859831
6 Q51 -0.088308 0.913772 -0.075861 0.921792
7 Q52 0.793805 0.838607 0.803484 0.851502
8 Q53 0.797445 0.840628 0.795383 0.852238
Self-
Efficacy 
9 Q54 0.595720 0.857341 0.574163 0.871674
1 Q16 0.065398 0.194444 0.007707 0.369557
2 Q20 0.096325 0.180354 0.268712 0.228909
3 Q22 0.130435 0.141147 -0.119968 0.430523
4 Q25 -0.241662 0.419932 -0.257456 0.490879
5 Q26 0.096325 0.180354 0.257841 0.235221
6 Q36 0.029727 0.221008 0.341125 0.185810
7 Q38 0.186927 0.147532 0.345325 0.183254
Perceived 
Severity 
8 Q41 0.500618 -0.179043 0.358417 0.175244
1 Q3 0.686406 0.151442 0.673670 0.095441
2 Q12 0.670635 -0.308036 0.667063 0.102956
3 Q24 0.282466 0.290625 0.355782 0.419195
Structural 
Elements 
4 Q34 -0.247992 0.763727 -0.199238 0.822543
1 Q9 0.340930 0.824267 0.319445 0.810831
2 Q11 0.806594 0.766374 0.819926 0.745706
3 Q19 0.532431 0.799613 0.479457 0.791205
4 Q21 0.036736 0.835165 0.058666 0.840553
5 Q23 0.701155 0.782235 0.730432 0.758174
6 Q32 0.641279 0.784950 0.617046 0.773444
7 Q35 0.498657 0.803564 0.557348 0.781252
8 Q39 0.537757 0.798909 0.492314 0.789580
Perceived 
Suscept-
ibility 
9 Q43 0.518476 0.802212 0.507269 0.787681
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    Raw Variables 
(Time 1) 
Standardized 
Variables 
(Time 1) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlati
on with 
Total 
Alpha 
1 Q5 0.220918 0.723855 0.176288 0.785261
2 Q6 0.696760 0.647771 0.748573 0.709030
3 Q7 -0.170779 0.752044 -0.140336 0.821383
4 Q8 0.704865 0.665896 0.728440 0.711969
5 Q10 0.576697 0.679581 0.598296 0.730495
6 Q13 0.684580 0.688629 0.685597 0.718156
7 Q17 0.703255 0.631899 0.717798 0.713514
8 Q18 0.684580 0.688629 0.685597 0.718156
9 Q31 0.120299 0.770183 0.108974 0.793283
Perceived 
Treatment 
Benefits 
10 Q40 0.213278 0.739356 0.229529 0.778782
 
* Not calculable due to lack of variance on several questions. 
 
Time 2 Results 
 
  
    Raw Variables 
(Time 2) 
Standardized 
Variables 
(Time 2) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlation 
with Total 
Alpha 
1 Q4 0.234278 0.560164 0.221685 0.695958
2 Q14 0.304612 0.560796 0.322089 0.664029
3 Q57 Total 0.621616 0.407467 0.516691 0.597097
4 Q60 Total 0.405767 0.474812 0.497854 0.603876
5 Q63 Total 0.145745 0.648575 0.280122 0.677585
Perceived 
Barriers 
6 Q66 Total 0.678651 0.374531 0.634702 0.553106
1 Q15 0.609577 0.634191 0.572354 0.656041
2 Q29 0.251124 0.737838 0.217016 0.757476
3 Q37 0.446304 0.693598 0.437072 0.696790
4 Q42 0.653325 0.601644 0.616524 0.642144
Cues-to-
action 
5 Q44 0.371002 0.700908 0.419636 0.701847
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    Raw Variables 
(Time 2) 
Standardized 
Variables 
(Time 2) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlation 
with Total 
Alpha 
6 
 
 
 
Q45 0.469089 0.672832 0.531680 0.668578
1 Q60.1 0.625139 0.745955 * * 
2 Q60.2 0.199122 0.785435 * * 
3 Q60.3 0.518034 0.757560 * * 
4 Q60.4 * 0.785577 * * 
5 Q60.5 * 0.785577 * * 
6 Q60.6 0.867325 0.709435 * * 
7 Q60.7 0.861893 0.711929 * * 
8 Q60.8 0.624838 0.745118 * * 
9 Q60.9 -0.040672 0.803876 * * 
10 Q60.10 0.620299 0.748962 * * 
11 Q60.11 0.673710 0.743949 * * 
12 Q60.12 * 0.785577 * * 
13 Q60.13 * 0.785577 * * 
14 Q60.14 0.336530 0.773852 * * 
Diet 
(Perceived 
Barriers 
Subscale) 
15 Q60.15 -0.228985 0.816722 * * 
1 Q63.1 -0.142712 0.832129 * * 
2 Q63.2 0.125606 0.812165 * * 
3 Q63.3 0.757240 0.779058 * * 
4 Q63.4 0.370208 0.803876 * * 
5 Q63.5 -0.222054 0.820658 * * 
6 Q63.6 0.023495 0.821709 * * 
7 Q63.7 0.584472 0.782042 * * 
8 Q63.8 0.568876 0.788217 * * 
9 Q63.9 0.235267 0.806537 * * 
10 Q63.10 * 0.810519 * 0.788295
11 Q63.11 0.755038 0.771706 * * 
12 Q63.12 0.340811 0.802124 * * 
13 Q63.13 0.734595 0.770422 * * 
14 Q63.14 0.488141 0.797534 * * 
Exercise 
(Perceived 
Barriers 
Subscale) 
15 Q63.15 0.811252 0.760170 * * 
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    Raw Variables 
(Time 2) 
Standardized 
Variables 
(Time 2) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlation 
with Total 
Alpha 
16 
 
 
 
 
 
 
Q63.16 0.862941 0.749550 * * 
1 Q57.1 0.735215 0.608316 * * 
2 Q57.2 0.700152 0.627864 * * 
3 Q57.3 0.214844 0.669204 * * 
4 Q57.4 0.635690 0.594278 * * 
5 Q57.5 * 0.679543 * * 
6 Q57.6 * 0.679543 * * 
7 Q57.7 * 0.679543 * * 
8 Q57.8 * 0.679543 * * 
9 Q57.9 0.563125 0.607026 * * 
10 Q57.10 0.856284 0.581445 * * 
11 Q57.11 0.239077 0.671541 * * 
12 Q57.12 0.639137 0.598643 * * 
13 Q57.13 -0.205589 0.785280 * * 
14 Q57.14 * 0.679543 * * 
Medication 
(Perceived 
Barriers 
Subscale) 
15 Q57.15 * 0.679543 * * 
1 Q66.1 0.045659 0.587611 * * 
2 Q66.2 * 0.541570 * * 
3 Q66.3 -0.113210 0.557229 * * 
4 Q66.4 0.535879 0.491424 * * 
5 Q66.5 0.295427 0.499239 * * 
6 Q66.6 0.630478 0.373984 * * 
7 Q66.7 0.522430 0.427240 * * 
8 Q66.8 0.873038 0.424065 * * 
9 Q66.9 0.535879 0.491424 * * 
10 Q66.10 * 0.541570 * * 
11 Q66.11 * 0.541570 * * 
12 Q66.12 -0.287693 0.661352 * * 
13 Q66.13 -0.010391 0.547328 * * 
14 Q66.14 * 0.541570 * * 
Monitoring 
(Perceived 
Barriers 
Subscale) 
15 Q66.15 * 0.541570 * * 
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    Raw Variables 
(Time 2) 
Standardized 
Variables 
(Time 2) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlation 
with Total 
Alpha 
16 Q66.16 0.372630 0.471608 * * 
17 
 
 
 
 
 
Q66.17 * 0.541570 * * 
1 Q1 0.594980 0.298701 0.571275 0.488387
2 Q2 0.281579 0.509031 0.367003 0.574122
3 Q27 0.344881 0.513950 0.423287 0.551445
4 Q28 0.581190 0.394495 0.584742 0.482396
5 Q30 -0.063670 0.703919 -0.137447 0.747960
Motivation 
6 Q33 0.328489 0.488014 0.427466 0.549733
1 Q46 0.643451 0.812901 0.645958 0.842984
2 Q47 0.661317 0.811440 0.656759 0.841931
3 Q48 0.607231 0.823698 0.638925 0.843667
4 Q49 0.892538 0.782875 0.863070 0.821157
5 Q50 0.285608 0.845138 0.328559 0.872375
6 Q51 0.020769 0.892200 0.050979 0.895769
7 Q52 0.734934 0.801339 0.720377 0.835664
8 Q53 0.634029 0.818998 0.629826 0.844548
Self-
Efficacy 
9 Q54 0.888635 0.794098 0.877142 0.819692
1 Q16 0.472642 0.617869 0.448771 0.606487
2 Q20 0.107143 0.687500 0.133929 0.683556
3 Q22 0.686106 0.534211 0.657716 0.549027
4 Q25 0.226518 0.694319 0.231649 0.660807
5 Q26 0.218218 0.677083 0.147106 0.680548
6 Q36 0.650626 0.587753 0.683508 0.541566
7 Q38 0.482008 0.625767 0.492177 0.594980
Perceived 
Severity 
8 Q41 0.196012 0.676955 0.117607 0.687257
1 Q3 0.687500 0.382813 0.716078 0.328611
2 Q12 0.636995 0.168367 0.642607 0.391415
3 Q24 0.147834 0.677165 0.144869 0.742721
Structural 
Elements 
4 Q34 0.213813 0.587413 0.255744 0.674931
1 Q9 0.725243 0.848924 0.738991 0.822461
2 Q11 0.808341 0.831067 0.757140 0.820543
Perceived 
Suscept-
ibility 3 Q19 0.778496 0.831392 0.765925 0.819611
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    Raw Variables 
(Time 2) 
Standardized 
Variables 
(Time 2) 
Scale or 
Subscale 
Number 
of 
Question 
on Scale 
Question 
from 
Questionnaire
Correlation 
with Total 
Alpha Correlation 
with Total 
Alpha 
4 Q21 0.227710 0.875102 0.212930 0.873553
5 Q23 0.563860 0.856592 0.538280 0.842964
6 Q32 0.761964 0.833667 0.752644 0.821019
7 Q35 -0.058026 0.897354 -0.069887 0.897641
8 Q39 0.938226 0.814339 0.972999 0.796896
9 Q43 0.662433 0.844720 0.661327 0.830547
1 Q5 0.728478 0.854664 0.789364 0.860131
2 Q6 0.686351 0.845879 0.789364 0.860131
3 Q7 -0.085498 0.886678 -0.094467 0.919683
4 Q8 0.647546 0.851685 0.630623 0.871935
5 Q10 0.705181 0.843750 0.630663 0.871932
6 Q13 0.728478 0.854664 0.789364 0.860131
7 Q17 0.814890 0.842818 0.826798 0.857272
8 Q18 0.728478 0.854664 0.789364 0.860131
9 Q31 0.564577 0.857054 0.475783 0.882965
Perceived 
Treatment 
Benefits 
10 Q40 0.705181 0.843750 0.630663 0.871932
 339 
Appendix 12:  SAS Output for Research Questions 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
                                    Class Level Information 
 
                         Class         Levels    Values 
 
                         group2             2    1_Intensive 2_Control 
 
 
                            Number of Observations Read         159 
                            Number of Observations Used         101 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
Dependent Variable: hgb1   Hemoglobin Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       0.2807848       0.2807848       0.16    0.6880 
 
      Error                       99     171.3821855       1.7311332 
 
      Corrected Total            100     171.6629703 
 
 
                       R-Square     Coeff Var      Root MSE     hgb1 Mean 
 
                       0.001636      15.43597      1.315725      8.523762 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.28078476      0.28078476       0.16    0.6880 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.28078476      0.28078476       0.16    0.6880 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
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Dependent Variable: hgb2   Hemoglobin Wk 12 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       0.0014198       0.0014198       0.00    0.9776 
 
      Error                       99     177.8302634       1.7962653 
 
      Corrected Total            100     177.8316832 
 
 
                       R-Square     Coeff Var      Root MSE     hgb2 Mean 
 
                       0.000008      18.78244      1.340248      7.135644 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.00141980      0.00141980       0.00    0.9776 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.00141980      0.00141980       0.00    0.9776 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
Dependent Variable: hgb3   Hemoglobin Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       0.0437294       0.0437294       0.02    0.8798 
 
      Error                       99     188.1966667       1.9009764 
 
      Corrected Total            100     188.2403960 
 
 
                       R-Square     Coeff Var      Root MSE     hgb3 Mean 
 
                       0.000232      19.75243      1.378759      6.980198 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.04372937      0.04372937       0.02    0.8798 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.04372937      0.04372937       0.02    0.8798 
 
                                     Rsch Question 1 Anova 
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                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
 
                               Repeated Measures Level Information 
 
                        Dependent Variable        hgb1     hgb2     hgb3 
 
                             Level of time           1        2        3 
 
 
        MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no time Effect 
                               H = Type III SSCP Matrix for time 
                                     E = Error SSCP Matrix 
 
                                       S=1    M=0    N=48 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
 
        Wilks' Lambda               0.47527443      54.10         2        98    <.0001 
        Pillai's Trace              0.52472557      54.10         2        98    <.0001 
        Hotelling-Lawley Trace      1.10404757      54.10         2        98    <.0001 
        Roy's Greatest Root         1.10404757      54.10         2        98    <.0001 
 
 
    MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no time*group2 Effect 
                           H = Type III SSCP Matrix for time*group2 
                                     E = Error SSCP Matrix 
 
                                      S=1    M=0    N=48 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
 
        Wilks' Lambda               0.99713008       0.14         2        98    0.8686 
        Pillai's Trace              0.00286992       0.14         2        98    0.8686 
        Hotelling-Lawley Trace      0.00287818       0.14         2        98    0.8686 
        Roy's Greatest Root         0.00287818       0.14         2        98    0.8686 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                        Tests of Hypotheses for Between Subjects Effects 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1       0.0428302       0.0428302       0.01    0.9150 
      Error                       99     370.6043645       3.7434784 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                   Univariate Tests of Hypotheses for Within Subject Effects 
 
                                                                                    Adj Pr > F 
Source                     DF    Type III SS    Mean Square   F Value   Pr > F    G - G    H - F 
 
time                        2    146.1588793     73.0794397     86.75   <.0001   <.0001   <.0001 
time*group2                 2      0.2831037      0.1415519      0.17   0.8455   0.7693   0.7741 
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Error(time)               198    166.8047510      0.8424482 
 
 
                              Greenhouse-Geisser Epsilon    0.7100 
                              Huynh-Feldt Epsilon           0.7247 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for hgb1 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  99 
                          Error Mean Square                   1.731133 
                          Critical Value of Studentized Range  2.80611 
                          Minimum Significant Difference        0.5202 
                          Harmonic Mean of Cell Sizes         50.37624 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        8.5792     48    2_Control 
                             A 
                             A        8.4736     53    1_Intensive 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for hgb1 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             99 
                            Error Mean Square              1.731133 
                            Critical Value of t             1.98422 
                            Minimum Significant Difference   0.5202 
                            Harmonic Mean of Cell Sizes    50.37624 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
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                             A        8.5792     48    2_Control 
                             A 
                             A        8.4736     53    1_Intensive 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for hgb2 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  99 
                          Error Mean Square                   1.796265 
                          Critical Value of Studentized Range  2.80611 
                          Minimum Significant Difference        0.5299 
                          Harmonic Mean of Cell Sizes         50.37624 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        7.1396     48    2_Control 
                             A 
                             A        7.1321     53    1_Intensive 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for hgb2 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             99 
                            Error Mean Square              1.796265 
                            Critical Value of t             1.98422 
                            Minimum Significant Difference   0.5299 
                            Harmonic Mean of Cell Sizes    50.37624 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
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                             A        7.1396     48    2_Control 
                             A 
                             A        7.1321     53    1_Intensive 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for hgb3 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  99 
                          Error Mean Square                   1.900976 
                          Critical Value of Studentized Range  2.80611 
                          Minimum Significant Difference        0.5451 
                          Harmonic Mean of Cell Sizes         50.37624 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        7.0000     53    1_Intensive 
                             A 
                             A        6.9583     48    2_Control 
 
                                     Rsch Question 1 Anova 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for hgb3 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             99 
                            Error Mean Square              1.900976 
                            Critical Value of t             1.98422 
                            Minimum Significant Difference   0.5451 
                            Harmonic Mean of Cell Sizes    50.37624 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        7.0000     53    1_Intensive 
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                             A 
                             A        6.9583     48    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                                    Class Level Information 
 
                         Class         Levels    Values 
 
                         group2             2    1_Intensive 2_Control 
 
 
                            Number of Observations Read         159 
                            Number of Observations Used         153 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: preself   Self Efficacy Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        1.459638        1.459638       0.06    0.8037 
 
      Error                      151     3553.481538       23.532990 
 
      Corrected Total            152     3554.941176 
 
 
                      R-Square     Coeff Var      Root MSE    preself Mean 
 
                      0.000411      16.00292      4.851081        30.31373 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      1.45963801      1.45963801       0.06    0.8037 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      1.45963801      1.45963801       0.06    0.8037 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: presus   Susceptibility Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        3.488396        3.488396       0.11    0.7407 
 
      Error                      151     4793.348205       31.744028 
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      Corrected Total            152     4796.836601 
 
 
                      R-Square     Coeff Var      Root MSE    presus Mean 
 
                      0.000727      20.14560      5.634184       27.96732 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.48839618      3.48839618       0.11    0.7407 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.48839618      3.48839618       0.11    0.7407 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: pretb   Benefits Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        9.422061        9.422061       0.58    0.4480 
 
      Error                      151     2457.885128       16.277385 
 
      Corrected Total            152     2467.307190 
 
 
                       R-Square     Coeff Var      Root MSE    pretb Mean 
 
                       0.003819      11.10819      4.034524      36.32026 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      9.42206134      9.42206134       0.58    0.4480 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      9.42206134      9.42206134       0.58    0.4480 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: presev   Severity Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        0.875063        0.875063       0.05    0.8177 
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      Error                      151     2479.294872       16.419171 
 
      Corrected Total            152     2480.169935 
 
 
                      R-Square     Coeff Var      Root MSE    presev Mean 
 
                      0.000353      15.90469      4.052058       25.47712 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.87506285      0.87506285       0.05    0.8177 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.87506285      0.87506285       0.05    0.8177 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: precue   Cue-to-Action Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       20.047702       20.047702       1.27    0.2620 
 
      Error                      151     2388.592821       15.818496 
 
      Corrected Total            152     2408.640523 
 
 
                      R-Square     Coeff Var      Root MSE    precue Mean 
 
                      0.008323      22.24932      3.977247       17.87582 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     20.04770236     20.04770236       1.27    0.2620 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     20.04770236     20.04770236       1.27    0.2620 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: prestr   Structural Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        0.738472        0.738472       0.06    0.8102 
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      Error                      151     1925.902051       12.754318 
 
      Corrected Total            152     1926.640523 
 
 
                      R-Square     Coeff Var      Root MSE    prestr Mean 
 
                      0.000383      32.83725      3.571319       10.87582 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.73847159      0.73847159       0.06    0.8102 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.73847159      0.73847159       0.06    0.8102 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: premot   Motivation Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        3.500251        3.500251       0.36    0.5509 
 
      Error                      151     1479.179487        9.795891 
 
      Corrected Total            152     1482.679739 
 
 
                      R-Square     Coeff Var      Root MSE    premot Mean 
 
                      0.002361      17.34391      3.129839       18.04575 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.50025138      3.50025138       0.36    0.5509 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.50025138      3.50025138       0.36    0.5509 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
Dependent Variable: prebar   Barriers Wk 1 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
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      Model                        1       330.83656       330.83656       0.57    0.4511 
 
      Error                      151     87524.10462       579.62983 
 
      Corrected Total            152     87854.94118 
 
 
                      R-Square     Coeff Var      Root MSE    prebar Mean 
 
                      0.003766      25.43714      24.07550       94.64706 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     330.8365611     330.8365611       0.57    0.4511 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     330.8365611     330.8365611       0.57    0.4511 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
 
                              Repeated Measures Level Information 
 
 Dependent Variable     preself   presus    pretb   presev   precue   prestr   premot   prebar 
 
  Level of subscale           1        2        3        4        5        6        7        8 
 
 
      MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no subscale Effect 
                             H = Type III SSCP Matrix for subscale 
                                     E = Error SSCP Matrix 
 
                                     S=1    M=2.5    N=71.5 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
 
        Wilks' Lambda               0.01650840    1234.06         7       145    <.0001 
        Pillai's Trace              0.98349160    1234.06         7       145    <.0001 
        Hotelling-Lawley Trace     59.57523541    1234.06         7       145    <.0001 
        Roy's Greatest Root        59.57523541    1234.06         7       145    <.0001 
 
 
  MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no subscale*group2 Effect 
                         H = Type III SSCP Matrix for subscale*group2 
                                     E = Error SSCP Matrix 
 
                                    S=1    M=2.5    N=71.5 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
 
        Wilks' Lambda               0.96608372       0.73         7       145    0.6491 
        Pillai's Trace              0.03391628       0.73         7       145    0.6491 
        Hotelling-Lawley Trace      0.03510698       0.73         7       145    0.6491 
        Roy's Greatest Root         0.03510698       0.73         7       145    0.6491 
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                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                        Tests of Hypotheses for Between Subjects Effects 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1        40.12381        40.12381       0.44    0.5094 
      Error                      151     13852.64744        91.73939 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                   Univariate Tests of Hypotheses for Within Subject Effects 
 
                                                                                    Adj Pr > F 
Source                     DF    Type III SS    Mean Square   F Value   Pr > F    G - G    H - F 
 
subscale                    7    741048.7019    105864.1003   1206.46   <.0001   <.0001   <.0001 
subscale*group2             7       330.2443        47.1778      0.54   0.8063   0.5081   0.5101 
Error(subscale)          1057     92749.1413        87.7475 
 
 
                              Greenhouse-Geisser Epsilon    0.1843 
                              Huynh-Feldt Epsilon           0.1864 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for preself 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                   23.53299 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        1.5501 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       30.4133     75    1_Intensive 
                             A 
                             A       30.2179     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
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                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for preself 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square              23.53299 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   1.5501 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       30.4133     75    1_Intensive 
                             A 
                             A       30.2179     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for presus 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                   31.74403 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        1.8003 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       28.1154     78    2_Control 
                             A 
                             A       27.8133     75    1_Intensive 
 
                                   Rsch Question 2 - Pretests 
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                                       The GLM Procedure 
 
                              Bonferroni (Dunn) t Tests for presus 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square              31.74403 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   1.8003 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       28.1154     78    2_Control 
                             A 
                             A       27.8133     75    1_Intensive 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for pretb 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                   16.27738 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        1.2891 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       36.5733     75    1_Intensive 
                             A 
                             A       36.0769     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
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                              Bonferroni (Dunn) t Tests for pretb 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square              16.27738 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   1.2891 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       36.5733     75    1_Intensive 
                             A 
                             A       36.0769     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for presev 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                   16.41917 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        1.2948 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       25.5513     78    2_Control 
                             A 
                             A       25.4000     75    1_Intensive 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
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                              Bonferroni (Dunn) t Tests for presev 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square              16.41917 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   1.2948 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       25.5513     78    2_Control 
                             A 
                             A       25.4000     75    1_Intensive 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for precue 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                    15.8185 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        1.2708 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       18.2308     78    2_Control 
                             A 
                             A       17.5067     75    1_Intensive 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                              Bonferroni (Dunn) t Tests for precue 
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 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square               15.8185 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   1.2708 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       18.2308     78    2_Control 
                             A 
                             A       17.5067     75    1_Intensive 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for prestr 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                   12.75432 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        1.1411 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       10.9467     75    1_Intensive 
                             A 
                             A       10.8077     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                              Bonferroni (Dunn) t Tests for prestr 
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 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square              12.75432 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   1.1411 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       10.9467     75    1_Intensive 
                             A 
                             A       10.8077     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for premot 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                   9.795891 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        1.0001 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       18.2000     75    1_Intensive 
                             A 
                             A       17.8974     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                              Bonferroni (Dunn) t Tests for premot 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
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                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square              9.795891 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   1.0001 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       18.2000     75    1_Intensive 
                             A 
                             A       17.8974     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for prebar 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                 151 
                          Error Mean Square                   579.6298 
                          Critical Value of Studentized Range  2.79420 
                          Minimum Significant Difference        7.6928 
                          Harmonic Mean of Cell Sizes         76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        96.147     75    1_Intensive 
                             A 
                             A        93.205     78    2_Control 
 
                                   Rsch Question 2 - Pretests 
 
                                       The GLM Procedure 
 
                              Bonferroni (Dunn) t Tests for prebar 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
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                            Alpha                              0.05 
                            Error Degrees of Freedom            151 
                            Error Mean Square              579.6298 
                            Critical Value of t             1.97580 
                            Minimum Significant Difference   7.6928 
                            Harmonic Mean of Cell Sizes    76.47059 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        96.147     75    1_Intensive 
                             A 
                             A        93.205     78    2_Control 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                                    Class Level Information 
 
                         Class         Levels    Values 
 
                         group2             2    1_Intensive 2_Control 
 
 
                            Number of Observations Read         159 
                            Number of Observations Used          87 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: postself   Self Efficacy Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        3.594690        3.594690       0.17    0.6769 
 
      Error                       85     1747.991516       20.564606 
 
      Corrected Total             86     1751.586207 
 
 
                     R-Square     Coeff Var      Root MSE    postself Mean 
 
                     0.002052      14.66107      4.534822         30.93103 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.59469046      3.59469046       0.17    0.6769 
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      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.59469046      3.59469046       0.17    0.6769 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: postsus   Susceptibility Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       30.743872       30.743872       0.95    0.3330 
 
      Error                       85     2756.865323       32.433710 
 
      Corrected Total             86     2787.609195 
 
 
                      R-Square     Coeff Var      Root MSE    postsus Mean 
 
                      0.011029      20.24807      5.695060        28.12644 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     30.74387197     30.74387197       0.95    0.3330 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     30.74387197     30.74387197       0.95    0.3330 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: posttb   Benefits Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       0.1143879       0.1143879       0.01    0.9103 
 
      Error                       85     761.2879109       8.9563284 
 
      Corrected Total             86     761.4022989 
 
 
                      R-Square     Coeff Var      Root MSE    posttb Mean 
 
                      0.000150      8.038468      2.992713       37.22989 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
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      group2                       1      0.11438793      0.11438793       0.01    0.9103 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.11438793      0.11438793       0.01    0.9103 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: postsev   Severity Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       90.994113       90.994113       4.65    0.0339 
 
      Error                       85     1663.902439       19.575323 
 
      Corrected Total             86     1754.896552 
 
 
                      R-Square     Coeff Var      Root MSE    postsev Mean 
 
                      0.051852      17.03953      4.424401        25.96552 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     90.99411270     90.99411270       4.65    0.0339 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     90.99411270     90.99411270       4.65    0.0339 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: postcue   Cue-to-Action Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       24.134884       24.134884       2.02    0.1592 
 
      Error                       85     1016.922587       11.963795 
 
      Corrected Total             86     1041.057471 
 
 
                      R-Square     Coeff Var      Root MSE    postcue Mean 
 
                      0.023183      19.05775      3.458872        18.14943 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
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      group2                       1     24.13488378     24.13488378       2.02    0.1592 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     24.13488378     24.13488378       2.02    0.1592 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: poststr   Structural Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       8.1302337       8.1302337       0.77    0.3819 
 
      Error                       85     894.4904560      10.5234171 
 
      Corrected Total             86     902.6206897 
 
 
                      R-Square     Coeff Var      Root MSE    poststr Mean 
 
                      0.009007      26.35167      3.243982        12.31034 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      8.13023366      8.13023366       0.77    0.3819 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      8.13023366      8.13023366       0.77    0.3819 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: postmot   Motivation Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        3.238874        3.238874       0.21    0.6463 
 
      Error                       85     1298.278367       15.273863 
 
      Corrected Total             86     1301.517241 
 
 
                      R-Square     Coeff Var      Root MSE    postmot Mean 
 
                      0.002489      21.06639      3.908179        18.55172 
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      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.23887447      3.23887447       0.21    0.6463 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      3.23887447      3.23887447       0.21    0.6463 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
Dependent Variable: postbar   Barriers Wk 24 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       198.56696       198.56696       0.55    0.4623 
 
      Error                       85     30959.38706       364.22808 
 
      Corrected Total             86     31157.95402 
 
 
                      R-Square     Coeff Var      Root MSE    postbar Mean 
 
                      0.006373      20.66427      19.08476        92.35632 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     198.5669604     198.5669604       0.55    0.4623 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     198.5669604     198.5669604       0.55    0.4623 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
 
                              Repeated Measures Level Information 
 
 Dependent Variable    postself  postsus   posttb  postsev  postcue  poststr  postmot  postbar 
 
  Level of subscale           1        2        3        4        5        6        7        8 
 
 
      MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no subscale Effect 
                             H = Type III SSCP Matrix for subscale 
                                     E = Error SSCP Matrix 
 
                                     S=1    M=2.5    N=38.5 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
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        Wilks' Lambda               0.01091692    1022.50         7        79    <.0001 
        Pillai's Trace              0.98908308    1022.50         7        79    <.0001 
        Hotelling-Lawley Trace     90.60094620    1022.50         7        79    <.0001 
        Roy's Greatest Root        90.60094620    1022.50         7        79    <.0001 
 
 
  MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no subscale*group2 Effect 
                         H = Type III SSCP Matrix for subscale*group2 
                                     E = Error SSCP Matrix 
 
                                    S=1    M=2.5    N=38.5 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
 
        Wilks' Lambda               0.91975818       0.98         7        79    0.4485 
        Pillai's Trace              0.08024182       0.98         7        79    0.4485 
        Hotelling-Lawley Trace      0.08724230       0.98         7        79    0.4485 
        Roy's Greatest Root         0.08724230       0.98         7        79    0.4485 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                        Tests of Hypotheses for Between Subjects Effects 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1       20.449197       20.449197       0.29    0.5896 
      Error                       85     5928.361148       69.745425 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                   Univariate Tests of Hypotheses for Within Subject Effects 
 
                                                                                    Adj Pr > F 
Source                     DF    Type III SS    Mean Square   F Value   Pr > F    G - G    H - F 
 
subscale                    7    386952.6550     55278.9507    935.18   <.0001   <.0001   <.0001 
subscale*group2             7       339.0688        48.4384      0.82   0.5713   0.4066   0.4092 
Error(subscale)           595     35170.7645        59.1105 
 
 
                              Greenhouse-Geisser Epsilon    0.2036 
                              Huynh-Feldt Epsilon           0.2086 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                       Tukey's Studentized Range (HSD) Test for postself 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
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                          Error Mean Square                   20.56461 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.9365 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       31.1463     41    2_Control 
                             A 
                             A       30.7391     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for postself 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              20.56461 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.9365 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       31.1463     41    2_Control 
                             A 
                             A       30.7391     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for postsus 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   32.43371 
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                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference         2.432 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        28.756     41    2_Control 
                             A 
                             A        27.565     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for postsus 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              32.43371 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference    2.432 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        28.756     41    2_Control 
                             A 
                             A        27.565     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for posttb 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   8.956328 
                          Critical Value of Studentized Range  2.81184 
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                          Minimum Significant Difference         1.278 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       37.2683     41    2_Control 
                             A 
                             A       37.1957     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                              Bonferroni (Dunn) t Tests for posttb 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              8.956328 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference    1.278 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       37.2683     41    2_Control 
                             A 
                             A       37.1957     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for postsev 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   19.57532 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.8894 
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                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       27.0488     41    2_Control 
 
                             B       25.0000     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for postsev 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              19.57532 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.8894 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       27.0488     41    2_Control 
 
                             B       25.0000     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for postcue 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                    11.9638 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.4771 
                          Harmonic Mean of Cell Sizes         43.35632 
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                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       18.7073     41    2_Control 
                             A 
                             A       17.6522     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for postcue 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square               11.9638 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.4771 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       18.7073     41    2_Control 
                             A 
                             A       17.6522     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for poststr 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   10.52342 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.3853 
                          Harmonic Mean of Cell Sizes         43.35632 
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                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       12.6341     41    2_Control 
                             A 
                             A       12.0217     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for poststr 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              10.52342 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.3853 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       12.6341     41    2_Control 
                             A 
                             A       12.0217     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for postmot 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   15.27386 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.6689 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
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                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A       18.7561     41    2_Control 
                             A 
                             A       18.3696     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for postmot 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              15.27386 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.6689 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A       18.7561     41    2_Control 
                             A 
                             A       18.3696     46    1_Intensive 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                        Tukey's Studentized Range (HSD) Test for postbar 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   364.2281 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        8.1499 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
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                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        93.783     46    1_Intensive 
                             A 
                             A        90.756     41    2_Control 
 
                                  Rsch Question 2 - Posttests 
 
                                       The GLM Procedure 
 
                             Bonferroni (Dunn) t Tests for postbar 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              364.2281 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   8.1499 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        93.783     46    1_Intensive 
                             A 
                             A        90.756     41    2_Control 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                                    Class Level Information 
 
                         Class         Levels    Values 
 
                         group2             2    1_Intensive 2_Control 
 
 
                            Number of Observations Read         159 
                            Number of Observations Used          87 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
Dependent Variable: selfd   Difference in Self Efficacy 
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                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       41.803251       41.803251       1.74    0.1903 
 
      Error                       85     2038.127784       23.977974 
 
      Corrected Total             86     2079.931034 
 
 
                       R-Square     Coeff Var      Root MSE    selfd Mean 
 
                       0.020098      2028.646      4.896731      0.241379 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     41.80325081     41.80325081       1.74    0.1903 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     41.80325081     41.80325081       1.74    0.1903 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
Dependent Variable: susd   Difference in Susceptibility 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       21.403176       21.403176       1.04    0.3113 
 
      Error                       85     1753.654295       20.631227 
 
      Corrected Total             86     1775.057471 
 
 
                       R-Square     Coeff Var      Root MSE     susd Mean 
 
                       0.012058      2469.800      4.542161      0.183908 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     21.40317646     21.40317646       1.04    0.3113 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     21.40317646     21.40317646       1.04    0.3113 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
Dependent Variable: tbd   Difference in Benefits 
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                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       0.0177716       0.0177716       0.00    0.9633 
 
      Error                       85     707.4994698       8.3235232 
 
      Corrected Total             86     707.5172414 
 
 
                       R-Square     Coeff Var      Root MSE      tbd Mean 
 
                       0.000025      643.5885      2.885052      0.448276 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.01777160      0.01777160       0.00    0.9633 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.01777160      0.01777160       0.00    0.9633 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
Dependent Variable: sevd   Difference in Severity 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        0.008343        0.008343       0.00    0.9825 
 
      Error                       85     1471.393955       17.310517 
 
      Corrected Total             86     1471.402299 
 
 
                       R-Square     Coeff Var      Root MSE     sevd Mean 
 
                       0.000006      1809.857      4.160591      0.229885 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.00834339      0.00834339       0.00    0.9825 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.00834339      0.00834339       0.00    0.9825 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
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Dependent Variable: cued   Difference in Cue-to-Action 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       0.0013713       0.0013713       0.00    0.9911 
 
      Error                       85     939.5848356      11.0539392 
 
      Corrected Total             86     939.5862069 
 
 
                       R-Square     Coeff Var      Root MSE     cued Mean 
 
                       0.000001     -4820.882      3.324746     -0.068966 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.00137127      0.00137127       0.00    0.9911 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.00137127      0.00137127       0.00    0.9911 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
Dependent Variable: strd   Difference in Structural 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       1.9249156       1.9249156       0.25    0.6191 
 
      Error                       85     657.1325557       7.7309712 
 
      Corrected Total             86     659.0574713 
 
 
                       R-Square     Coeff Var      Root MSE     strd Mean 
 
                       0.002921      234.8546      2.780462      1.183908 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      1.92491559      1.92491559       0.25    0.6191 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      1.92491559      1.92491559       0.25    0.6191 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
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Dependent Variable: motd   Difference in Motivation 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1       0.0123414       0.0123414       0.00    0.9685 
 
      Error                       85     668.2635207       7.8619238 
 
      Corrected Total             86     668.2758621 
 
 
                       R-Square     Coeff Var      Root MSE     motd Mean 
 
                       0.000018      1355.224      2.803912      0.206897 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.01234139      0.01234139       0.00    0.9685 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1      0.01234139      0.01234139       0.00    0.9685 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
Dependent Variable: bard   Difference in Barriers 
 
                                              Sum of 
      Source                      DF         Squares     Mean Square    F Value    Pr > F 
 
      Model                        1        59.63106        59.63106       0.19    0.6619 
 
      Error                       85     26327.21951       309.73199 
 
      Corrected Total             86     26386.85057 
 
 
                       R-Square     Coeff Var      Root MSE     bard Mean 
 
                       0.002260     -1444.463      17.59920     -1.218391 
 
 
      Source                      DF       Type I SS     Mean Square    F Value    Pr > F 
 
      group2                       1     59.63106252     59.63106252       0.19    0.6619 
 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1     59.63106252     59.63106252       0.19    0.6619 
 
                                 Rsch Question 2 - Differences 
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                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
 
                              Repeated Measures Level Information 
 
 Dependent Variable       selfd     susd      tbd     sevd     cued     strd     motd     bard 
 
  Level of subscale           1        2        3        4        5        6        7        8 
 
 
      MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no subscale Effect 
                             H = Type III SSCP Matrix for subscale 
                                     E = Error SSCP Matrix 
 
                                     S=1    M=2.5    N=38.5 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
 
        Wilks' Lambda               0.88546610       1.46         7        79    0.1939 
        Pillai's Trace              0.11453390       1.46         7        79    0.1939 
        Hotelling-Lawley Trace      0.12934872       1.46         7        79    0.1939 
        Roy's Greatest Root         0.12934872       1.46         7        79    0.1939 
 
 
  MANOVA Test Criteria and Exact F Statistics for the Hypothesis of no subscale*group2 Effect 
                         H = Type III SSCP Matrix for subscale*group2 
                                     E = Error SSCP Matrix 
 
                                    S=1    M=2.5    N=38.5 
 
        Statistic                        Value    F Value    Num DF    Den DF    Pr > F 
 
        Wilks' Lambda               0.95165321       0.57         7        79    0.7755 
        Pillai's Trace              0.04834679       0.57         7        79    0.7755 
        Hotelling-Lawley Trace      0.05080295       0.57         7        79    0.7755 
        Roy's Greatest Root         0.05080295       0.57         7        79    0.7755 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                        Tests of Hypotheses for Between Subjects Effects 
 
      Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
 
      group2                       1       15.303571       15.303571       0.28    0.5950 
      Error                       85     4567.730912       53.738011 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
                             Repeated Measures Analysis of Variance 
                   Univariate Tests of Hypotheses for Within Subject Effects 
 
                                                                                    Adj Pr > F 
Source                     DF    Type III SS    Mean Square   F Value   Pr > F    G - G    H - F 
 
subscale                    7      259.68257       37.09751      0.74   0.6416   0.4426   0.4458 
subscale*group2             7      109.49866       15.64267      0.31   0.9494   0.6666   0.6722 
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Error(subscale)           595    29995.14502       50.41201 
 
 
                              Greenhouse-Geisser Epsilon    0.2110 
                              Huynh-Feldt Epsilon           0.2164 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for selfd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   23.97797 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        2.0911 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        0.9756     41    2_Control 
                             A 
                             A       -0.4130     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                              Bonferroni (Dunn) t Tests for selfd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              23.97797 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   2.0911 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
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                             A        0.9756     41    2_Control 
                             A 
                             A       -0.4130     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for susd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   20.63123 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.9397 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        0.6522     46    1_Intensive 
                             A 
                             A       -0.3415     41    2_Control 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for susd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              20.63123 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.9397 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
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                             A        0.6522     46    1_Intensive 
                             A 
                             A       -0.3415     41    2_Control 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                          Tukey's Studentized Range (HSD) Test for tbd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   8.323523 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference         1.232 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        0.4634     41    2_Control 
                             A 
                             A        0.4348     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for tbd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              8.323523 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference    1.232 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        0.4634     41    2_Control 
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                             A 
                             A        0.4348     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for sevd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   17.31052 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.7767 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        0.2391     46    1_Intensive 
                             A 
                             A        0.2195     41    2_Control 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for sevd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              17.31052 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.7767 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        0.2391     46    1_Intensive 
                             A 
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                             A        0.2195     41    2_Control 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for cued 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   11.05394 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.4198 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A      -0.06522     46    1_Intensive 
                             A 
                             A      -0.07317     41    2_Control 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for cued 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              11.05394 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.4198 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A      -0.06522     46    1_Intensive 
                             A 
                             A      -0.07317     41    2_Control 
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                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for strd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   7.730971 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.1874 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        1.3415     41    2_Control 
                             A 
                             A        1.0435     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for strd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              7.730971 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.1874 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        1.3415     41    2_Control 
                             A 
                             A        1.0435     46    1_Intensive 
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                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for motd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                   7.861924 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        1.1974 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        0.2195     41    2_Control 
                             A 
                             A        0.1957     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for motd 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square              7.861924 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   1.1974 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        0.2195     41    2_Control 
                             A 
                             A        0.1957     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
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                                       The GLM Procedure 
 
                         Tukey's Studentized Range (HSD) Test for bard 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                          Alpha                                   0.05 
                          Error Degrees of Freedom                  85 
                          Error Mean Square                    309.732 
                          Critical Value of Studentized Range  2.81184 
                          Minimum Significant Difference        7.5155 
                          Harmonic Mean of Cell Sizes         43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                Tukey Grouping          Mean      N    group2 
 
                             A        -0.341     41    2_Control 
                             A 
                             A        -2.000     46    1_Intensive 
 
                                 Rsch Question 2 - Differences 
 
                                       The GLM Procedure 
 
                               Bonferroni (Dunn) t Tests for bard 
 
 NOTE: This test controls the Type I experimentwise error rate, but it generally has a higher 
                                 Type II error rate than REGWQ. 
 
 
                            Alpha                              0.05 
                            Error Degrees of Freedom             85 
                            Error Mean Square               309.732 
                            Critical Value of t             1.98827 
                            Minimum Significant Difference   7.5155 
                            Harmonic Mean of Cell Sizes    43.35632 
 
                                NOTE: Cell sizes are not equal. 
 
 
                  Means with the same letter are not significantly different. 
 
 
                  Bon Grouping          Mean      N    group2 
 
                             A        -0.341     41    2_Control 
                             A 
                             A        -2.000     46    1_Intensive 
 
                                  Success at Week 12 by Group 
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                                       The FREQ Procedure 
 
                                    Table of group2 by suc12 
 
                             group2(Group)     suc12(Success at Wk 12) 
 
                             Frequency   ‚ 
                             Percent     ‚ 
                             Row Pct     ‚ 
                             Col Pct     ‚1_Succes‚2_Unsucc‚  Total 
                                         ‚sful    ‚essful  ‚ 
                             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ 
                             1_Intensive ‚     33 ‚     27 ‚     60 
                                         ‚  27.05 ‚  22.13 ‚  49.18 
                                         ‚  55.00 ‚  45.00 ‚ 
                                         ‚  55.00 ‚  43.55 ‚ 
                             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ 
                             2_Control   ‚     27 ‚     35 ‚     62 
                                         ‚  22.13 ‚  28.69 ‚  50.82 
                                         ‚  43.55 ‚  56.45 ‚ 
                                         ‚  45.00 ‚  56.45 ‚ 
                             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ 
                             Total             60       62      122 
                                            49.18    50.82   100.00 
 
 
                            Statistics for Table of group2 by suc12 
 
                     Statistic                     DF       Value      Prob 
                     ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ 
                     Chi-Square                     1      1.5999    0.2059 
                     Likelihood Ratio Chi-Square    1      1.6034    0.2054 
                     Continuity Adj. Chi-Square     1      1.1745    0.2785 
                     Mantel-Haenszel Chi-Square     1      1.5868    0.2078 
                     Phi Coefficient                       0.1145 
                     Contingency Coefficient               0.1138 
                     Cramer's V                            0.1145 
 
 
                                      Fisher's Exact Test 
                               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ 
                               Cell (1,1) Frequency (F)        33 
                               Left-sided Pr <= F          0.9261 
                               Right-sided Pr >= F         0.1392 
 
                               Table Probability (P)       0.0653 
                               Two-sided Pr <= P           0.2771 
 
                                  Success at Week 12 by Group 
 
                                       The FREQ Procedure 
 
                            Statistics for Table of group2 by suc12 
 
                          Estimates of the Relative Risk (Row1/Row2) 
 
               Type of Study                   Value       95% Confidence Limits 
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ 
               Case-Control (Odds Ratio)      1.5844        0.7753        3.2376 
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               Cohort (Col1 Risk)             1.2630        0.8774        1.8180 
               Cohort (Col2 Risk)             0.7971        0.5589        1.1369 
 
                                       Sample Size = 122 
 
                                  Success at Week 24 by Group 
 
                                       The FREQ Procedure 
 
                                    Table of group2 by suc24 
 
                             group2(Group)     suc24(Success at Wk 24) 
 
                             Frequency   ‚ 
                             Percent     ‚ 
                             Row Pct     ‚ 
                             Col Pct     ‚1_Succes‚2_Unsucc‚  Total 
                                         ‚sful    ‚essful  ‚ 
                             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ 
                             1_Intensive ‚     29 ‚     24 ‚     53 
                                         ‚  28.16 ‚  23.30 ‚  51.46 
                                         ‚  54.72 ‚  45.28 ‚ 
                                         ‚  50.00 ‚  53.33 ‚ 
                             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ 
                             2_Control   ‚     29 ‚     21 ‚     50 
                                         ‚  28.16 ‚  20.39 ‚  48.54 
                                         ‚  58.00 ‚  42.00 ‚ 
                                         ‚  50.00 ‚  46.67 ‚ 
                             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ 
                             Total             58       45      103 
                                            56.31    43.69   100.00 
 
 
                            Statistics for Table of group2 by suc24 
 
                     Statistic                     DF       Value      Prob 
                     ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ 
                     Chi-Square                     1      0.1127    0.7371 
                     Likelihood Ratio Chi-Square    1      0.1128    0.7370 
                     Continuity Adj. Chi-Square     1      0.0188    0.8910 
                     Mantel-Haenszel Chi-Square     1      0.1116    0.7383 
                     Phi Coefficient                      -0.0331 
                     Contingency Coefficient               0.0331 
                     Cramer's V                           -0.0331 
 
 
                                      Fisher's Exact Test 
                               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ 
                               Cell (1,1) Frequency (F)        29 
                               Left-sided Pr <= F          0.4457 
                               Right-sided Pr >= F         0.7033 
 
                               Table Probability (P)       0.1490 
                               Two-sided Pr <= P           0.8429 
 
                                  Success at Week 24 by Group 
 
                                       The FREQ Procedure 
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                            Statistics for Table of group2 by suc24 
 
                          Estimates of the Relative Risk (Row1/Row2) 
 
               Type of Study                   Value       95% Confidence Limits 
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ 
               Case-Control (Odds Ratio)      0.8750        0.4012        1.9082 
               Cohort (Col1 Risk)             0.9434        0.6715        1.3255 
               Cohort (Col2 Risk)             1.0782        0.6943        1.6742 
 
                                       Sample Size = 103 
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